Abstract is: Calcium oxalate (in archaic terminology, oxalate of lime) is a calcium salt of oxalic acid with the chemical formula CaC2O4. It forms hydrates CaC2O4·nH2O, where n varies from 1 to 3. Anhydrous and all hydrated forms are colorless or white. The monohydrate CaC2O4·H2O occurs naturally as the mineral whewellite, forming envelope-shaped crystals, known in plants as raphides. The two rarer hydrates are dihydrate CaC2O4·2H2O, which occurs naturally as the mineral weddellite, and trihydrate CaC2O4·3H2O, which occurs naturally as the mineral , are also recognized. Some foods have high quantities of calcium oxalates and can produce sores and numbing on ingestion and may even be fatal. Tribes with diets that depend highly on fruits and vegetables high in calcium oxalate, such as in Micronesia, reduce the level of it by boiling and cooking them. They are a constituent in 76% of human kidney stones. Calcium oxalate is also found in beerstone, a scale that forms on containers used in breweries.
| P7049 | AICS Chemical ID (BEING DELETED) | 4940 |
| P1014 | Art & Architecture Thesaurus ID | 300379564 |
| P508 | BNCF Thesaurus ID | 50908 |
| P8072 | CAB ID | 79019 |
| P233 | canonical SMILES | C(=O)(C(=O)[O-])[O-].[Ca+2] |
| P231 | CAS Registry Number | 563-72-4 |
| P683 | ChEBI ID | 60579 |
| P592 | ChEMBL ID | CHEMBL3184709 |
| P661 | ChemSpider ID | 30549 |
| P8494 | DSSTOX compound identifier | DTXCID007214 |
| P3117 | DSSTox substance ID | DTXSID6027214 |
| P232 | EC number | 209-260-1 |
| P2566 | ECHA Substance Infocard ID | 100.008.419 |
| P646 | Freebase ID | /m/01hclm |
| P227 | GND ID | 4223755-5 |
| P2057 | Human Metabolome Database ID | HMDB0302182 |
| P234 | InChI | InChI=1S/C2H2O4.Ca/c3-1(4)2(5)6;/h(H,3,4)(H,5,6);/q;+2/p-2 |
| P235 | InChIKey | QXDMQSPYEZFLGF-UHFFFAOYSA-L |
| P665 | KEGG ID | C17478 |
| P244 | Library of Congress authority ID | sh85018789 |
| P486 | MeSH descriptor ID | D002129 |
| P672 | MeSH tree code | D02.241.081.337.593.750.500 |
| P6366 | Microsoft Academic ID | 2776179656 |
| P2004 | NALT ID | 21120 |
| P8189 | National Library of Israel J9U ID | 987007293770505171 |
| P10283 | OpenAlex ID | C2776179656 |
| C2909497934 | ||
| P662 | PubChem CID | 33005 |
| 16212978 | ||
| P1579 | Reaxys registry number | 3915709 |
| P3345 | RxNorm ID | 1485048 |
| P5076 | Römpp online ID | RD-03-00157 |
| P4342 | Store norske leksikon ID | kalsiumoksalat |
| P11089 | UniChem compound ID | 1071145 |
| P652 | UNII | 2612HC57YE |
| P1343 | described by source | Granat Encyclopedic Dictionary | Q4532138 |
| P527 | has part(s) | oxygen | Q629 |
| carbon | Q623 | ||
| calcium | Q706 | ||
| P2067 | mass | 127.942 | |
| P361 | part of | calcium oxalate binding | Q21111340 |
| Q64598658 | 18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome |
| Q64149839 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab |
| Q66082284 | 6 Years Study on Changes in Bone Quality, Bone Turnover and Curve Severity in AIS With and Without Calcium and Vit-D Supplementation |
| Q67134231 | 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density |
| Q63837561 | A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy |
| Q63808320 | A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism |
| Q64789107 | A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 |
| Q64695597 | A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001) |
| Q64710345 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD |
| Q65385156 | A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk |
| Q65383897 | A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia |
| Q66066496 | A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® |
| Q66078454 | A New Paradigm for Vitamin D Sufficiency |
| Q64654167 | A Novel Oral Natural Extract for the Treatment of Senile Purpura |
| Q64223201 | A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia |
| Q66039186 | A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients |
| Q66036435 | A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer |
| Q66039208 | A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer |
| Q66342925 | A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease |
| Q63838712 | A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients |
| Q64047784 | A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 1 |
| Q64047796 | A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2 |
| Q65361783 | A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice |
| Q66034979 | A School-Based Osteoporosis Prevention Program for Adolescent Girls |
| Q66024732 | A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors |
| Q65347963 | A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands |
| Q64625784 | A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients |
| Q65366812 | A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures |
| Q65475101 | A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) |
| Q66342285 | A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate |
| Q65381238 | A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) |
| Q64045540 | A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006) |
| Q65540237 | A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease |
| Q66029991 | A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes |
| Q64637722 | A Study on the Impact of Calcium on Woman's Vascular Health |
| Q63830246 | A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053) |
| Q64665501 | A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED) |
| Q63807033 | A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration |
| Q64640205 | A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease |
| Q66342638 | A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors |
| Q65385955 | A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED) |
| Q64720628 | A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea |
| Q63836539 | A Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort |
| Q65353225 | A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations |
| Q65381823 | A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D |
| Q66032347 | A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) |
| Q63845077 | A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects |
| Q65472353 | A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women |
| Q65363784 | A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions. |
| Q64679131 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042) |
| Q66037503 | A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects |
| Q66068708 | A Study to Measure the Efficacy of a Toothpaste on Dentinal Hypersensitivity |
| Q64044415 | A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262) |
| Q64604690 | A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome |
| Q64818514 | A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients |
| Q64695912 | A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass |
| Q67126210 | A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza |
| Q65355672 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study |
| Q67134001 | Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block |
| Q66035814 | Adding Phosphorus to Osteoporosis Drug Treatment |
| Q65465666 | Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation |
| Q66403032 | Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer |
| Q66079145 | Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) |
| Q64047364 | Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease |
| Q66079531 | Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis |
| Q65353754 | Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss |
| Q65354271 | Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors |
| Q64802258 | Altered Calcium and Vitamin D in PMDD or Severe PMS |
| Q64664184 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
| Q66034061 | Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors |
| Q64223092 | Amlodipine for Myocardial Iron in Thalassemia |
| Q64725204 | An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants |
| Q64364041 | An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorecta |
| Q64599457 | An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes |
| Q64625491 | An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study. |
| Q64656456 | An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia |
| Q64187094 | An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia |
| Q64647295 | Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures |
| Q64663389 | Analysis of Calcium Balance in Chronic Kidney Disease |
| Q65376509 | Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study |
| Q67127334 | Anterior Bridging Cage With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis |
| Q66061162 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia |
| Q64029744 | Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice |
| Q66070359 | Antibacterial Effect of Light-activated Calcium Silicate Versus Light-activated Calcium Hydroxide |
| Q63808553 | Antibiotic Loaded Calcium Sulfate RCT |
| Q65336971 | Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis |
| Q64666499 | Antimicrobial Pulpotomy of Primary Molars |
| Q66409898 | Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America |
| Q66036684 | Aortic Calcium: Epidemiology and Progression -- Ancillary to MESA |
| Q64793138 | Apexification Treatment With MTA(Mineral Trioxide Aggregate) and Ca(OH)2 |
| Q67125504 | Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation |
| Q66069569 | Application of Different Biomaterials in the Preservation of Vital Pulp in Carious Deciduous Teeth |
| Q66407860 | Aquamin and Prevention of Colon Cancer |
| Q64643033 | Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? |
| Q64793110 | Arterial Function and Atherosclerosis in Essential Thrombocythemia |
| Q64651183 | Arterial Wall Calcium Load in Pseudoxanthoma Elasticum |
| Q63812410 | Aspirin in Reduction of Tension II Study |
| Q74279207 | Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines |
| Q64602497 | Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy |
| Q66068330 | Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS) |
| Q65364673 | Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG) |
| Q65348375 | Assessing the Impact of Contraceptives on Bone Health Using 41Ca |
| Q64351192 | Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service |
| Q83806563 | Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT) |
| Q66075752 | Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD) |
| Q66064885 | Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach. |
| Q65470586 | Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth |
| Q64717849 | Assessment of the Effect of Food on ABT-143 Bioavailability |
| Q65382563 | Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients |
| Q65368828 | Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium |
| Q63817718 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer |
| Q65390002 | Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia |
| Q63837762 | Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation |
| Q63830238 | Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation |
| Q66026052 | Attached Stone Project: Do Calcium Oxalate Renal Calculi Originate From Randall's Plaque? |
| Q65545291 | Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy |
| Q63807838 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement |
| Q65538378 | Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) |
| Q65344334 | Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer |
| Q63819023 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer |
| Q64709326 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
| Q66059196 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
| Q66345327 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer |
| Q65390112 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer |
| Q66079586 | Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition. |
| Q64598388 | Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition |
| Q64598829 | Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition |
| Q63840553 | Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions |
| Q63840542 | Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions |
| Q63840526 | Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions |
| Q63840537 | Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions |
| Q66079567 | Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions |
| Q64665770 | Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium |
| Q63837117 | Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium |
| Q67128694 | Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Q66072077 | Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study |
| Q65346263 | Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium |
| Q66035890 | Bone Development in Adolescent Girls: Effects of Calcium and Exercise |
| Q66394540 | Bone Health in Hyperemesis Gravidarum |
| Q63831121 | Bone Health in Pregnancy |
| Q64636190 | Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS) |
| Q65387325 | Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27 |
| Q65537858 | Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury |
| Q63843620 | Bone Quality and Quantity Following Guided Bone Regeneration Prior to Dental Implant Placement |
| Q66035113 | Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery |
| Q66060010 | Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes |
| Q65348754 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer |
| Q74283191 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC |
| Q65545532 | CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients |
| Q64350505 | CASAD for Severe Diarrhea in the Emergency Department |
| Q64614068 | CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers |
| Q66030664 | CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer |
| Q65367731 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer |
| Q64029663 | CT Calcium Scoring in Suspected Stable Angina |
| Q66083278 | Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome |
| Q64803482 | Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention |
| Q65473061 | Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors |
| Q65347479 | Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation. |
| Q65386358 | Calcium Absorption and Retention From Marine Products |
| Q63813924 | Calcium Absorption in Patients With Rothmund-Thomson Syndrome |
| Q64598939 | Calcium Absorption in Postmenopausal Thai Women |
| Q64717012 | Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan |
| Q64817503 | Calcium Balance Studies in Children With CKD and on Dialysis |
| Q76981427 | Calcium Channel Blockade in Primary Aldosteronism |
| Q64217099 | Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow |
| Q65541327 | Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging |
| Q64791597 | Calcium Chloride for Prevention of Uterine Atony During Cesarean |
| Q65544499 | Calcium DXA: Impact of Calcium Supplements on Lumbar Spine Bone Mineral Density |
| Q64601374 | Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome |
| Q64599130 | Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome |
| Q64698846 | Calcium Dobesilate for Chronic Venous Wounds |
| Q66403425 | Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease |
| Q66073063 | Calcium Electroporation for Head and Neck Cancer |
| Q64354816 | Calcium Electroporation for Treatment of Cutaneous Metastases |
| Q64354815 | Calcium Electroporation for the Treatment of Keloids |
| Q65390889 | Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery |
| Q76980879 | Calcium Handling and Epicardial Ablation |
| Q65374299 | Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors |
| Q65345380 | Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth |
| Q64646213 | Calcium Intake and Fat Excretion |
| Q64348538 | Calcium Ionophore Solution Can Increase Fertilization Rate in Patients During Intracytoplasmic Sperm Injection(ICSI) Who Have Poor Ovarian Reserve? |
| Q64816926 | Calcium Kinetic Responses to Exercise |
| Q66396987 | Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study |
| Q64725186 | Calcium Metabolism in Asian Adolescents |
| Q64651620 | Calcium Metabolism in Mexican American Adolescents |
| Q65358395 | Calcium Over Postprandial Effects of Fatty Meal on Metabolism, Blood Pressure, Oxidative Stress, Endothelial Function. |
| Q65317324 | Calcium Phosphate Cement Registry (CPC Registry) |
| Q64722859 | Calcium Retention as Influenced by Dietary Components That Induce an Acid Load |
| Q66390931 | Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment |
| Q66074470 | Calcium Sulfate Spacer in Open Tibia Fractures |
| Q65386997 | Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite) |
| Q66027253 | Calcium Supplementation in Postmenopausal Women |
| Q66345034 | Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China |
| Q64650978 | Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients |
| Q66060868 | Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis |
| Q66035930 | Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer |
| Q64806562 | Calcium and Gut Hormones |
| Q64395028 | Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents |
| Q64045756 | Calcium and Lipid Metabolism |
| Q64641983 | Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy |
| Q64661513 | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer |
| Q63834014 | Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease |
| Q66061652 | Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease |
| Q65387717 | Calcium and Vitamin D Malnutrition in Elderly Women |
| Q65382739 | Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits |
| Q64709178 | Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia |
| Q65546110 | Calcium and Vitamin D vs Markers of Adenomatous Polyps |
| Q74133203 | Calcium for Out-of-Hospital Cardiac Arrest |
| Q64725110 | Calcium, Dairy, and Body Fat in Adolescents |
| Q64679741 | Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study |
| Q63833757 | Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females |
| Q64677043 | Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis |
| Q64806560 | Calcium-protein Co-ingestion and Gut Hormones |
| Q66044655 | Calcium-vitamin D & Periodontal Therapy for Improving Metabolic and Inflammatory Profile Among Pregnant Women |
| Q65385881 | Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention |
| Q83806015 | Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation |
| Q64697425 | Caloric Restriction and Body Weight in Adults |
| Q66393745 | Can Calcium Ionophore Application Enhance the ICSI Outcomes in Severe Male Factor Infertility? |
| Q64710357 | Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis |
| Q63816714 | Caphosol in Oral Mucositis Due to Targeted Therapy |
| Q64663122 | Caphosol in Sarcoma Patients With Mucositis |
| Q64598688 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma |
| Q66064758 | Caries Prevention Potential of Pearl Powder Versus CPP-ACP on Enamel White Spot Lesions |
| Q63816460 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers |
| Q66080460 | Celecoxib After Tonsillectomy |
| Q65378722 | Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer |
| Q65380940 | Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer |
| Q64789302 | Changes in Renal Papillary Density After Hydration Therapy in Calcium Stone Formers |
| Q66059192 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) |
| Q65381484 | Chemoprevention of Colorectal Adenomas |
| Q65316516 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction |
| Q65472867 | Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver |
| Q66037569 | Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer |
| Q66037971 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer |
| Q66035496 | Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer |
| Q65471024 | Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery |
| Q66402390 | Clinical & Radiographical Evaluation of the Effect of Dycal & Biodentine in DPC in Primary Teeth |
| Q66409916 | Clinical Comparison of Vital Pulp Capping Restorative Protocols |
| Q63838109 | Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2 |
| Q65347756 | Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity |
| Q64658250 | Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women |
| Q66063694 | Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment of Deep Carious Second Primary Molars, Randomized Clinical Trial |
| Q66071055 | Coffee Consumption and Coronary Artery Calcium Score |
| Q64673597 | Colorectal Inflammatory Response to a Western-Style Diet |
| Q64348406 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer |
| Q65389922 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma |
| Q65375803 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer |
| Q66037138 | Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
| Q66036653 | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated |
| Q63808075 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia |
| Q65380303 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| Q64662831 | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer |
| Q65541554 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Q64396576 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer |
| Q63815972 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer |
| Q64717835 | Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
| Q66034624 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer |
| Q65375649 | Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
| Q66066821 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia |
| Q66031455 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes |
| Q65475029 | Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
| Q64664055 | Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer |
| Q66035925 | Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery |
| Q66034997 | Combination Chemotherapy in Treating Patients With Colorectal Cancer |
| Q66035419 | Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver |
| Q66033876 | Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer |
| Q66034582 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan |
| Q66036981 | Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas |
| Q66033618 | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer |
| Q66035736 | Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer |
| Q65538369 | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors |
| Q63807824 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
| Q65472985 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma |
| Q65363158 | Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer |
| Q64720221 | Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System |
| Q66037810 | Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma |
| Q63836202 | Combination of Probiotic and Calcium in Healthy Adults |
| Q66071702 | Combined Bleaching Technique: Efficacy and Tooth Sensitivity |
| Q76981540 | Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration |
| Q64647007 | Combined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons |
| Q74285994 | Community Benefit of No-charge Calcium Score Screening Program |
| Q65364297 | Comparative Bioavailability of Two Forms of Vitamin C |
| Q65349246 | Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions |
| Q64816993 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Dyenix) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women |
| Q83805032 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread |
| Q66401627 | Comparison Between Biodentine and Calcium Hydroxide in the Indirect Pulp Treatment on Primary Teeth |
| Q64220742 | Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome |
| Q64604031 | Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring |
| Q63840410 | Comparison of Absorbability Between Calcium Tablet and Calcium Ion Water |
| Q66034869 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer |
| Q65354246 | Comparison of Calcium Channel Blockers and Beta Blockers on Tourniquet-induced Hypertension During Intravenous Regional Anesthesia |
| Q67125520 | Comparison of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism |
| Q64791142 | Comparison of Calcium Phosphate Cement With Patient-specific Implants for Cranial Reconstruction: a Randomized-controlled Trial |
| Q66034662 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer |
| Q63816319 | Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients |
| Q65377791 | Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS) |
| Q63831181 | Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery |
| Q64656410 | Comparison of Oral Sodium Phosphate and Sennoside A+B Calcium Lavage for Colonoscopy Preparation |
| Q64817444 | Comparison of Three Calcium Supplements |
| Q66040699 | Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS |
| Q83794106 | Comparison of the Efficacy of Calcium Hydroxide With Silver Nanoparticle and Conventional Calcium Hydroxide Intra Canal Medications on Post-Operative Pain in Symptomatic Root Canal Treatment Failure Cases: |
| Q64172266 | Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Osteotomies |
| Q65345655 | Consistencies in Responses to Sodium Bicarbonate? |
| Q64602602 | Cornell University-Micronutrient Initiative Calcium Supplementation Study |
| Q67134366 | Coronary Assessment for Mortality Prediction |
| Q66545575 | Coronary Calcium Scoring Versus Standard Care for Emergency Department Chest Pain Patients |
| Q64721731 | Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury |
| Q63835467 | Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia |
| Q64808455 | Creatine Supplementation and Cognitive and Physical Tests |
| Q83795309 | Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization |
| Q64048113 | Cyclic Versus Daily Teriparatide on Bone Mass |
| Q66408862 | Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis |
| Q65347940 | Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome |
| Q64672458 | Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia |
| Q74132980 | Dairy Intervention in People With Obesity |
| Q63818087 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| Q64717762 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| Q76978369 | Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab |
| Q64642840 | Delivery Vehicles for Prenatal Calcium Supplementation |
| Q64350831 | Denosumab China Phase III Study |
| Q66028634 | Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception |
| Q65351197 | Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium for the Calculation of GFR and Validity Compared to the Renal Clearance of Inulin |
| Q66401313 | Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children |
| Q65389625 | Dialysis Clinical Outcomes Revisited (DCOR) Trial |
| Q66401424 | Dietary Calcium Intake in Premenstrual Syndrome |
| Q65380071 | Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy |
| Q65346774 | Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics |
| Q67129587 | Dietary Intake of Salmon and Bone Health |
| Q65396765 | Dietary Intervention Program for Pre-eclampsia in Women at Risk |
| Q64817578 | Direct Pulp Capping With MTA and Calcium Hydroxide. |
| Q64716521 | Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? |
| Q64726534 | Does Omeprazole Decrease Intestinal Calcium Absorption? |
| Q64791269 | Does Preoperative Calcium and Calcitriol Decrease Rates of Post Thyroidectomy Hypocalcemia? |
| Q64726656 | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? |
| Q64647265 | Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation |
| Q64029669 | Dose Effects of SCF on Calcium Metabolism and GI Microflora in Adolescents |
| Q66546719 | Dried Plums and Bone Health in Postmenopausal Women |
| Q66078630 | Drug Delivery Devices for Osteomyelitis |
| Q65545525 | EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) |
| Q64673963 | Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER) |
| Q67124893 | Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium |
| Q83794412 | Early Vascular Adjustments to Prevent Preeclampsia |
| Q66076246 | Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin |
| Q66067546 | Ectoin® Mouth Wash (EML03) in the Prevention and Treatment of Radiation-induced Oral Mucositis |
| Q64651217 | Effect Of Different Lining Materials in Stepwise Excavation |
| Q64217448 | Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People (KnoVIB) |
| Q64697008 | Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment |
| Q64657663 | Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE) |
| Q64610362 | Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide |
| Q65363328 | Effect of Antihypertensive Agents Over Sleep Apnea |
| Q64042145 | Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds |
| Q65349765 | Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption |
| Q65352493 | Effect of Calcium Chloride on Recovery From Neuromuscular Blockade |
| Q64680662 | Effect of Calcium Glycerophosphate (CaGP) - Fluoride Dentifrice on Dental Biofilm pH |
| Q64637555 | Effect of Calcium Plus Vitamin D Supplementation on Adolescent Mother and Infant Bone Health |
| Q63818711 | Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study |
| Q64660509 | Effect of Calcium Supplement Particle Size and Vitamin D Supplement on Calcium Retention in Adolescent Girls |
| Q66062698 | Effect of Calcium and Vitamin D Supplementation With and Without Collagen Peptides in Postmenopausal Women With Osteopenia |
| Q65475182 | Effect of Calcium and Vitamin D on Bone Loss From the Hip |
| Q64717360 | Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers |
| Q64717336 | Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers |
| Q65387549 | Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss. |
| Q66079437 | Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity |
| Q64791812 | Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride Varnish on Remineralization of White Spot Lesion in Primary Teeth |
| Q65334429 | Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women |
| Q66024682 | Effect of Dietary Protein Source on Calcium Metabolism |
| Q63811877 | Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy |
| Q64602172 | Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer |
| Q64662663 | Effect of High-Calcium Milk and Weight-Bearing Exercise on Bone Mineral Status of Pre-Pubertal Girls |
| Q65370944 | Effect of High-calcium Intake on Appetite, Insulinemia and Incretins |
| Q65370356 | Effect of High-calcium Intake on Substrate Metabolism During Exercise |
| Q65379118 | Effect of Increased Intake of Low Fat Dairy Products on Weight Loss and Insulin Resistance |
| Q64655225 | Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy |
| Q64817423 | Effect of Liners on Pulpal Outcome and Restoration Survival After Partial Caries Excavation |
| Q65361693 | Effect of Nutrition on Bone Metabolism as Assessed by 41Ca |
| Q66410929 | Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women |
| Q65370630 | Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol |
| Q64653749 | Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 |
| Q66081145 | Effect of Photodynamic Therapy on Deep Caries in Permanent Tooth,A Controlled Clinical Trial |
| Q83794436 | Effect of Phototherapy on Serum Calcium |
| Q64679200 | Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing |
| Q64699175 | Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy |
| Q64694467 | Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) |
| Q63836187 | Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers |
| Q66080336 | Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents |
| Q65354585 | Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis |
| Q66074121 | Effect of Tri Calcium Phosphate on Efficacy and Sensitivity With Vital Tooth Whitening Using 20% Carbamide Peroxide |
| Q66407537 | Effect of Vinegar Consumption on 24-hour Urinary Risk Factors Associated With Stone Formation |
| Q65537741 | Effect of Vitamin D and Calcium on Genes in the Colon |
| Q65387582 | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss |
| Q67126312 | Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients |
| Q64817537 | Effectiveness of Bioactiveglass Air Abrasion Versus Fluoride Varnish in Management of Dentin Hypersensitivity |
| Q64189450 | Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning |
| Q65384889 | Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT |
| Q65542927 | Effectiveness of Supplemental Calcium in Preventing Postpartum Depression |
| Q64030148 | Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash |
| Q63838207 | Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA) |
| Q64354118 | Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture |
| Q63808337 | Effects of Calcium Supplementation on Women in the Curves for Women Program |
| Q64716111 | Effects of Calcium and Phytate on Zinc Absorption |
| Q66042579 | Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 |
| Q64216549 | Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis |
| Q64396263 | Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus |
| Q65390359 | Effects of Dairy Foods on Adolescent Pregnant Mothers and Their Newborns |
| Q64651220 | Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton |
| Q66074762 | Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis |
| Q66079192 | Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease |
| Q65537947 | Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry |
| Q66402129 | Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People |
| Q66387937 | Effects of Probiotics and Calcium Supplementation on Growth, Development, and Metabolic Parameters |
| Q66402789 | Effects of Sleeve Gastrectomy on Calcium Metabolism and the Skeleton |
| Q64791750 | Effects of Sodium Bicarbonate Supplementation on Intermittent and Intense Task |
| Q64220304 | Effects of Soluble Phosphate in Humans |
| Q64047817 | Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis |
| Q63839357 | Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis |
| Q66347434 | Effects of Two Sugar Substituted Chewing Gums on Caries and Gingivitis Variables |
| Q64363811 | Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals |
| Q65465892 | Effects of Vitamin D and Calcium Supplementation on Health and Well-being of Vitamin D Deficient UAE Citizens |
| Q64029595 | Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients |
| Q63830689 | Effects of Vitamin D in Parkinson's Disease (PD) |
| Q64726857 | Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants |
| Q64151622 | Effects of a Hydroxyapatite-based Mouth Gel on Calcium Content of Plaque |
| Q65375710 | Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon |
| Q64698953 | Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy |
| Q64718042 | Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) |
| Q64673670 | Efficacy and Safety Study of Non-percutaneous Vertebroplasty With Macroporous Calcium Phosphate Cement (MCPC) |
| Q65358006 | Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis |
| Q64722910 | Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) |
| Q74276512 | Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk |
| Q83794181 | Efficacy and Safety of a Citrate-based Anticoagulation With Calcium-free Phosphate-containing Fluid in Renal Replacement Therapy |
| Q66343958 | Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients |
| Q64609221 | Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial |
| Q64789797 | Efficacy of Chlorhexidine as a Final Irrigant in Single-visit Root Canal Treatment |
| Q74275646 | Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging |
| Q66546653 | Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia |
| Q83804496 | Efficacy of Silver Diamine Fluoride and Its Parental Perception |
| Q65375778 | Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients |
| Q64349269 | Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV |
| Q65347142 | Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture |
| Q66346070 | Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation |
| Q64642634 | Encapsulated Calcium Absorption in Pregnancy |
| Q66059473 | Encouraging Calcium Absorption and Bone Formation During Early Puberty |
| Q65370221 | Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy |
| Q66044316 | Energy for the Brain |
| Q66033021 | Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer |
| Q65537423 | Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood |
| Q64806248 | Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain |
| Q66074089 | Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled |
| Q64599165 | Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria |
| Q66345862 | Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium |
| Q64607756 | Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya |
| Q66041459 | Evaluation of CPP-ACP Prophylactic Effect on Enamel Surface During Orthodontic Treatment |
| Q66409849 | Evaluation of Calcium and Vitamin D Supplementation During Marine Corps Training |
| Q65332487 | Evaluation of Micropore"s SpiraLith Absorbents |
| Q64790421 | Evaluation of Platelet Rich Fibrin / Biphasic Calcium Phosphate Effect Versus Autogenous Bone Graft on Reconstruction of Alveolar Cleft |
| Q66072410 | Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy |
| Q65333123 | Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes |
| Q65544521 | Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects |
| Q64724298 | Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment |
| Q66034088 | Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer |
| Q64640909 | Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity |
| Q65368434 | Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity |
| Q64599721 | Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC) |
| Q65339647 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer |
| Q66083748 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer |
| Q64665382 | Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes |
| Q66393039 | Fixed vs Free Dose of ACEi/CCB Combination Therapy |
| Q66036343 | Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer |
| Q66031428 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer |
| Q66078104 | Focused Field of View Calcium Scoring Prior to Coronary CT Angiography |
| Q64665761 | Folate Absorption Across the Large Intestine |
| Q66083932 | Fracture Healing Assessed by HR-pQCT After Administration of Calcium and Vitamin D |
| Q65536254 | Fructooligosaccharide and Calcium Absorption in Adolescent Girls |
| Q64600827 | Functional Effect of Treatment of Glottic Insufficiency With Calcium Hydroxyapatite |
| Q66410777 | Functional Yogurt Powder Effect on Bone Health Biomarkers |
| Q64221399 | GAit, MEmory, Dietary and Vitamin D |
| Q66408939 | Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis |
| Q63817000 | Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls |
| Q66037599 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer |
| Q66395608 | Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages |
| Q65350674 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer |
| Q65348561 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer |
| Q64808264 | Genetic Screening and Assisted Oocyte Activation in Couples With Diminished/Aberrant Embryonic Development. |
| Q64189298 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies |
| Q63845115 | Glucocorticoid Induced Whole Body Catabolisme |
| Q64715651 | Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis |
| Q65363449 | Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet |
| Q64150122 | Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT |
| Q64608006 | Heartland Osteoporosis Prevention Study |
| Q64666246 | Heparin for Pregnant Women With Thrombophilia |
| Q65388511 | Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection |
| Q65381470 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver |
| Q65541507 | High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status |
| Q63807103 | High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART |
| Q64651471 | High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer |
| Q63843344 | How Does Magnesium Status Influence Calcium Homeostasis? |
| Q65403083 | How Much Reliable iv Calcium for the Treatment of Hyperkalemia? |
| Q65372494 | Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants |
| Q66043144 | Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period. |
| Q66042027 | Hyperphosphatemia in Children With Chronic Kidney Disease |
| Q64808249 | Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) |
| Q63816872 | IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction |
| Q63844375 | IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer |
| Q74271824 | Ileostomy Observation Study |
| Q66076304 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
| Q64353590 | Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle |
| Q64641330 | Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation |
| Q65539958 | Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) |
| Q74276432 | Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome |
| Q63818778 | Impact of Vitamin D on Diabetic Kidney Disease in African Americans |
| Q64048263 | Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® |
| Q65353525 | Improving Bone Health in Adolescence Through Targeted Behavioral Intervention |
| Q66072151 | Improving Function,Welfare of Late-stage Cancer Subjects by ACC |
| Q64598263 | Increasing Calcium Dietary Intake Helps to Control Blood Presure and Body Weight |
| Q64217075 | Increasing Household Purchase and Child Consumption of Calcium Products |
| Q66071172 | Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments in Retreatment Cases |
| Q64803153 | Influence of Temporary Filling Material Composition on the Success Rate of Endodontic Treatments |
| Q64697190 | Influence of Vitamin-B-complex on Cognitive Ability of Kindergarten Kids |
| Q63817056 | Injectable Filler for Cheek Flattening |
| Q64151264 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy |
| Q66038280 | Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers |
| Q64376131 | Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers |
| Q65351618 | Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro |
| Q64710022 | Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women |
| Q66396578 | Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC |
| Q63818612 | Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafoli |
| Q63818614 | Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Me |
| Q64351988 | Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. |
| Q66398211 | Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass |
| Q66081470 | Ionized Calcium and Behavioural Disorders in Older Adults (CALICO Study) |
| Q66037742 | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
| Q65318304 | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer |
| Q64654527 | Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer |
| Q66037074 | Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer |
| Q66034065 | Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
| Q65353721 | Isoflavone Treatment for Postmenopausal Osteopenia. |
| Q65542239 | Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women |
| Q64602805 | Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia |
| Q64643514 | Levothyroxine for Children With Euthyroid Sick Syndrome |
| Q64350106 | Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations |
| Q66039709 | Lipitor as a Treatment for Alzheimer's Disease |
| Q64789787 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer |
| Q63812675 | Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
| Q66065628 | Lithothamnion Species on Blood Lactate During Exhaustive Exercise in Trained Cyclists |
| Q66038446 | Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer |
| Q63838901 | Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients |
| Q65542956 | Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency |
| Q64047529 | Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism |
| Q65349770 | Low Dose Calcium to Prevent Preeclampsia |
| Q64692954 | Low Salt Diet in Idiopathic Hypercalciuria |
| Q64657291 | Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome |
| Q66043681 | Lung Function in Patients With Early Type 2 Diabetes Mellitus |
| Q65539152 | MBCP Safety and Performance in the Osteonecrosis of Femur Head |
| Q64348893 | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer |
| Q64661801 | MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) |
| Q66039582 | MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis |
| Q64794267 | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) |
| Q64171151 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer |
| Q65347645 | Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial |
| Q67124989 | Mandibular Furcation II Regeneration |
| Q67124987 | Mandibular Furcation III Regeneration (FURC-III-REGEN) |
| Q66047184 | Mature Vinegar Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis |
| Q83793872 | Maxillary Sinus Lift With and Without Self-hardening Biphasic Calcium Phosphate. |
| Q64042826 | Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically? |
| Q66408859 | Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients |
| Q64722404 | Micronutrients and Child Health Study |
| Q64718149 | Milk Supplementation and Energy Balance. |
| Q64172170 | ModificatiOn and Treatment of stenoseD Calcified inFrainguinal Lesions With Laser atherectomY in a Pilot Study |
| Q74276985 | Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism |
| Q66036992 | Monoclonal Antibody Therapy in Treating Patients With Leukemia |
| Q65538337 | Multi Detector-Row Computed Tomography (MDCT) Calcium Score of Heart Transplanted Patients |
| Q64708979 | Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection |
| Q65334932 | Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration |
| Q83806484 | NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure |
| Q63818287 | Nephrolithiasis Prevention by Lemon Juice |
| Q66077884 | New Transporting Solution in Parathyroid Allotransplantation |
| Q66399778 | Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia |
| Q65392755 | Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium |
| Q66040021 | Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women |
| Q66065293 | Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer |
| Q64788756 | Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy |
| Q66063585 | Novel Combination Therapy for Osteoporosis in Men |
| Q64710013 | Nursing-Home Residents Given Bread Fortified With Vitamin D3 |
| Q65335578 | Nutrient Support to Body Composition and Healthy Ageing |
| Q79112154 | Nutrition Education to Promote Calcium Intake Among 30-65 Year-old Women in Vietnam |
| Q64791207 | Nutritional Interventional in Pediatric Patients With Osteogenesis Imperfecta |
| Q64724531 | Nutritional Supplements on Blood Pressure 2008 |
| Q63830614 | ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution |
| Q64724989 | OSTPRE-Fracture Prevention Study |
| Q64664063 | Olfactory Dysfunction of Rhinosinusitis - Cyclic Adenosine Monophosphate (cAMP)/Calcium Signaling Study |
| Q66029823 | OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study |
| Q80365608 | Omega-3 PUFA in Prevention of Cardiovascular and Metabolic Diseases (CARDMET3) |
| Q66071500 | Opioid Induced Gait Variability |
| Q64625937 | Optimal Anemia Treatment in End Stage Renal Disease (ERSD) |
| Q64819082 | Oral Calcium in Pregnant Women With Hypertension |
| Q65376589 | Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity |
| Q65465900 | Oral Hygiene Regimen in Patients on HCT |
| Q64683782 | Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects |
| Q65544166 | Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects |
| Q65383960 | Osteoporosis Prevention With Low Dose Alendronate |
| Q64718480 | Osteoporosis and Dental Implant |
| Q63835490 | Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients |
| Q63808123 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer |
| Q64803285 | PLGA-coated Biphasic Calcium Phosphate in Sinus Lift |
| Q64819377 | PRebiotic to IMprovE Calcium Absorption |
| Q66408812 | PTH And Calcium Responses to Exercise (PACE) in Older Adults |
| Q64188968 | PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2) |
| Q65475280 | Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation |
| Q64364070 | Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC). |
| Q63813721 | Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer |
| Q64678531 | Partial Removal of Caries Dentines |
| Q76979304 | Patient Compliance for Metabolic Evaluation and Medical Management in Calcium Stone Patients |
| Q66034162 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed |
| Q66402678 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia |
| Q65465740 | Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients |
| Q76981562 | Perspectives on CPPD Outcome Domains |
| Q64680110 | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer |
| Q64621657 | Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin |
| Q64789429 | Phase 2 Dose-finding IMU-838 for Ulcerative Colitis |
| Q64642756 | Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100" |
| Q64599928 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer |
| Q64837080 | Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects |
| Q66033669 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
| Q64151406 | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer |
| Q66546363 | Photodynamic Therapy in Endodontic Treatment |
| Q66061541 | Physical Activity, Calcium, and Bone in Children |
| Q64395591 | Pilot Study of Orphenadrine` in the Treatment of Muscle Cramps in Patients With Cirrhosis |
| Q64607206 | Pilot Study of Partial Enteral Nutrition With a Unique Diet for the Treatment of Adult Patients With Crohn's Disease |
| Q64793802 | Plaque Calcium Characterization and Ruptured Plaques |
| Q66070044 | Plasma Concentrations of Calcium, Phosphate, FGF23, Klotho, 25 (OH) D3 and 1,25 (OH) 2D3 From Patients Who Wants to Have Children |
| Q63830684 | Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial |
| Q66076031 | Post Operative Pain and Level of Endotoxins With Calcium Hydroxide and Calcium Hydroxide Mixed With Chlorhexidine in Treating Necrotic Teeth |
| Q65475053 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer |
| Q66074492 | Postoperative Pain in Single-visit and Multiple-visit Retreatment Cases |
| Q64677170 | Postprandial Effects of Milk and Milk Constituents |
| Q66409889 | Predictors of Coronary Artery Calcium Progression in Adults With a Prior Zero Coronary Artery Calcium Score |
| Q67133076 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study |
| Q80366861 | Preoperative Hypocalcaemia, a Comparative Clinical Trial |
| Q66044332 | Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus |
| Q66405659 | Preventing Osteoporosis Using Denosumab |
| Q64222391 | Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation |
| Q66064268 | Prevention of Enamel Demineralization Using CPP-ACP-NaF Varnish |
| Q65378466 | Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection |
| Q64677848 | Prevention of Myopia of Prematurity by Calcium Supplementation |
| Q64694425 | Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients |
| Q65470425 | Prevention of Osteoporosis in Breast Cancer Survivors |
| Q64664829 | Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium) |
| Q64699004 | Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery? |
| Q64693249 | Processed Meat and Colon Carcinogenesis |
| Q66035888 | Program to Prevent Osteoporosis in Girls |
| Q64375897 | Prolonged Gadolinium Retention After MRI Imaging |
| Q64659399 | Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn |
| Q65542298 | Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery |
| Q66066320 | Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors. |
| Q64172381 | Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study |
| Q64187284 | Psychological Impact of Amenorrhea in Women With Endometriosis |
| Q64697069 | Pulp Capping With Two Different Agents |
| Q64791717 | Pulpotomy Technique Preserving Vitality of Traumatized Anterior Permanent Immature Teeth |
| Q66062068 | Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis |
| Q66045064 | QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer |
| Q66068382 | Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism |
| Q76980418 | RADIESSE Injection in Perioral and Marionette Lines |
| Q76983078 | RANKL Inhibition and Mammographic Breast Density |
| Q66403733 | RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints |
| Q65389952 | Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer |
| Q80365287 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers |
| Q64040794 | Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis |
| Q66062531 | Regenerative Treatment of Traumatized Immature Permanent Incisors With Pulp Necrosis |
| Q64794725 | Regional Anticoagulation of Dialysis Circuits With a Calcium-free Citrate-containing Dialysate |
| Q65379805 | Regulation of Bone Formation in Renal Osteodystrophy |
| Q63816521 | Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism |
| Q74277836 | Remineralization Effect of Fluoride Varnishes on Permanent Molars |
| Q66065903 | Reminerlization Potential of GSE Gel versusCPP-ACP in Carious White Spot Lesions in Post Orthodontic Patients |
| Q66024418 | Renal Artery Calcium and Hypertension |
| Q64598946 | Renal Effects of Mediterranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD |
| Q65373868 | Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology |
| Q63812217 | Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD) |
| Q64649372 | Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers |
| Q63818547 | Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease |
| Q66037358 | Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer |
| Q66080846 | Risk Reduction for Alzheimer's Disease |
| Q64652731 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma |
| Q65386387 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma |
| Q65347048 | Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium |
| Q64638822 | Rosuvastatin Calcium Bioequivalence Study - Fast |
| Q64150325 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia |
| Q64648868 | S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma |
| Q64353392 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
| Q66032857 | S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed |
| Q66033748 | S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer |
| Q65384366 | SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture. |
| Q64140135 | STOP Heart Disease in Breast Cancer Survivors Trial |
| Q64676696 | Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents |
| Q65386130 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone |
| Q65349888 | Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma |
| Q65539712 | Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis |
| Q65369400 | Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants |
| Q65470296 | Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis |
| Q64187799 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) |
| Q79111697 | Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli |
| Q65473616 | Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis |
| Q66070137 | Safinamide Steady State Interaction With Rosuvastatin |
| Q64717693 | Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab |
| Q64123270 | Selinexor With Multiple Standard Chemotherapy Regimens in Treating Patients With Advanced Malignancies |
| Q64396504 | Serum Vitamin D Levels in Critically Ill Patients Undergoing Regional Citrate Anticoagulation CRRT |
| Q64836681 | Serum iPTH, Calcium and Phosphate, and the Risk of Mortality in Beijing Elderly Hemodialysis Population |
| Q64657491 | Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease |
| Q63833950 | Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) |
| Q64354875 | Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy |
| Q65397726 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer |
| Q63840943 | Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers. |
| Q64792005 | Soluble Corn Fiber on BMD in Pre-pubertal Boys and Girls (PREBONE-Kids) |
| Q63811736 | Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer |
| Q65544601 | Soy Protein and Breast Cancer Risk Reduction |
| Q63832521 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer |
| Q66046569 | Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk |
| Q64042758 | Statin Therapy for Ischemic and Nonischemic Cardiomyopathy |
| Q64661638 | Statin and Atheroma Vulnerability Evaluation |
| Q65362585 | Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center |
| Q63841160 | Stem Cell Recruitment in Osteoporosis Therapy |
| Q64048237 | Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus |
| Q64349406 | Stop Community MRSA Colonization Among Patients |
| Q64716413 | Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD |
| Q65368114 | Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) |
| Q64716603 | Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin |
| Q67128702 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer |
| Q66029665 | Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density |
| Q64642467 | Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer |
| Q67133984 | Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence |
| Q65378737 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium |
| Q65382250 | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) |
| Q64223003 | Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer |
| Q66407176 | Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy AND MK-4280A as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) |
| Q64725292 | Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer |
| Q66342794 | Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program |
| Q80366027 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) |
| Q65546037 | Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis |
| Q64623287 | Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception |
| Q64649223 | Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients |
| Q65377015 | Study of Vitamin D Supplementation to Male HIV Sero-positive Patients |
| Q64396440 | Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis |
| Q65351839 | Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders |
| Q64656309 | Study of the Effect of a Calcium-rich Diet on Bone Health in Girls |
| Q66395075 | Study of the Influence of Dosages of 1-84 and 7-84 Fragments of Parathyroid Hormone Compared to Conventional Dosage on the Balance of Calcium and Phosphate in Hemodialysis (PTH) |
| Q66083189 | Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years |
| Q64720334 | Study of the Osteoprotector Effects of a Milk Product Based on Anthocyans and Enriched in Calcium and Vitamin D |
| Q66062019 | Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects |
| Q64139466 | Study on the Predictive Value of the Natural Calcium Isotope Ratio in Urine and Serum for the Diagnosis of Osteoporosis |
| Q64350441 | Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism. |
| Q66403512 | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism |
| Q64655441 | Study to Determine How Exercise and Calcium Affect Pubertal Bone |
| Q64718146 | Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) |
| Q66033946 | Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium |
| Q65537431 | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. |
| Q66084129 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors |
| Q66027496 | Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women |
| Q63830608 | Study to Observe the Capability to Absorb Calcium as an Measure of Adequate Levels of Vitamin D |
| Q66028934 | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors |
| Q63842439 | Successful Pregnancy and Delivery After AOA |
| Q65355810 | Sulphate-bicarbonate-calcium Water, Body Weight and Gut Microbiota |
| Q64139502 | Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments |
| Q66039296 | Supplemental Calcium in Overweight People |
| Q65469660 | Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA |
| Q64349434 | Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients |
| Q67125717 | Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms |
| Q66036770 | Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer |
| Q66065164 | Survival Benefits of Statins in Breast Cancer Patients |
| Q66034890 | Survival TRaining for ENhancing Total Health (STRENGTH) |
| Q63837740 | Swiss Study on Vitamin D and Calcium in Nursing Homes |
| Q64220687 | Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women |
| Q63817561 | Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate |
| Q64716038 | Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer |
| Q64720723 | Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery |
| Q64722394 | Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia |
| Q63807354 | Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial |
| Q64655433 | Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis |
| Q66029613 | Texture Analysis for Postmenopausal Osteoporosis |
| Q64352073 | The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake |
| Q64805051 | The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH |
| Q63841867 | The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement |
| Q64792663 | The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism |
| Q66396107 | The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) |
| Q64185571 | The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations |
| Q66036231 | The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients |
| Q64395128 | The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis |
| Q66410670 | The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT |
| Q65471521 | The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure |
| Q65381418 | The Effect of Calcium and Vitamin D in Patients With Heart Failure |
| Q65382768 | The Effect of Calcium on Fecal Fat and Energy Excretion |
| Q65383826 | The Effect of Calcium on Postprandial Lipid Profile and Appetite |
| Q63813100 | The Effect of Chymosin on the Intestinal Absorption of Calcium |
| Q64375787 | The Effect of Different Lining Strategies on Amalgam Restorations |
| Q65365957 | The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 |
| Q67127028 | The Effect of Laser Combined With Pulp-capping Agents on Direct Pulp Capping |
| Q64717964 | The Effect of Protein on Calcium Absorption and Gastric Acid Production |
| Q63832962 | The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism |
| Q66044182 | The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA |
| Q65383317 | The Effect of Vitamin D Supplementation During Caloric Restriction on Intestinal Calcium Absorption |
| Q66342948 | The Effect of Vitamin D Supplementation in Type 2 Diabetes |
| Q65376836 | The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study |
| Q64716969 | The Effect of Vitamin D and Calcium on Bone in Pediatric HIV |
| Q64665188 | The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium |
| Q64796331 | The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia |
| Q65343801 | The Effects and Safety of Low Calcium Dialysis on Coronary Artery Calcification in Maintenance Hemodialysis Patients |
| Q64653429 | The Effects of Dairy Products on Energy Balance |
| Q66343387 | The Effects of Different Dialysate Calcium Concentration |
| Q66073494 | The Effects of Intravenous Fluids on Perfusion Index and Pleth Variability Index |
| Q64709045 | The Effects of Potassium on Physiological and Cardiovascular Variables in Healthy Persons |
| Q66404232 | The Effects of Probiotic and HMB Supplementation on Immune and Digestive Function in Special Operations Soldiers |
| Q64676695 | The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension |
| Q63816898 | The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring |
| Q66344085 | The Effects of the Food Preservative Propionic Acid in Post-prandial Metabolism |
| Q64393743 | The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome |
| Q65343858 | The Efficacy of Venavine Intensive® on the Quality of Life in Females With Chronic Venous Insufficiency |
| Q64621183 | The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis |
| Q64040404 | The Evaluation of Cow's Milk Formula - Study B |
| Q66068509 | The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo |
| Q66409597 | The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork |
| Q65390037 | The FREEDOM Study: a Randomised Controlled Trial of Sunlight and Calcium in Older People |
| Q63816476 | The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery |
| Q66062433 | The Impact of a Low or High Phosphate Diet on Phosphate and Calcium Excretion in Healthy People |
| Q66071477 | The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, C |
| Q66071481 | The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. |
| Q64714589 | The Interaction Between Calcium and Vitamin D Intake |
| Q64724924 | The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) |
| Q63815457 | The Jetstream G3™ Calcium Study |
| Q64397581 | The Relationship Between Ca Intake , Blood Level of Ca, PTH, TSH, Vitamin D, and Urine Ca, P and Cardiac Calcium Scoring |
| Q64817253 | The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis |
| Q74132560 | The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression |
| Q64608010 | The Role of Vitamin D in Female Reproductive Tract Immunity |
| Q65346380 | The Role of Vitamin D3 and Calcium Supplementation in Attenuating T2DM Severity |
| Q64795320 | The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. |
| Q64336222 | The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid |
| Q66404362 | The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) |
| Q64793813 | The Use of D5LR Versus LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores |
| Q64717082 | Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study |
| Q66027301 | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I |
| Q64722024 | Third Year Evaluation on Genistein Efficacy and Safety |
| Q66395896 | Tin Filter Calcium Scoring |
| Q74132828 | To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions |
| Q63807022 | To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension |
| Q66393750 | To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH) |
| Q64657448 | To Investigate the Role of Upstream High Dose Statin in STEMI |
| Q64795017 | To Study the Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare Improvement in Late-stage Solid Cancer Subjects |
| Q64790735 | Tocolysis in Prevention of Preterm Labor |
| Q66344712 | Tolerance of Two Forms of Vitamin C in Acid-sensitive Adults |
| Q64396490 | Tooth Bleaching for Young Patients Using a Hydrogen Peroxide-based Gel |
| Q65331709 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I |
| Q64348820 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery |
| Q66059523 | Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients |
| Q63839006 | Treatment for Calcium Phosphate Kidney Stone Disease |
| Q66061527 | Treatment of Calcium Deficiency in Young Women |
| Q66071006 | Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss |
| Q66024867 | Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker |
| Q66061371 | Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 |
| Q66070023 | Treatment of Postorthodontic White Spot Lesions |
| Q65365186 | Treatment of Root Caries in an Older Irish Population. |
| Q67124891 | Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism |
| Q64223165 | Treatments of the Necrosed Immature Teeth (REV) |
| Q66044821 | Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis |
| Q66040698 | Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS |
| Q66036839 | Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer |
| Q66073057 | University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation |
| Q64680969 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer |
| Q64796447 | Use of FFR-CT in Stable Intermediate Chest Pain Patients With Severe Coronary Calcium Score |
| Q64672078 | Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients |
| Q63835094 | Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures |
| Q64171573 | Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia |
| Q64395277 | Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis |
| Q63834464 | Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers |
| Q64639306 | VERtebral Fracture Treatment Comparisons in Osteoporotic Women |
| Q64614157 | Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) |
| Q66409786 | Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis |
| Q63807812 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
| Q74282215 | Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD). |
| Q64664098 | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
| Q65376494 | Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis |
| Q63812740 | Vitamin D HIV Study on Postmenopausal Women |
| Q66043814 | Vitamin D Level vs Semen Parameters |
| Q64801826 | Vitamin D Status in Inflammatory Bowel Disease |
| Q63832173 | Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption |
| Q64662808 | Vitamin D Supplementation After Parathyroid Surgery |
| Q63813902 | Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial |
| Q63829185 | Vitamin D Supplementation and Physical Function in Older Adults |
| Q65383293 | Vitamin D Supplementation in Older Women |
| Q64720400 | Vitamin D Supplementation in Younger Women |
| Q64350239 | Vitamin D Treatment and Hypocalcemic Pregnant Women |
| Q65383390 | Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes |
| Q65536560 | Vitamin D and Calcium Study |
| Q66545771 | Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz |
| Q64665102 | Vitamin D and Genetics in Nutritional Rickets |
| Q64652773 | Vitamin D and Muscle Strength and Surface (Electromyography) EMG |
| Q66393868 | Vitamin D and Physical Performance Before and After Intervention and Birth Outcome in Pregnant Somali and Swedish Women |
| Q64717281 | Vitamin D, Insulin Resistance, and Cardiovascular Disease |
| Q66027964 | Vitamin D/Calcium Polyp Prevention Study |
| Q74280180 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer |
| Q64151079 | Vitamin K2 for Reduction the Calcium at Carotid Bifurcation in Patients With Subcritical Lesions |
| Q65396730 | Vitamin Supplementation After Bariatric Surgery |
| Q64665680 | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment |
| Q65360572 | Young Adults With Life Threatening Cow's Milk Allergy: Risks of Decrease Bone Mineralization and Methods of Calcium Supplementation |
| Q66035853 | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer |
| Q64603134 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer |
| Q65390905 | Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy |
| Q66034703 | Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases |
| Q66036838 | Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer |
| Q65380174 | Zoledronic Acid for Osteoporosis in the Elderly |
| Q64217200 | Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) |
| Q63832891 | Zoledronic Acid in MS-patients With Osteoporosis |
| Q65390072 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant |
| Q63841264 | Zometa Study in Pediatric Acute Lymphoblastic Leukemia |
| Q66073969 | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA |
| Q64336200 | to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia |
| Q74502525 | 'Bad dietary habits' and recurrent calcium oxalate nephrolithiasis |
| Q41678360 | *calcium-oxalate lithogenesis: crystallization in the presence of urine from healthy subjects |
| Q32061732 | 14C-oxalate autoradiographic studies on distribution of oxalate and calcium oxalate crystal fixation in rat kidney |
| Q70938598 | 14COxalate absorption by normal persons, calcium oxalate stone formers, and patients with surgically disturbed intestinal function |
| Q58789394 | A Case of Chronic Calcium Oxalate Nephropathy due to Short Bowel Syndrome and Cholecystectomy |
| Q42214511 | A Case of Randall's Plugs Associated to Calcium Oxalate Dihydrate Calculi. |
| Q52434187 | A Method for Discrimination Between Calcium Oxalate Kidney Stone Formers and Normals |
| Q68295225 | A New Approach to the Study of Urinary Macromolecules as a Participant in Calcium Oxalate Crystallization |
| Q71750962 | A New Histochemical Method for the Demonstration of Calcium Oxalate in Tissues Following Ethylene Glycol Poisoning |
| Q64234806 | A Retrospective Study of Kidney Stone Recurrence in Adults |
| Q42673951 | A cationic protein from a urate-calcium oxalate stone: isolation and purification of a shared protein. |
| Q71135754 | A comparative study between etiological factors of calcium oxalate monohydrate and calcium oxalate dihydrate urolithiasis |
| Q38474256 | A comparative study of experimental rat models of renal calcium oxalate stone formation |
| Q79720514 | A comparative study of methods for precipitating calcium oxalate from homogeneous solution |
| Q80059490 | A comparative study on several models of experimental renal calcium oxalate stones formation in rats |
| Q33987255 | A comparison of the binding of urinary calcium oxalate monohydrate and dihydrate crystals to human kidney cells in urine. |
| Q68242190 | A contribution to the formation mechanism of calcium oxalate urinary calculi. I. Stabilising urinary constituents in the formation of weddellite |
| Q39138337 | A contribution to the formation mechanism of calcium oxalate urinary calculi. II. In vitro experiments concerning the theory of the formation of Whewellite and Weddellite urinary calculi |
| Q39138343 | A contribution to the formation mechanism of calcium oxalate urinary calculi. III. On the role of magnesium in the formation of oxalate calculi |
| Q66968814 | A contribution to the formation mechanism of calcium oxalate urinary calculi. IV. Experimental investigations of the intrarenal crystallisation of calcium oxalate in rabbit |
| Q69768448 | A critical evaluation of the urinary inhibiting activity in idiopathic calcium oxalate nephrolithiasis |
| Q36283994 | A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall's plaque. |
| Q73022334 | A new approach to calculate the risk of calcium oxalate crystallization from unprepared native urine |
| Q42288894 | A new approach to studying inhibitors of calcium oxalate crystal growth. |
| Q60451178 | A new differential method for determining orders and rates of reactions and its application to solid state reactions. Oart II. some empirical observations on the isothermal dehydration of calcium oxalate monohydrate |
| Q46419423 | A new era in the treatment of calcium oxalate stones? |
| Q71305972 | A new procedure to evaluate the inhibitory capacity of calcium oxalate crystallization in whole urine |
| Q44630762 | A new spectrophotometric method for measuring calcium oxalate monohydrate crystal aggregation in the absence of supersaturation: inhibitory effects of urinary glycoproteins. |
| Q42162890 | A non-classical view on calcium oxalate precipitation and the role of citrate |
| Q44584910 | A novel assay to evaluate promoting effects of proteins on calcium oxalate crystal invasion through extracellular matrix based on plasminogen/plasmin activity |
| Q31404964 | A novel basic protein from human kidney which inhibits calcium oxalate crystal growth |
| Q33458479 | A novel calcium oxalate crystal growth inhibitory protein from the seeds of Dolichos biflorus (L.). |
| Q69984798 | A one-compartment model for calcium oxalate tissue deposition during xylitol infusions in humans |
| Q44758762 | A porcine model of calcium oxalate kidney stone disease |
| Q71491190 | A preliminary laboratory investigation of "niao shi mixture" in preventing experimental calcium oxalate renal calculus in rats |
| Q50966953 | A quantitative investigation of the effects on the growth of calcium oxalate crystals on potential inhibitors. |
| Q47321941 | A reappraisal of the coulter counter technique for measuring calcium oxalate crystal size |
| Q40449177 | A retrospective study of the prevalence of calcium oxalate crystals in veterinary Aspergillus cases. |
| Q40277098 | A review of possible roles of urates in calcium oxalate urolithiasis |
| Q71583867 | A simple diagnostic method for the differentiation of Tamm-Horsfall glycoproteins from healthy probands and those from recurrent calcium oxalate renal stone formers |
| Q74462161 | A simple method for quantitating the propensity for calcium oxalate crystallization in urine |
| Q67755268 | A simple method for studying the formation of calcium oxalate |
| Q52702224 | A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. |
| Q74429063 | A stable animal model of diet-induced calcium oxalate crystalluria |
| Q44629043 | A stone farm: development of a method for simultaneous production of multiple calcium oxalate stones in vitro |
| Q69467337 | A study of crystalluria in calcium oxalate stone patients treated with thiazides |
| Q67581659 | A study of inhibitory effect of chondroitin polysulfate on stone formation of calcium oxalate |
| Q41497139 | A study of the phase transformation of calcium oxalate trihydrate-monohydrate |
| Q44465166 | A study of the risk factors in calcium oxalate stone formation--simple method for measuring metastable limits by the microplate method |
| Q46582325 | A study on calcium oxalate crystals in Tinantia anomala (Commelinaceae) with special reference to ultrastructural changes during anther development |
| Q71289270 | A study on calcium oxalate monohydrate renal uroliths. II. Fine inner structure |
| Q45353027 | A survey of the effect of some drugs, chemicals, and enzymes on calcium oxalate precipitation in the rat kidney |
| Q37439745 | A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. |
| Q46880865 | A traditional Chinese herbal antilithic formula, Wulingsan, effectively prevents the renal deposition of calcium oxalate crystal in ethylene glycol-fed rats |
| Q46632224 | AB152. Analysis of altered microRNA expression profile in calcium oxalate stone formation. |
| Q41581638 | Abnormalities in the erythrocyte membrane transport of oxalate in calcium oxalate lithogenesis |
| Q44010458 | Abnormalities of oxalate metabolism and urinary lithiasis. IV. Studies on the amount of oxalic acid excreted from calcium oxalate stone patients (author's transl) |
| Q77897138 | Absorption of calcium oxalate does not require dissociation in rats |
| Q36935489 | Acidic polyanion poly(acrylic acid) prevents calcium oxalate crystal deposition |
| Q35528594 | Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys |
| Q43120549 | Activity and expression of vitamin K-dependent gamma-glutamyl carboxylase in patients with calcium oxalate urolithiasis |
| Q78052968 | Acute effects of calcium sodium citrate supplementation of a test meal on mineral homeostasis, oxalate, and calcium oxalate crystallization in the urine of healthy humans--preliminary results in patients with idiopathic calcium urolithiasis |
| Q67724500 | Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis |
| Q77546814 | Adhesion and endocytosis of calcium oxalate crystals on renal tubular cells |
| Q33722896 | Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents |
| Q44344821 | Adhesion between molecules and calcium oxalate crystals: critical interactions in kidney stone formation |
| Q40283254 | Adhesion force between calcium oxalate monohydrate crystal and kidney epithelial cells and possible relevance for kidney stone formation |
| Q41388917 | Adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells and some effects of glycosaminoglycans or cell injuries |
| Q42818505 | Adhesion of calcium oxalate monohydrate crystals to anionic sites on the surface of renal epithelial cells |
| Q41353628 | Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions |
| Q41082752 | Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells |
| Q40893025 | Adsorption characteristics of amino acids on to calcium oxalate |
| Q49377236 | Adsorption of ethylenediaminetetraacetic dianhydride modified oxalate decarboxylase on calcium oxalate |
| Q39417694 | Adsorption of naturally occurring polymers onto calcium oxalate crystal surfaces |
| Q73943167 | Advantage of zero-crossing-point first-derivative spectrophotometry for the quantification of calcium oxalate crystalline phases by infrared spectrophotometry |
| Q69467248 | Age and sex as factors in oxalic acid excretion in healthy persons and calcium oxalate stone patients |
| Q47690043 | Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers |
| Q67573027 | Agglomeration of calcium oxalate monohydrate in synthetic urine |
| Q77096965 | Aggregation During Precipitation from Solution. A Pore Diffusion-Reaction Model for Calcium Oxalate Monohydrate |
| Q44264965 | Aggregation and dispersion characteristics of calcium oxalate monohydrate: effect of urinary species |
| Q39146435 | Aggregation of calcium oxalate crystals: Effect of urine and various inhibitors |
| Q84089975 | Aggregation of freshly precipitated calcium oxalate crystals in urine of calcium stone patients and controls |
| Q39529409 | Alarm Photosynthesis: Calcium Oxalate Crystals as an Internal CO2 Source in Plants. |
| Q68516268 | Alkali citrate for preventing recurrence of calcium oxalate stones |
| Q72495587 | Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study |
| Q68684671 | Alkaline citrate in prevention of recurrent calcium oxalate stones |
| Q67867519 | Alkalinizing treatment as a preventative of recurrent calcium oxalate lithiasis |
| Q58096103 | Allicin attenuates calcium oxalate crystal deposition in the rat kidney by regulating gap junction function |
| Q69893276 | Allopurinol for calcium oxalate stones? |
| Q69000166 | Allopurinol for the prevention of calcium oxalate calculi |
| Q41554565 | Allopurinol in the prevention of calcium oxalate renal stones. Preliminary results |
| Q67549269 | Allopurinol in the recurrence prevention of calcium oxalate lithiasis |
| Q78167844 | Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers |
| Q37379491 | Alpha-enolase on apical surface of renal tubular epithelial cells serves as a calcium oxalate crystal receptor |
| Q41336750 | Alterations in MDCK and LLC-PK1 cells exposed to oxalate and calcium oxalate monohydrate crystals. |
| Q69023775 | Alterations in RBC lactate dehydrogenase isoenzyme pattern in calcium oxalate stone formers |
| Q71765289 | Alterations in circadian rhythmicity in calcium oxalate renal stone formers |
| Q39129971 | Alterations in macrophage cellular proteome induced by calcium oxalate crystals: the association of HSP90 and F-actin is important for phagosome formation |
| Q39985015 | Altered proteins in MDCK renal tubular cells in response to calcium oxalate dihydrate crystal adhesion: a proteomics approach |
| Q36426105 | Aluminum citrate prevents renal injury from calcium oxalate crystal deposition |
| Q28550565 | An Assessment of Engineered Calcium Oxalate Crystal Formation on Plant Growth and Development as a Step toward Evaluating Its Use to Enhance Plant Defense |
| Q35930613 | An Oxalyl-CoA Dependent Pathway of Oxalate Catabolism Plays a Role in Regulating Calcium Oxalate Crystal Accumulation and Defending against Oxalate-Secreting Phytopathogens in Medicago truncatula |
| Q40530146 | An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells |
| Q46823540 | An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor |
| Q44632460 | An approximate estimate of the ion-activity product of calcium oxalate in rat urine |
| Q44757417 | An architectural study of mixed uric acid and calcium oxalate stones by polarized light microscopy of thin section |
| Q45198675 | An experimental study of effect of different extracts of Alisma orientalis on urinary calcium oxalate stones formation in rats |
| Q52718055 | An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. |
| Q41032565 | An increasing number of calcium oxalate stone events worsens treatment outcome |
| Q71779841 | An optical micromethod for the determination of relative crystallisation rates of calcium oxalate in gels: method and preliminary results |
| Q46887233 | An outbreak of Streptococcus pyogenes infection associated with calcium oxalate urolithiasis in guineapigs (Cavia porcellus) |
| Q41812136 | An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine |
| Q75803525 | An unusual case of calcium oxalate deposits in the kidney of a young infant |
| Q43253710 | Analysis of HK-2 cells exposed to oxalate and calcium oxalate crystals: proteomic insights into the molecular mechanisms of renal injury and stone formation |
| Q35199169 | Analysis of altered microRNA expression profiles in proximal renal tubular cells in response to calcium oxalate monohydrate crystal adhesion: implications for kidney stone disease |
| Q44665084 | Analysis of calcium, oxalate, and citrate interaction in idiopathic calcium urolithiasis in children |
| Q50765095 | Analysis of glycosaminoglycans induced in newly formed calcium oxalate crystals using an undiluted urine system. |
| Q46280681 | Analytical investigation of calcium oxalate films on marble monuments. |
| Q46119738 | Analytical precision of the Urolizer for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI. |
| Q83266266 | Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys |
| Q46279460 | Anhydrous Amorphous Calcium Oxalate Nanoparticles from Ionic Liquids: Stable Crystallization Intermediates in the Formation of Whewellite |
| Q57618863 | Anhydrous Calcium Oxalate Polymorphism: A Combined Computational and Synchrotron X-ray Diffraction Study |
| Q40675893 | Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals |
| Q54945958 | Anti-Transforming Growth Factor β IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease. |
| Q36575955 | Antilithiatic Activity of phlorotannin rich extract of Sarghassum Wightii on Calcium Oxalate Urolithiais - InVitro and In Vivo Evaluation |
| Q82261774 | Antilithic effects of extracts from Urtica dentata hand on calcium oxalate urinary stones in rats |
| Q35759961 | Antioxidant properties of polysaccharide from the brown seaweed Sargassum graminifolium (Turn.), and its effects on calcium oxalate crystallization |
| Q46929650 | Antioxidant therapy prevents ethylene glycol-induced renal calcium oxalate crystal deposition in Wistar rats |
| Q46260714 | Antiurolithiatic Potential of Neeri against Calcium-Oxalate Stones by Crystallization Inhibition, Free Radicals Scavenging, and NRK-52E Cell Protection from Oxalate Injury |
| Q46545480 | Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization |
| Q70725943 | Applications of Low-Temperature Ashing with High-Frequency Oxygen Plasma in Pharmacognostical Studies : Identifications of Crude Drugs "Uvae Ursi Folium"and "Vitis-Idaeae Folium"by Calcium Oxalate Crystals |
| Q70737794 | Applications of Low-Temperature Ashing with High-Frequency Oxygen Plasma in Pharmacognostical Studies : Identifications of Crude Drugs Uvae Ursi Folium and Vitis-Idaeae Folium and Their Related Plants by Calcium Oxalate Crystals |
| Q70725899 | Applications of Low-Temperature Ashing with High-Frequency Oxygen Plasma in Pharmacognostical Studies : Observations of Calcium Oxalate Crystals in Ashed Tissues of Leaves of Cassia angustifolia VAHL and Camellia japonica L |
| Q69642735 | Appraisal of calcium oxalate solubility In sodium chloride and sodium-calcium chloride solutions |
| Q53626096 | Aqueous extract of Costus arabicus inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells. |
| Q70052304 | Architecture of calcium oxalate monohydrate urinary calculi |
| Q41127077 | Architecture of mixed calcium oxalate dihydrate and monohydrate stones |
| Q28262357 | Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning? |
| Q46309389 | Are new-generation bisphosphonates effective for the inhibition of calcium oxalate stone formation in a rat model? |
| Q43632737 | Arginine form of p21 gene codon 31 is less prominent in patients with calcium oxalate stone |
| Q68471568 | Arthritis associated with calcium oxalate crystals in an anephric patient treated with peritoneal dialysis |
| Q51554564 | Ascorbic acid in idiopathic recurrent calcium urolithiasis in humans--does it have an abettor role in oxalate, and calcium oxalate crystallization? |
| Q34554875 | Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis |
| Q46480472 | Aspects of calcium oxalate crystallization: theory, in vitro studies, and in vivo implementation |
| Q70891244 | Aspects of the influence of magnesium ions on the formation of calcium oxalate |
| Q44519960 | Aspects on Estimation of the Risk of Calcium Oxalate Crystallization in Urine |
| Q55347983 | Aspergillus Section Nigri-Associated Calcium Oxalate Crystals in an Eurasian Eagle Owl (Bubo bubo). |
| Q70393038 | Assessment of urine saturation and inhibitory index in patients with calcium oxalate kidney stone and normals |
| Q44038673 | Association Study of Klotho Gene Polymorphism With Calcium Oxalate Stones in The Uyghur Population of Xinjiang, China |
| Q43791275 | Association between dietary factors and calcium oxalate and magnesium ammonium phosphate urolithiasis in cats |
| Q43499943 | Association between patient-related factors and risk of calcium oxalate and magnesium ammonium phosphate urolithiasis in cats |
| Q50893328 | Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis. |
| Q44436482 | Association of E-Cadherin Gene 3’-UTR C/T Polymorphism with Calcium Oxalate Stone Disease |
| Q44447954 | Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation |
| Q71754513 | Association of calcium oxalate monohydrate crystals with MDCK cells |
| Q43993180 | Association of dietary fatty acids with urinary oxalate excretion in calcium oxalate stone-formers in their fourth decade |
| Q43217443 | Association of interleukin-18 gene polymorphisms with calcium oxalate kidney stone disease |
| Q46814579 | Association of interleukin-1beta gene and receptor antagonist polymorphisms with calcium oxalate urolithiasis |
| Q31892282 | Association of the vitamin D receptor gene start codon Fok I polymorphism with calcium oxalate stone disease |
| Q71895064 | Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine |
| Q46778860 | Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children |
| Q46970247 | Association of urokinase gene 3'-UTR polymorphism with calcium oxalate nephrolithiasis |
| Q45285881 | Association of vitamin D receptor-gene (FokI) polymorphism with calcium oxalate nephrolithiasis |
| Q54333718 | Association study of DGKH gene polymorphisms with calcium oxalate stone in Chinese population. |
| Q43885047 | Associations between dietary factors in canned food and formation of calcium oxalate uroliths in dogs |
| Q43930331 | Associations between dry dietary factors and canine calcium oxalate uroliths |
| Q39012092 | Associations of diet and breed with recurrence of calcium oxalate cystic calculi in dogs |
| Q67490057 | Asteroid bodies and calcium oxalate crystals: Two infrequent findings in fine‐needle aspirates of parotid sarcoidosis |
| Q42919584 | Attachment of Calcium Oxalate Monohydrate Crystals on Patterned Surfaces of Proteins and Lipid Bilayers |
| Q41738354 | Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation |
| Q71489379 | Automated and computer-controlled method for the measurement of the crystallization of calcium oxalate monohydrate in urine |
| Q52589595 | Autophagy inhibition attenuates hyperoxaluria-induced renal tubular oxidative injury and calcium oxalate crystal depositions in the rat kidney. |
| Q71728293 | Backscattered electron imaging of crystal matrix protein on the surface of calcium oxalate crystals using colloidal gold |
| Q50496581 | Bacteria can promote calcium oxalate crystal growth and aggregation. |
| Q68031725 | Basic studies of citrate therapy on urolithiasis--the effect of citrate on solubility of calcium oxalate crystal and on calcium deposition of murine kidney in experimental oxalate stone |
| Q47907273 | Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine |
| Q37850357 | Bilateral very large calcium oxalate stones in the seminal vesicles: case report and literature review |
| Q69695355 | Binding of calcium by organic anions, determined by perturbation of the equilibrium solubility of [14C]calcium oxalate |
| Q69082464 | Binding of glycosaminoglycan inhibitors to calcium oxalate crystals in relation to ionic strength |
| Q70668629 | Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide |
| Q70392008 | Biochemical studies in calcium oxalate stone formers, with special reference to the effects of thiazide treatment |
| Q43095518 | Biogenic synthesis of calcium oxalate crystal by reaction of calcium ions with spinach lixivium |
| Q70627157 | Biological rhythmicity and crystallization--urine profiles and Se-studies on calcium oxalate stone genesis |
| Q53767226 | Biomimetic Mineralization of the Alginate/Gelatin/Calcium Oxalate Matrix for Immobilization of Pectinase: Influence of Matrix on the Pectinolytic Activity. |
| Q59150654 | Biomineralization of Fungal Hyphae with Calcite (CaCO3) and Calcium Oxalate Mono- and Dihydrate in Carboniferous Limestone Microcosms |
| Q28346632 | Biosynthesis of L-ascorbic acid and conversion of carbons 1 and 2 of L-ascorbic acid to oxalic acid occurs within individual calcium oxalate crystal idioblasts |
| Q40818940 | Birefringent (calcium oxalate) crystals in thyroid diseases. A clinicopathological study with possible implications for differential diagnosis. |
| Q50913879 | Bladder secretion of inhibitors of calcium oxalate crystal growth. |
| Q43185537 | Bonn Risk Index based micromethod for assessing risk of urinary calcium oxalate stone formation. |
| Q51900505 | Brain death with calcium oxalate deposition in the kidney: clue to the diagnosis of ethylene glycol poisoning. |
| Q45045726 | Brewster angle microscopy of calcium oxalate monohydrate precipitation at phospholipid monolayer phase boundaries |
| Q58510460 | CALCIUM OXALATE FILMS ON STONE SURFACES: EXPERIMENTAL ASSESSMENT OF THE CHEMICAL FORMATION |
| Q78546263 | CALCIUM OXALATE SOLUBILITY: THE EFFECT OF INORGANIC SALTS, UREA, CREATININE, AND ORGANIC ACIDS |
| Q76887713 | CRYSTALS OF CALCIUM OXALATE IN KIDNEYS IN UREMIA |
| Q76671727 | CRYSTALS OF CALCIUM OXALATE IN THE HUMAN KIDNEY. STUDIES BY MEANS OF ELECTRON MICROPROBE AND X-RAY DIFFRACTION |
| Q30494278 | CT visible internal stone structure, but not Hounsfield unit value, of calcium oxalate monohydrate (COM) calculi predicts lithotripsy fragility in vitro |
| Q61874763 | Cadmium associates with oxalate in calcium oxalate crystals and competes with calcium for translocation to stems in the cadmium bioindicator Gomphrena claussenii |
| Q34397262 | Calciphytoliths (calcium oxalate crystals) analysis for the identification of decayed tea plants (Camellia sinensis L.). |
| Q43682108 | Calcitonin receptor gene polymorphism: a possible genetic marker for patients with calcium oxalate stones |
| Q42342183 | Calcium Oxalate Calculus in the Urethra |
| Q42346038 | Calcium Oxalate Calculus in the Urethra |
| Q39128126 | Calcium Oxalate Crystalluria |
| Q71786321 | Calcium Oxalate Crystalluria and Urine Saturation in Recurrent Renal Stone-Formers |
| Q36597351 | Calcium Oxalate Crystals in Breast Biopsies The Missing Microcalcifications |
| Q50094586 | Calcium Oxalate Crystals in Ethylene Glycol Toxicity |
| Q56039796 | Calcium Oxalate Crystals in Monocotyledons: A Review of their Structure and Systematics |
| Q55356641 | Calcium Oxalate Crystals in a Lens with Advanced Cataractous Changes. |
| Q66978418 | Calcium Oxalate Crystals in the Aqueous |
| Q58719497 | Calcium Oxalate Differentiates Human Monocytes Into Inflammatory M1 Macrophages |
| Q37443747 | Calcium Oxalate Induces Renal Injury through Calcium-Sensing Receptor. |
| Q34020162 | Calcium Oxalate Renal Stones |
| Q35052256 | Calcium Oxalate Stone Agglomeration Inhibition [tm] Reflects Renal Stone-Forming Activity |
| Q42284481 | Calcium Oxalate Stone Fragment and Crystal Phagocytosis by Human Macrophages. |
| Q57051015 | Calcium Oxalate and Medullary Architecture in Xanthomaculina Convoluta |
| Q45264952 | Calcium Oxalate: Crystallographic Analysis in Solid Aggregates in Urinary Sediments |
| Q57227530 | Calcium acetate induces calcium uptake and formation of calcium-oxalate crystals in isolated leaflets of Gleditsia triacanthos L |
| Q56657175 | Calcium carbonate and calcium oxalate as cuticular hardening agents in oribatid mites (Acari: Oribatida) |
| Q57224947 | Calcium carbonate crystals promote calcium oxalate crystallization by heterogeneous or epitaxial nucleation: possible involvement in the control of urinary lithogenesis |
| Q34564816 | Calcium channels are involved in calcium oxalate crystal formation in specialized cells of Pistia stratiotes L |
| Q37243246 | Calcium oxalate (Weddellite) crystals within ductal carcinoma in situ. |
| Q44384870 | Calcium oxalate aggregation in whole urine, new aspects of calcium stone formation and metaphylaxis |
| Q41484591 | Calcium oxalate and calcium phosphate capacities of cardiac sarcoplasmic reticulum |
| Q78309446 | Calcium oxalate and calcium phosphate crystals in detached retinas |
| Q74220244 | Calcium oxalate and iron accumulation in sarcoidosis |
| Q38612341 | Calcium oxalate and other crystals associated with kidney diseases and arthritis |
| Q53796863 | Calcium oxalate and the von Kossa method with reference to the influence of citric acid |
| Q42688468 | Calcium oxalate biomineralization by Piloderma fallax in response to various levels of calcium and phosphorus |
| Q66760923 | Calcium oxalate biomineralization in plants |
| Q40263613 | Calcium oxalate calculi found attached to the renal papilla: Preliminary evidence for early mechanisms in stone formation |
| Q38872845 | Calcium oxalate calculi-induced clusterin expression in kidney |
| Q78725836 | Calcium oxalate clearance of blood lipids |
| Q44721068 | Calcium oxalate crystal adherence in the rat bladder: restoration of anti-adherence after acid treatment |
| Q44669214 | Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys |
| Q41006549 | Calcium oxalate crystal attachment to cultured kidney epithelial cell lines |
| Q40791075 | Calcium oxalate crystal attachment to cultured rat kidney epithelial cell, NRK-52E. |
| Q42574944 | Calcium oxalate crystal deposition in a patient with Aspergilloma due to Aspergillus niger |
| Q40954495 | Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy |
| Q36764652 | Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter |
| Q42796833 | Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys |
| Q70518719 | Calcium oxalate crystal deposition in necrotizing otomycosis caused by Aspergillus niger |
| Q68714846 | Calcium oxalate crystal formation in patients with hyperparathyroidism and hyperthyroidism and related metabolic disturbances |
| Q71252957 | Calcium oxalate crystal formation in the kidneys of rats injected with 4-hydroxy-L-proline |
| Q71075096 | Calcium oxalate crystal growth in human urinary stones |
| Q71341963 | Calcium oxalate crystal growth in normal urine: role of contraceptive hormones |
| Q67895214 | Calcium oxalate crystal growth in the presence of mucin |
| Q67980128 | Calcium oxalate crystal growth studies in polyacrylamide gels: Part I--Influence of urea and amino acids on crystal aggregation |
| Q70065745 | Calcium oxalate crystal growth studies in polyacrylamide gels: Part II--Influence of synthetic polypeptides and natural macromolecules on crystal aggregation |
| Q71185316 | Calcium oxalate crystal growth. A new constant composition method for modelling urinary stone formation |
| Q69231037 | Calcium oxalate crystal interaction with rat renal inner papillary collecting tubule cells |
| Q72063416 | Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development |
| Q44692963 | Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats |
| Q71903496 | Calcium oxalate crystal matrix extract: the most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro |
| Q44059063 | Calcium oxalate crystal morphology mutants from Medicago truncatula |
| Q44064864 | Calcium oxalate crystal morphology. |
| Q46276614 | Calcium oxalate crystal production and density at different phenological stages of soybean plants (Glycine max L.) from the southeast of the Pampean Plain, Argentina |
| Q36327251 | Calcium oxalate crystal related kidney injury in a patient receiving Roux-en Y hepaticojejunostomy due to gall bladder cancer |
| Q70714156 | Calcium oxalate crystal-induced cytolysis in polymorphonuclear leukocytes and erythrocytes |
| Q41207828 | Calcium oxalate crystallisation kinetics and the effects of calcium and gamma-carboxyglutamic acid |
| Q57376777 | Calcium oxalate crystallization in the presence of amphiphilic phosphoproteins |
| Q43804155 | Calcium oxalate crystallization in undiluted postprandial urine of healthy male volunteers as influenced by citrate |
| Q44827988 | Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine. |
| Q50857696 | Calcium oxalate crystallization in urine of healthy men and women: a comparative study. |
| Q45325259 | Calcium oxalate crystallization in urine: role of urate and glycosaminoglycans |
| Q78167836 | Calcium oxalate crystallization kinetics at different concentrations of human and artificial urine, with a constant calcium to oxalate ratio |
| Q73405951 | Calcium oxalate crystallization kinetics studied by oxalate-induced turbidity in fresh human urine and artificial urine |
| Q68021274 | Calcium oxalate crystallization properties in urine with different specific electrical conductivities |
| Q42482602 | Calcium oxalate crystallizing properties of polyanions elaborated by cultured renal proximal tubular cells |
| Q41974990 | Calcium oxalate crystalluria |
| Q69416177 | Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers |
| Q77972310 | Calcium oxalate crystalluria in a goat |
| Q70969628 | Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate |
| Q68039992 | Calcium oxalate crystalluria, a curiosity or a diagnostical aid? |
| Q47297431 | Calcium oxalate crystalluria: crystal size in urine |
| Q37230624 | Calcium oxalate crystals (Weddellite) within the secretions of ductal carcinoma in situ--a rare phenomenon |
| Q79426018 | Calcium oxalate crystals and methyl salicylate as toxic principles of the fresh leaves from Palicourea longiflora, an endemic species in the Amazonas state |
| Q42292540 | Calcium oxalate crystals and oxalate induce an epithelial-to-mesenchymal transition in the proximal tubular epithelial cells: Contribution to oxalate kidney injury. |
| Q44770451 | Calcium oxalate crystals in a nasolabial cyst |
| Q33325300 | Calcium oxalate crystals in acute ethylene glycol poisoning: a confocal laser scanning microscope study in a fatal case. |
| Q44941587 | Calcium oxalate crystals in an aspirate sample from a benign breast cyst |
| Q72331935 | Calcium oxalate crystals in benign breast cyst fluid |
| Q74654855 | Calcium oxalate crystals in benign cyst fluid from the breast. A case report |
| Q41282113 | Calcium oxalate crystals in breast biopsies. An overlooked form of microcalcification associated with benign breast disease. |
| Q28534468 | Calcium oxalate crystals in eucalypt ectomycorrhizae: morphochemical characterization |
| Q40078629 | Calcium oxalate crystals in fetal bovine serum: implications for cell culture, phagocytosis and biomineralization studies in vitro |
| Q36801354 | Calcium oxalate crystals in human pathology. Molecular analysis with the laser Raman microprobe |
| Q78830950 | Calcium oxalate crystals in kidneys in acute tubular nephrosis and other renal diseases with functional failure |
| Q73187816 | Calcium oxalate crystals in plants |
| Q30665711 | Calcium oxalate crystals in several kinds of Cinnamon bark |
| Q57228849 | Calcium oxalate crystals in the aragonite-producing green alga penicillus and related genera |
| Q46176843 | Calcium oxalate crystals in the bone marrow |
| Q70152954 | Calcium oxalate crystals in the breast. Pathology and significance |
| Q71734220 | Calcium oxalate crystals in the kidney and thyroid of leprosy patients |
| Q46537823 | Calcium oxalate crystals in the thyroid. Their identification, prevalence, origin, and possible significance |
| Q78085196 | Calcium oxalate crystals in thyroid fine needle aspiration cytology |
| Q43639399 | Calcium oxalate crystals in tomato and tobacco plants: morphology and in vitro interactions of crystal-associated macromolecules |
| Q36764889 | Calcium oxalate crystals increased enolase-1 secretion from renal tubular cells that subsequently enhanced crystal and monocyte invasion through renal interstitium |
| Q36497205 | Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion |
| Q46398237 | Calcium oxalate crystals induces tight junction disruption in distal renal tubular epithelial cells by activating ROS/Akt/p38 MAPK signaling pathway |
| Q67312956 | Calcium oxalate crystals localized in the eye. Subretinal and retinal deposits, including deposits in the pigment epithelium |
| Q78309452 | Calcium oxalate crystals within ocular tissues; a clinicopathologic and histochemical study |
| Q83846720 | Calcium oxalate crystals--an unexpected finding in a breast aspirate |
| Q35588644 | Calcium oxalate crystals: an integral component of the Sclerotinia sclerotiorum/Brassica carinata pathosystem |
| Q70459048 | Calcium oxalate deposition in growing bone: anatomical and radiological study in a case of primary oxalosis |
| Q35842715 | Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications. |
| Q46379037 | Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study |
| Q72033970 | Calcium oxalate deposition in the periodontium secondary to chronic renal failure |
| Q71894557 | Calcium oxalate determination of the kidneys in ethylene glycol poisoning |
| Q39282098 | Calcium oxalate dihydrate crystal growth |
| Q39559004 | Calcium oxalate dihydrate crystal induced changes in glycoproteome of distal renal tubular epithelial cells |
| Q70594921 | Calcium oxalate dihydrate formation in urine |
| Q50137596 | Calcium oxalate druses affect leaf optical properties in selenium-treated Fagopyrum tataricum. |
| Q78603591 | Calcium oxalate excretion and hematuria in vitamin B6-deficient rats fed phthalylsulfathiazole |
| Q43655412 | Calcium oxalate granuloma of the nose of a chronically dialysed nephritic patient |
| Q44731816 | Calcium oxalate in breast lesions biopsied for calcification detected in screening mammography: incidence and clinical significance |
| Q52847746 | Calcium oxalate in mammalian thyroids: a re-evaluation. |
| Q43660306 | Calcium oxalate in plants |
| Q34414846 | Calcium oxalate in plants: formation and function |
| Q57227084 | Calcium oxalate in sarcoid granulomas. With particular reference to the small ovoid body and a note on the finding of dolomite |
| Q35196780 | Calcium oxalate in the sputum may aid in the diagnosis of pulmonary aspergillosis: A report of two cases |
| Q72630589 | Calcium oxalate is associated with benign breast tissue. Can we avoid biopsy? |
| Q74467885 | Calcium oxalate is the main toxic component in clinical presentations of alocasis macrorrhiza (L) Schott and Endl poisonings |
| Q70813944 | Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis |
| Q35556983 | Calcium oxalate kidney stones: another reason to encourage moderate calcium intakes and other dietary changes |
| Q72819472 | Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets |
| Q45157917 | Calcium oxalate microcalcifications in the breast |
| Q44225885 | Calcium oxalate microcrystalline arthropathy in primary oxalosis |
| Q70390996 | Calcium oxalate microcrystalline-associated arthritis in end-stage renal disease |
| Q43552983 | Calcium oxalate microdeposition in failing kidney grafts |
| Q35050995 | Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein |
| Q45057670 | Calcium oxalate monohydrate binding protein: a diagnostic biomarker for calcium oxalate kidney stone formers |
| Q44201267 | Calcium oxalate monohydrate crystal binding substance produced from Madin-Darby canine kidney cells |
| Q41630837 | Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation |
| Q48372034 | Calcium oxalate monohydrate crystals in ethylene glycol poisoning. |
| Q35889393 | Calcium oxalate monohydrate crystals internalized into renal tubular cells are degraded and dissolved by endolysosomes |
| Q41321238 | Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells |
| Q39388165 | Calcium oxalate monohydrate crystals stimulate monocyte chemoattractant protein-1 and transforming growth factor β1 expression in human renal epithelial cells |
| Q45289224 | Calcium oxalate monohydrate precipitation at membrane lipid rafts |
| Q40423202 | Calcium oxalate monohydrate renal calculi. Formation and development mechanism |
| Q45188773 | Calcium oxalate monohydrate, a metabolite of ethylene glycol, is toxic for rat renal mitochondrial function |
| Q41895002 | Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys |
| Q72898118 | Calcium oxalate nephrolithiasis, a free or fixed particle disease |
| Q52715570 | Calcium oxalate nephrolithiasis: an easy way to detect an imbalance between promoting and inhibiting factors |
| Q67978136 | Calcium oxalate nephrolithiasis: defective oxalate transport |
| Q28373261 | Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium |
| Q42789038 | Calcium oxalate nephrolithiasis: urinary "medium size peptides"analysis using MALDI-TOF mass spectrometry |
| Q44409516 | Calcium oxalate precipitates in a renomedullary interstitial cell tumor |
| Q51467406 | Calcium oxalate precipitation by diffusion using laminar microfluidics: toward a biomimetic model of pathological microcalcifications. |
| Q69520042 | Calcium oxalate precipitation in a flow system: an attempt to simulate the early stages of stone formation in the renal tubules |
| Q51796673 | Calcium oxalate precipitation in urine following T.U.R. with glycine as irrigation fluid. |
| Q71375105 | Calcium oxalate retention in subjects with crystalluria |
| Q47882121 | Calcium oxalate retinopathy associated with generalized oxalosis: x-ray diffraction and electron microscopic studies of crystal deposits |
| Q28293564 | Calcium oxalate retinopathy associated with methoxyflurane abuse |
| Q46908292 | Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria. |
| Q68025966 | Calcium oxalate smear layer: mineralogical and crystallographic study |
| Q72350681 | Calcium oxalate solubility in urine: the state of relative saturation |
| Q74823514 | Calcium oxalate solubility in urine; experimental urolithiasis. XIV |
| Q72209420 | Calcium oxalate solubility: the effect of trace metals |
| Q72870229 | Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton |
| Q43271665 | Calcium oxalate stone and gout |
| Q68215389 | Calcium oxalate stone disease: congenital defect of metabolism? |
| Q67430014 | Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria |
| Q34593332 | Calcium oxalate stone disease: role of lipid peroxidation and antioxidants |
| Q43889651 | Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats |
| Q33967195 | Calcium oxalate stone formation in the inner ear as a result of an Slc26a4 mutation |
| Q46519851 | Calcium oxalate stone formation risk - a case of disturbed relative concentrations of urinary components |
| Q46661520 | Calcium oxalate stone formation. New pathogenetic aspects of an old disease |
| Q70956601 | Calcium oxalate stone morphology: fine tuning our therapeutic distinctions |
| Q44591952 | Calcium oxalate stones and hyperoxaluria. What is certain? What is new? |
| Q51661158 | Calcium oxalate stones in a colonic surgical suture: an uncommon endoscopic finding. |
| Q77207961 | Calcium oxalate stones in feline littermates |
| Q51213367 | Calcium oxalate supersaturation increases early after Roux-en-Y gastric bypass. |
| Q37164214 | Calcium oxalate toxicity in renal epithelial cells: the mediation of crystal size on cell death mode |
| Q43939414 | Calcium oxalate urinary calculi: clinical and chemical aspects. |
| Q37697686 | Calcium oxalate urolithiasis |
| Q72259351 | Calcium oxalate urolithiasis in a cat with a functional parathyroid adenocarcinoma |
| Q33802394 | Calcium oxalate urolithiasis in cats |
| Q28592220 | Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6 |
| Q41065793 | Calcium oxalate urolithiasis in the canine: surgical management and preventative strategies. |
| Q39830887 | Calcium oxalate urolithiasis in the rat: is it a model for human stone disease? A review of recent literature |
| Q68294911 | Calcium oxalate urolithiasis. Proceedings from the Finlayson Colloquium |
| Q34005551 | Calcium oxalate, and not other metabolites, is responsible for the renal toxicity of ethylene glycol |
| Q70956567 | Calcium oxalate-crystal membrane interactions: dependence on membrane lipid composition |
| Q70048708 | Calcium oxalate-loaded sarcoplasmic reticulum vesicles from developing skeletal muscle are highly differentiated |
| Q71609375 | Calcium oxalate-phosphate gallstones, a unique chemical type of gallstone |
| Q42972096 | Calcium oxalate: calcium phosphate transformations |
| Q80905486 | Calcium oxalate: occurrence in soils and effect on nutrient and geochemical cycles |
| Q40552753 | Calcium phosphate and calcium oxalate crystal handling is dependent upon CLC-5 expression in mouse collecting duct cells. |
| Q71927217 | Calcium phosphate/calcium oxalate crystal association in urinary stones: implications for heterogeneous nucleation of calcium oxalate |
| Q72074311 | Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis |
| Q43789228 | Calcium-oxalate urolithiasis in children. I. Properties of the concretions, incidence, pathogenesis and risk factors |
| Q28306869 | Calprotectin-like protein is related to soluble organic matrix in calcium oxalate urinary stone |
| Q41466321 | Can Randall's plug composed of calcium oxalate form via the free particle mechanism? |
| Q45223776 | Can a relationship reflect the risk of calcium oxalate urolithiasis? |
| Q70342195 | Can new formation of calcium oxalate calculi be prevented by diet alone? Report on a personal test |
| Q39841143 | Can the formation of calcium oxalate stones be explained by crystallization processes in urine? |
| Q33535466 | Canine calcium oxalate urolithiasis. Case-based applications of therapeutic principles |
| Q64120086 | Canine calcium oxalate urolithiasis: Frequency of Whewellite and Weddellite stones from 1979 to 2015 |
| Q39094717 | Catechin prevents the calcium oxalate monohydrate induced renal calcium crystallization in NRK-52E cells and the ethylene glycol induced renal stone formation in rat. |
| Q37923104 | Cats and calcium oxalate: strategies for managing lower and upper tract stone disease |
| Q68590059 | Cell injury associated calcium oxalate crystalluria |
| Q54276548 | Cell polarity and calcium oxalate crystal adherence to cultured collecting duct cells. |
| Q34699475 | Cell wall sheath surrounding calcium oxalate crystals in mulberry idioblasts |
| Q30040079 | Cell-Mediated Crystallization of Calcium Oxalate in Plants |
| Q40915494 | Cells of proximal and distal tubular origin respond differently to challenges of oxalate and calcium oxalate crystals. |
| Q43789988 | Cellular adaptive response of distal renal tubular cells to high-oxalate environment highlights surface alpha-enolase as the enhancer of calcium oxalate monohydrate crystal adhesion |
| Q70652473 | Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates |
| Q33211444 | Changes in calcium oxalate crystal morphology as a function of supersaturation |
| Q71301318 | Changes in calcium oxalate crystal, morphology as a function of concentration |
| Q34237316 | Changes in mitochondrial proteome of renal tubular cells induced by calcium oxalate monohydrate crystal adhesion and internalization are related to mitochondrial dysfunction |
| Q44681991 | Changes in proportion of canine urinary calculi composed of calcium oxalate or struvite in specimens analyzed from 1981 through 2001. |
| Q67802205 | Changes in serum lipids and lipoproteins in calcium oxalate stone forming rats treated with sodium pentosan polysulphate |
| Q57130741 | Changes in size and composition of pigweed (Amaranthus hybridus L.) calcium oxalate crystals under CO starvation conditions |
| Q69586926 | Changes in urinary composition of calcium oxalate stone formers |
| Q36659120 | Changes in urinary nanocrystallites in calcium oxalate stone formers before and after potassium citrate intake |
| Q45981831 | Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation. |
| Q40993374 | Characterization of Inner Medullary Collecting Duct Plug Formation Among Idiopathic Calcium Oxalate Stone Formers |
| Q41191234 | Characterization of calcium oxalate and calcium phosphate deposits in sarcoplasmic reticulum vesicles |
| Q43161026 | Characterization of calcium oxalate biominerals in Pereskia species (Cactaceae). |
| Q42926448 | Characterization of calcium oxalate biominerals in some (non-Cactaceae) succulent plant species |
| Q40112363 | Characterization of calcium oxalate crystal-induced changes in the secretome of U937 human monocytes |
| Q46704836 | Characterization of glycosaminoglycans in tubular epithelial cells: calcium oxalate and oxalate ions effects |
| Q84127746 | Characterization of hyaluronic acid interaction with calcium oxalate crystals: implication of crystals faces, pH and citrate |
| Q34779340 | Characterization of melamine-containing and calcium oxalate crystals in three dogs with suspected pet food-induced nephrotoxicosis |
| Q35059504 | Characterization of secondary metabolites from the raphides of calcium oxalate contained in three araceae family plants using laser microdissection and ultra-high performance liquid chromatography-quadrupole/time of flight-mass spectrometry. |
| Q72684645 | Characterization of urinary macromolecular inhibitors of calcium oxalate crystal aggregation |
| Q72063422 | Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine |
| Q47585249 | Characterizations of PMCA2-interacting complex and its role as a calcium oxalate crystal-binding protein |
| Q67534994 | Chemical Simulation on Inhibition of Calcium Oxalate Stone by the Extract from a Traditional Chinese Medicine Tiankui Soup |
| Q67534601 | Chemical Simulation on Inhibition of Calcium Oxalate Stones by Eucheuma striatum Polysaccharide |
| Q46282076 | Chemical basis of the effects of Tamm-Horsfall protein on the formation of calcium oxalate stones |
| Q68678698 | Chemical measurement of calcium oxalate crystalluria: results in various causes of calcium urolithiasis |
| Q46278080 | Chemical structure of dicarboxylic acids and their capacity inhibiting of calcium oxalate crystal growth |
| Q52618366 | Chemolysis of calcium oxalate stones: study in vitro and possible clinical application. |
| Q68130766 | Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not |
| Q45260097 | Chronic stress and calcium oxalate stone disease: influence on blood cortisol and urine composition |
| Q44845814 | Chronic stress and calcium oxalate stone disease: is it a potential recurrence risk factor? |
| Q72659276 | Circadian periodicity of urinary inhibitor of calcium oxalate crystallization in healthy Indians and renal stone formers |
| Q48863781 | Circadian rhythms of urinary saturation levels of calcium oxalate and calcium phosphate in normal male individuals |
| Q72787097 | Circadian variations in the risk of urinary calcium oxalate stone formation |
| Q58454458 | Citrate Modulates Calcium Oxalate Crystal Growth by Face-Specific Interactions |
| Q72717066 | Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation |
| Q73487565 | Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former |
| Q44846310 | Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones |
| Q45219200 | Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium |
| Q46617343 | Citrate, not phosphate, can dissolve calcium oxalate monohydrate crystals and detach these crystals from renal tubular cells |
| Q44186372 | Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones? |
| Q36196051 | Citrus Bioflavonoids Ameliorate Hyperoxaluria Induced Renal Injury and Calcium Oxalate Crystal Deposition in Wistar Rats |
| Q67986031 | Clinical and anatomic aspects of oxalosis. Apropos of a case |
| Q72775113 | Clinical and biochemical differences in patients with pure calcium oxalate monohydrate and calcium oxalate dihydrate kidney stones |
| Q81041156 | Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers |
| Q72000606 | Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease |
| Q70421788 | Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers |
| Q70376739 | Clinical manifestations of calcium oxalate monohydrate and dihydrate urolithiasis |
| Q69520060 | Clinical results of allopurinol treatment in prevention of calcium oxalate stone formation |
| Q35917931 | Clinical review 32: Calcium oxalate nephrolithiasis |
| Q74010399 | Clinical significance of calcium oxalate crystals in the breast: a cause for mammographic-pathologic discrepancy |
| Q68058737 | Clinical significance of phosphate in calcium oxalate renal stones |
| Q43066528 | Clinicopathological features and CD57 expression in renal cell carcinoma in acquired cystic disease of the kidneys: with special emphasis on a relation to the duration of haemodialysis, the degree of calcium oxalate deposition, histological type, an |
| Q67502869 | Collagenous spherulosis in syringomas |
| Q52872498 | Colorimetric determination of urinary oxalate recovered as calcium oxalate. Application of a simple correction factor for incomplete preciptation |
| Q44912132 | Combined liver kidney transplantation in primary hyperoxaluria type I. Prevention of the recidive of calcium oxalate deposits in the renal graft |
| Q39587285 | Comparative faecal microbiota of dogs with and without calcium oxalate stones |
| Q69764652 | Comparative study of the circadian rhythmicity in the urinary concentration of glycosaminoglycans in patients of calcium oxalate nephrolithiasis and in healthy adults |
| Q59059166 | Comparison of Physicochemical Properties of Nano- and Microsized Crystals in the Urine of Calcium Oxalate Stone Patients and Control Subjects |
| Q37726499 | Comparison of body condition score and urinalysis variables between dogs with and without calcium oxalate uroliths |
| Q36474358 | Comparison of epidemiological data between uric acid and calcium oxalate stone formers in the south of Portugal. |
| Q30845323 | Comparison of laser-probe and photometric determination of the urinary crystallization risk of calcium oxalate |
| Q41172250 | Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones |
| Q43488685 | Comparison of renal function and metabolic abnormalities of cystine stone patients and calcium oxalate stone patients in China |
| Q43257393 | Comparison of semi-empirical and computer derived methods for estimating urinary saturation of calcium oxalate |
| Q71716663 | Comparison of the Equil2 program and other methods for estimating the ion-activity product of urinary calcium oxalate: a new simplified method is proposed |
| Q64962529 | Comparison of the adhesion of calcium oxalate monohydrate to HK-2 cells before and after repair using tea polysaccharides. |
| Q38220295 | Comparison of the metabolic profile of mixed calcium oxalate/uric acid stone formers to that of pure calcium oxalate and pure uric acid stone formers |
| Q42951452 | Comparison of the specific incorporation of intracrystalline proteins into urinary calcium oxalate monohydrate and dihydrate crystals. |
| Q40096507 | Comparison of the x-ray attenuation properties of breast calcifications, aluminium, hydroxyapatite and calcium oxalate. |
| Q68537135 | Comparison of urinary tract infection in calcium oxalate and calcium phosphate stone formers |
| Q69548239 | Composition and texture of calcium oxalate calculi in children |
| Q59303640 | Computational prediction of the pattern of thermal gravimetry data for the thermal decomposition of calcium oxalate monohydrate |
| Q37375120 | Concave urinary crystallines: direct evidence of calcium oxalate crystals dissolution by citrate in vivo |
| Q80214254 | Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load |
| Q44667222 | Concentration of a potent calcium oxalate monohydrate crystal growth inhibitor in the urine of normal persons and kidney stone patients by ELISA-based assay system employing monoclonal antibodies |
| Q55109179 | Conservation of Monuments by a Three-Layered Compatible Treatment of TEOS-Nano-Calcium Oxalate Consolidant and TEOS-PDMS-TiO₂ Hydrophobic/Photoactive Hybrid Nanomaterials. |
| Q46945491 | Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis |
| Q33582212 | Contrasting histopathology and crystal deposits in kidneys of idiopathic stone formers who produce hydroxy apatite, brushite, or calcium oxalate stones |
| Q74130870 | Contribution of human uropontin to inhibition of calcium oxalate crystallization |
| Q46278809 | Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide |
| Q74462487 | Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules |
| Q51000444 | Controlled growth of calcium oxalate crystal in bicontinuous microemulsions containing amino acids. |
| Q36139840 | Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. |
| Q70877592 | Controlling influence of phosphocitrate in vitro and in vivo on calcium oxalate crystal formation and growth |
| Q44456778 | Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes |
| Q83204189 | Cooperation of phosphates and carboxylates controls calcium oxalate crystallization in ultrafiltered urine |
| Q41134761 | Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans |
| Q83035607 | Correspondence Re: "C. Guo, K.E. McMartin, The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation, Toxicology 208 (3) (2005) 347-355" |
| Q67536241 | Crystal Growth of Calcium Oxalate Induced by Defective Langmuir-Blodgett Films |
| Q44071761 | Crystal agglomeration is a major element in calcium oxalate urinary stone formation |
| Q67327478 | Crystal growth inhibitors in human urine. Effect on calcium oxalate kinetics |
| Q67967000 | Crystal growth of calcium oxalate in urine of stone-formers and normal controls |
| Q44896039 | Crystal growth of calcium oxalate monohydrate and calcium carbonate from dilute solutions. |
| Q68976133 | Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth |
| Q70975063 | Crystal morphologies in whewellite stones: electron microscopy |
| Q80529361 | Crystal morphology and texture in calcium oxalate monohydrate renal calculi |
| Q46522412 | Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation |
| Q45774232 | Crystal-matrix relationships in experimentally induced urinary calcium oxalate monohydrate crystals, an ultrastructural study |
| Q70619285 | Crystallisation of calcium oxalate dihydrate in normal urine in presence of sodium copper chlorophyllin |
| Q54419864 | Crystallization Properties in Urine from Calcium Oxalate Stone Formers |
| Q70570036 | Crystallization kinetics of calcium oxalate in fresh, minimally diluted urine: comparison of recurrent stone formers and healthy controls in a continuous mixed suspension mixed product removal crystallizer |
| Q43477645 | Crystallization of calcium oxalate from synthetic urine |
| Q57382320 | Crystallization of calcium oxalate hydrates by interaction of calcite marble with fungusAspergillus niger |
| Q62571561 | Crystallization of calcium oxalate monohydrate at dipalmitoylphosphatidylcholine monolayers in the presence of chondroitin sulfate A |
| Q72129364 | Crystallization of urinary calcium oxalate at standardized osmolality and pH in the frozen state |
| Q66961178 | Crystallization studies in a urothelial-lined living test tube (the catheterized female rat bladder). I. Calcium oxalate crystal adhesion to the chemically injured rat bladder |
| Q34197185 | Crystallochemical characterization of calcium oxalate crystals isolated from seed coats ofPhaseolus vulgaris and leaves ofVitis vinifera |
| Q71066576 | Crystallographic investigations of urinary calcium oxalate calculi |
| Q32033807 | Crystaloptical and spectroscopical findings with calcium oxalate crystals in the urine sediment: a contribution to the genesis of oxalate stones |
| Q47226916 | Curative treatment with extracts of Bombax ceiba fruit reduces risk of calcium oxalate urolithiasis in rats. |
| Q64125066 | Curcumin ameliorates glyoxylate-induced calcium oxalate deposition and renal injuries in mice |
| Q84233946 | Cyclooxygenase 2 and prostaglandin E2 regulate the attachment of calcium oxalate crystals to renal epithelial cells |
| Q36987692 | Cystic fibrosis and calcium oxalate nephrolithiasis |
| Q71048319 | Cystic transformation and calcium oxalate deposits in rete testis and efferent ducts in dialysis patients |
| Q43822652 | Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine |
| Q30695476 | Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages |
| Q73234269 | Damage attributable to extracorporeal shockwave lithotripsy and deposition of calcium oxalate crystals on ureteral stents |
| Q50506018 | Decreased expression of vitamin K epoxide reductase complex subunit 1 in kidney of patients with calcium oxalate urolithiasis. |
| Q42168443 | Decreased inhibitory activity of prothrombin to calcium oxalate crystallization by specific chemical modification of its gamma-carboxyglutamic acid residues |
| Q43961494 | Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis |
| Q44522097 | Decreased renal vitamin K-dependent gamma-glutamyl carboxylase activity in calcium oxalate calculi patients |
| Q47147471 | Defining and Systematic Analyses of Aggregation Indices to Evaluate Degree of Calcium Oxalate Crystal Aggregation |
| Q44129094 | Degree of saturation of urine with calcium oxalate in patients with metabolically active calcium-oxalate urolithiasis |
| Q53912550 | Demonstration of calcium oxalate crystals in plant tissues by the Pizzolato (AgNO3-H2O2) method. |
| Q70934169 | Dendrite formation by apparent repeated twinning of calcium oxalate dihydrate |
| Q68868966 | Deposition of calcium oxalate in the skin in two patients suffering from oxalosis caused by primary hyperoxaluria |
| Q72558617 | Deposition of calcium phosphate and calcium oxalate crystals in the kidneys |
| Q57848668 | Detection of calcium phosphates in calcium oxalate patinas |
| Q40541676 | Detection of protein Z in a renal calculus composed of calcium oxalate monohydrate with the use of liquid chromatography-mass spectrometry/mass spectrometry following two-dimensional polyacrylamide gel electrophoresis separation |
| Q57050972 | Determinant factors for the formation of the calcium oxalate minerals, weddellite and whewellite, on the surface of foliose lichens |
| Q67743232 | Determinants of supersaturation levels and crystallization rates of calcium oxalate from urines of normal humans and stone formers: effects of nondialyzable materials |
| Q72591831 | Determination of GOT activity on nucleation and crystal growth of calcium oxalate |
| Q44516050 | Determination of calcium oxalate (mono- and dihydrate) in mixtures with magnesium ammonium phosphate or uric acid: the use of simultaneous thermal analysis in urinary calculi |
| Q79059730 | Determination of rate of formation and nucleation time of calcium oxalate in various systems |
| Q44940150 | Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas |
| Q46629965 | Determination of uric acid in urine, saliva and calcium oxalate renal calculi by high-performance liquid chromatography/mass spectrometry. |
| Q70815538 | Determination of urinary calcium oxalate crystallization mechanisms and kinetics using flow cytometry |
| Q44042898 | Determination of urinary calcium-oxalate formation risk with BONN-Risk-Index and EQUIL applied to a family |
| Q50451859 | Determination of urine oxalate level in rats with renal calcium oxalate calculus by high-performance liquid chromatography |
| Q50437264 | Developing precipitation modes for preventing the calcium-oxalate contamination of sugar beet pectins |
| Q74370237 | Development of a turbidimetric assay to study the effect of urinary components on calcium oxalate precipitation |
| Q77867393 | Development of an in vitro assay for the screening of substances capable of dissolving calcium oxalate crystals |
| Q74453208 | Development of calcium oxalate crystals on urothelium: effect of free radicals |
| Q42732695 | Development of the calcium oxalate crystal macropattern in pomegranate (Punica granatum, Punicaceae). |
| Q52293160 | Developmental aspects of calcium oxalate tubular deposits and calculi induced in rat kidneys. |
| Q43976443 | Developmental morphology of calcium oxalate foreign body stones in rats |
| Q43834544 | Diagnosis of intestinal oxalate hyperabsorption in patients with idiopathic recurrent calcium oxalate urinary calculi |
| Q40589797 | Diagnostic value of calcium oxalate crystals in respiratory and pleural fluid cytology. A case report |
| Q43981068 | Diclofenac-Na--an alternative treatment possibility in therapy-resistant calcium oxalate urolithiasis? |
| Q41976571 | Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis |
| Q46133488 | Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study |
| Q37582208 | Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation |
| Q36817855 | Dietary and holistic treatment of recurrent calcium oxalate kidney stones: review of literature to guide patient education. |
| Q36440909 | Dietary calcium, calcium supplements, and the risk of calcium oxalate kidney stones |
| Q67507752 | Dietary effects upon calcium oxalate urolithiasis risk |
| Q54618019 | Dietary hydroxyproline induced calcium oxalate lithiasis and associated renal injury in the porcine model. |
| Q72158354 | Dietary hypercalciuria in patients with calcium oxalate kidney stones |
| Q81299122 | Dietary oxalate and calcium oxalate nephrolithiasis |
| Q44358485 | Dietary risk factors for hyperoxaluria in calcium oxalate stone formers |
| Q43554207 | Diets with either beef or plant proteins reduce risk of calcium oxalate precipitation in patients with a history of calcium kidney stones |
| Q73805278 | Different dietary calcium intake and relative supersaturation of calcium oxalate in the urine of patients forming renal stones |
| Q38721692 | Different effects of γ-linolenic acid (GLA) supplementation on plasma and red blood cell phospholipid fatty acid composition and calcium oxalate kidney stone risk factors in healthy subjects from two race groups with different risk profiles pose que |
| Q52709820 | Different estimates of the risk of calcium oxalate crystallization in urine. |
| Q50894672 | Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men. |
| Q37659357 | Differentiating calcium oxalate and hydroxyapatite stones in vivo using dual-energy CT and urine supersaturation and pH values |
| Q37665010 | Differentiation of calcium oxalate monohydrate and calcium oxalate dihydrate stones using quantitative morphological information from micro-computerized and clinical computerized tomography |
| Q43081669 | Dihydrate birefringent calcium oxalate or Weddellite calcification |
| Q42918048 | Diminution of oxalate induced renal tubular epithelial cell injury and inhibition of calcium oxalate crystallization in vitro by aqueous extract of Tribulus terrestris |
| Q36778367 | Diosmin reduces calcium oxalate deposition and tissue degeneration in nephrolithiasis in rats: a stereological study |
| Q45310601 | Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells |
| Q33350932 | Direct AFM measurements of adhesion forces between calcium oxalate monohydrate and kidney epithelial cells in the presence of Ca2+ and Mg2+ ions |
| Q30744979 | Direct measurement of calcium oxalate nucleation with a laser probe |
| Q41009534 | Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture |
| Q67972625 | Disappearing breast calcifications: mammographic-pathologic discrepancy due to calcium oxalate |
| Q47762357 | Discrimination Between Calcium Hydroxyapatite and Calcium Oxalate Using Multienergy Spectral Photon-Counting CT. |
| Q69589236 | Dissolution and growth of calcium oxalate monohydrate I. Effect of magnesium and pH |
| Q57051008 | Dissolution of Weddellite, Calcium Oxalate Dihydrate, in Pyxine Subcinerea |
| Q70278146 | Dissolution of calcium oxalate renal stones in patient with jejunoileal bypass and after reanastomosis |
| Q70490479 | Dissolved urate promotes calcium oxalate crystallization: epitaxy is not the cause |
| Q40596772 | Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis |
| Q34292839 | Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall's plaque |
| Q44976836 | Distribution of calcium oxalate crystals in floral organs of Araceae in relation to pollination strategy |
| Q71566348 | Distribution of organic matrix in calcium oxalate renal calculi |
| Q34207827 | Distribution of peroxisomes and glycolate metabolism in relation to calcium oxalate formation in Lemna minor L. |
| Q70796860 | Diurnal variation of urine composition in calcium oxalate stone disease during treatment with bendroflumethiazide |
| Q70713217 | Diurnal variations in calcium phosphate and calcium oxalate activity products in normal and stone-forming urines |
| Q71241172 | Diurnal variations of calcium, phosphorus, and magnesium in normal and calcium oxalate stone-forming urine |
| Q34188619 | Diversity and distribution of idioblasts producing calcium oxalate crystals in Dieffenbachia seguine (Araceae). |
| Q34849855 | Diversity in protein profiles of individual calcium oxalate kidney stones |
| Q69467253 | Do indomethacin, thiazide, pyridoxine or allopurinol prevent calcium oxalate stones? |
| Q41006117 | Do teas rich in antioxidants reduce the physicochemical and peroxidative risk factors for calcium oxalate nephrolithiasis in humans? Pilot studies with Rooibos herbal tea and Japanese green tea. |
| Q70310560 | Do thiazides prevent recurrent idiopathic renal calcium oxalate stones? |
| Q43407352 | Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? |
| Q38923261 | Does aridity influence the morphology, distribution and accumulation of calcium oxalate crystals in Acacia (Leguminosae: Mimosoideae)? |
| Q38603726 | Does hyperuricosuria play a role in calcium oxalate lithiasis? |
| Q73426445 | Does urinary oxalate interfere with the inhibitory role of glycosaminoglycans and semisynthetic sulfated polysaccharides in calcium oxalate crystallization? |
| Q71528328 | Does urine from stone-formers contain macromolecules which promote the crystal growth rate of calcium oxalate crystals in vitro? |
| Q52725269 | Drosophila: a fruitful model for calcium oxalate nephrolithiasis? |
| Q37614266 | Drug dosage protocol for calcium oxalate stone |
| Q59490527 | Durability of the artificial calcium oxalate protective on two Florentine monuments |
| Q35929779 | EGCG decreases binding of calcium oxalate monohydrate crystals onto renal tubular cells via decreased surface expression of alpha-enolase |
| Q40798639 | EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS |
| Q44499089 | Early changes of oxalate and calcium urine excretion in those with calcium oxalate stone formation after extracorporeal shock wave lithotripsy |
| Q45219603 | Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival |
| Q47109324 | Ectopic Bone as a Nidus for Calcium Oxalate Urocystolithiasis in a Cat. |
| Q49851020 | Editorial Comment on: Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers by Otto et al. (From: Otto BJ, Bozorgmehri S, Kuo J, et al. J Endourol 2017;31:1335-1341). |
| Q57047174 | Editorial Comment on: Calcium Oxalate Urolithiasis: A Case of Missing Microbes? by Batagello et al |
| Q43240434 | Editorial Comment to Renal tubular epithelial cell injury and oxidative stress induce calcium oxalate crystal formation in mouse kidney |
| Q67989963 | Effect of "Rosa Canina" infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis |
| Q32023283 | Effect of A. lanata leaf extract and Vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria |
| Q79439866 | Effect of Aerva lanata on calcium oxalate urolithiasis in rats |
| Q54281696 | Effect of Alkalinization on Calcium Oxalate Monohydrate Calculi during Extracorporeal Shock Wave Lithotripsy: In vivo Experiments |
| Q51743912 | Effect of Blumea balsamifera extract on the phase and morphology of calcium oxalate crystals. |
| Q83382431 | Effect of Costus igneus stem extract on calcium oxalate urolithiasis in albino rats |
| Q55686457 | Effect of Crystal Shape and Aggregation of Calcium Oxalate Monohydrate on Cellular Toxicity in Renal Epithelial Cells. |
| Q72217595 | Effect of Daily MgO and Vitamin B6 Administration to Patients with Recurring Calcium Oxalate Kidney Stones |
| Q70632783 | Effect of Desmodium styracifolium-triterpenoid on calcium oxalate renal stones |
| Q67534689 | Effect of Different Kinds of Potassium Carboxylates on Growth of Calcium Oxalate Crystals in Silica Gel System |
| Q41675865 | Effect of Ethyl Icosapentate on Urinary Calcium Excretion in Calcium Oxalate Stone Formers |
| Q71925520 | Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rats |
| Q41919477 | Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats |
| Q67565993 | Effect of Renal Epithelial Cell After Injury on Biomineralization of Calcium Oxalate |
| Q36796627 | Effect of Tamm-Horsfall protein on calcium oxalate precipitation |
| Q47357967 | Effect of Trigonella foenum-graecum and Ammi majus on calcium oxalate urolithiasis in rats |
| Q54279112 | Effect of alanine and dimethyl sulfoxide on the solubility of calcium phosphate, magnesium phosphate and calcium oxalate. |
| Q44772806 | Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys |
| Q42838679 | Effect of biomolecules from human renal matrix of calcium oxalate monohydrate (CaOx) stones on in vitro calcium phosphate crystallization |
| Q72204340 | Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis |
| Q43202736 | Effect of calcium oxalate on renal cells as revealed by real-time measurement of extracellular oxidative burst |
| Q59300002 | Effect of calcium oxalate on the photocatalytic degradation of Orange II on ZnO surface |
| Q43521014 | Effect of carbohydrate infusions on the formation of calcium oxalate deposits in the kidney: postmortem morphological and biochemical findings in humans and in animal experiments |
| Q74666619 | Effect of citrate and pyrophosphate on the stability of calcium oxalate dihydrate |
| Q57227017 | Effect of citrate on the urinary excretion of calcium and oxalate: relevance to calcium oxalate nephrolithiasis |
| Q74636776 | Effect of cola consumption on urinary biochemical and physicochemical risk factors associated with calcium oxalate urolithiasis |
| Q44110622 | Effect of cyclosporin A treatment on renal calcium oxalate binding in experimental hyperoxaluria |
| Q69651443 | Effect of diclofenac-Na on 24-hour urinary excretion of creatinine, calcium, uric acid and glycosaminoglycans in adult patients with recurrent calcium oxalate nephrolithiasis |
| Q68550788 | Effect of dietary calcium and magnesium on experimental renal tubular deposition of calcium oxalate crystal induced by ethylene glycol administration and its prevention with phytin and citrate |
| Q46177645 | Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation |
| Q37250069 | Effect of dietary control of urinary uric acid excretion in calcium oxalate stone formers and non-stone-forming controls |
| Q73516413 | Effect of dietary intake on urinary oxalate excretion in calcium oxalate stone formers in their forties |
| Q44317696 | Effect of dietary moisture and sodium content on urine composition and calcium oxalate relative supersaturation in healthy miniature schnauzers and labrador retrievers |
| Q34351568 | Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones |
| Q82062109 | Effect of dietary water intake on urinary output, specific gravity and relative supersaturation for calcium oxalate and struvite in the cat |
| Q71410306 | Effect of different fractions of macromolecules upon triggering of calcium oxalate and calcium phosphate crystal formation in whole urine |
| Q40313400 | Effect of diphosphonate on crystallization of calcium oxalate in vitro |
| Q43512613 | Effect of experimental hyperoxaluria on renal calcium oxalate monohydrate binding proteins in the rat. |
| Q43517149 | Effect of extract of Hirudo Medicinalis L. against adherence of calcium oxalate crystals to acid-injured bladder mucosa |
| Q67391149 | Effect of feeding on the composition of foreign-body stones in animal experiments. II. Calcium oxalate and magnesium therapy |
| Q74526081 | Effect of gamma-glutamyl carboxylation of renal microsomes on calcium oxalate monohydrate crystal binding in hyperoxaluria |
| Q69278509 | Effect of glycosaminoglycans on calcium oxalate crystal aggregation |
| Q67542782 | Effect of hydrochlorothiazide therapy on the crystallization of calcium oxalate in urine |
| Q46463233 | Effect of hyperprotidic diet associated or not with hypercalcic diet on calcium oxalate stone formation in rat. |
| Q84280792 | Effect of indigenous plant extracts on calcium oxalate crystallization having a role in urolithiasis |
| Q69467331 | Effect of inhibitors on the crystal growth of calcium oxalate |
| Q71341885 | Effect of macromolecules and of sodium dodecyl sulphate upon precipitation of calcium oxalate and phosphate from whole urine |
| Q70139531 | Effect of magnesium on calcium oxalate urolithiasis |
| Q46742076 | Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors |
| Q82945665 | Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation |
| Q67911968 | Effect of nifedipine on kidney output of calcium, oxalic acid, and saturation of urinary calcium oxalate |
| Q43226264 | Effect of phospholipase A2 hydrolysis products on calcium oxalate precipitation at lipid interfaces |
| Q57341723 | Effect of poly(acrylic acid) end-group functionality on inhibition of calcium oxalate crystal growth |
| Q57341702 | Effect of poly(acrylic acid) molecular mass and end-group functionality on calcium oxalate crystal morphology and growth |
| Q44004953 | Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial |
| Q45302226 | Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial |
| Q33780071 | Effect of potassium magnesium citrate and vitamin B-6 prophylaxis for recurrent and multiple calcium oxalate and phosphate urolithiasis |
| Q30330031 | Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. |
| Q73820451 | Effect of renal ischaemia reperfusion on calcium oxalate retention |
| Q73129403 | Effect of seed crystals of uric acid and monosodium urate on the crystallization of calcium oxalate in undiluted human urine in vitro |
| Q40349006 | Effect of sodium cellulose phosphate therapy on crystallization of calcium oxalate in urine |
| Q70263381 | Effect of sodium copper chlorophyllin on the formation of calcium oxalate crystals in rat kidney |
| Q67826617 | Effect of tetracycline on calcium oxalate calculi: in vivo and in vitro studies |
| Q71117851 | Effect of thiazides on the urinary calcium oxalate stone-forming potential in normal males |
| Q69595922 | Effect of trace elements on the kinetics of calcium oxalate crystallization--research on urolithiatic inhibitors |
| Q72209423 | Effect of trace metals on the crystallization of calcium oxalate |
| Q68474343 | Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis |
| Q46439944 | Effect of urinary macromolecules and chondroitin sulphate on calcium oxalate crystallization in urine |
| Q72538621 | Effect of urinary macromolecules on aggregation of calcium oxalate in recurrent calcium stone formers and healthy |
| Q40176659 | Effect of urine fractionation on attachment of calcium oxalate crystals to renal epithelial cells: implications for studying renal calculogenesis |
| Q56480876 | Effect of urine pH and magnesium on calcium oxalate saturation |
| Q43274212 | Effect of vitamin A supplemented diet on calcium oxalate renal stone formation in rats |
| Q79395713 | Effect of vitamin B6 and magnesium on renal deposition of calcium oxalate induced by ethylene glycol administration |
| Q74026468 | Effect of vitamin E and mannitol on renal calcium oxalate retention in experimental nephrolithiasis |
| Q44108636 | Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups |
| Q61444884 | Effects of Calcium Oxalate on Expression of Clusterin and Lower Urinary Tract Symptoms in Prostatitis and Benign Prostatic Hyperplasia Patients with Calculi |
| Q57374911 | Effects of Carboxylate-Modified, “Green” Inulin Biopolymers on the Crystal Growth of Calcium Oxalate |
| Q67531588 | Effects of Different Kinds of Potassium Carboxylates on the Growth of Calcium Oxalate Crystals in Lecithin-Water Liposomes |
| Q82447626 | Effects of Orthosiphon grandiflorus, Hibiscus sabdariffa and Phyllanthus amarus extracts on risk factors for urinary calcium oxalate stones in rats |
| Q67535362 | Effects of Sm~(3+) on the Crystallization of Calcium Oxalate in Pure H_2O System |
| Q43786442 | Effects of Tamm-Horsfall protein and albumin on calcium oxalate crystallization and importance of sialic acids. |
| Q73835111 | Effects of Tamm-Horsfall protein with normal and reduced sialic acid content upon the crystallization of calcium phosphate and calcium oxalate in human urine |
| Q60577475 | Effects of a urolith prevention diet on urine compositions of glycosaminoglycans, Tamm-Horsfall glycoprotein, and nephrocalcin in cats with calcium oxalate urolithiasis |
| Q44323677 | Effects of an aqueous extract from Phyllantus niruri on calcium oxalate crystallization in vitro |
| Q46745506 | Effects of an extract from Herniaria hirsuta on calcium oxalate crystallization in vitro |
| Q46110208 | Effects of apocynin and losartan treatment on renal oxidative stress in a rat model of calcium oxalate nephrolithiasis |
| Q72775125 | Effects of calcium chelating agents and acid mucopolysaccharides on the growth of calcium oxalate dihydrate crystals |
| Q39653496 | Effects of calcium oxalate monohydrate crystals on expression and function of tight junction of renal tubular epithelial cells |
| Q67997479 | Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine |
| Q40818602 | Effects of citrate on the different phases of calcium oxalate crystallization |
| Q70762485 | Effects of constituents of artificial urine on spontaneous precipitation of calcium oxalate monohydrate (whewellite) |
| Q44886620 | Effects of diet on urine composition of cats with calcium oxalate urolithiasis |
| Q73691399 | Effects of dietary potassium citrate supplementation on urine pH and urinary relative supersaturation of calcium oxalate and struvite in healthy dogs |
| Q46367003 | Effects of dietary supplementation with sodium chloride on urinary relative supersaturation with calcium oxalate in healthy dogs |
| Q68733886 | Effects of different doses of alkaline citrate on urine composition and crystallization of calcium oxalate |
| Q40987927 | Effects of etidronate disodium on crystallizations in synthetic urine and calcium oxalate crystal adhesion to Madin-Darby canine kidney (MDCK) cells |
| Q70806087 | Effects of high intake of dietary animal protein on mineral metabolism and urinary supersaturation of calcium oxalate in renal stone formers |
| Q47269584 | Effects of high molecular weight urinary macromolecules on crystallization of calcium oxalate dihydrate |
| Q69991109 | Effects of human urine on aggregation of calcium oxalate crystals |
| Q43630550 | Effects of hydrochlorothiazide and diet in dogs with calcium oxalate urolithiasis |
| Q80350390 | Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth |
| Q73580440 | Effects of inter-alpha-inhibitor and several of its derivatives on calcium oxalate crystallization in vitro |
| Q44436972 | Effects of intraperitoneally administered vitamin E and selenium on calcium oxalate renal stone formation: experimental study in rat |
| Q46801566 | Effects of luminal oxalate or calcium oxalate on renal tubular cells in culture |
| Q70291883 | Effects of magnesium deficiency on intratubular calcium oxalate formation and crystalluria in hyperoxaluric rats |
| Q70043438 | Effects of magnesium on calcium oxalate crystallization |
| Q70490482 | Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients |
| Q83259169 | Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: a pilot study |
| Q68694486 | Effects of sodium citrate, potassium citrate, and citric acid in preventing experimental calcium oxalate urolithiasis in rats |
| Q71341954 | Effects of sodium urate and uric acid crystals on the crystallization of calcium oxalate |
| Q46064617 | Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis |
| Q46529510 | Effects of trace metals on the inhibition of calcium oxalate crystallization |
| Q67247156 | Effects of urinary macromolecules on the crystallization of calcium oxalate |
| Q71808353 | Effects of urinary macromolecules on the nucleation of calcium oxalate in idiopathic stone formers and healthy controls |
| Q39911516 | Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation |
| Q71163201 | Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation |
| Q45183409 | Effects of urinary prothrombin fragment 1 in the formation of calcium oxalate calculus |
| Q46592012 | Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load. |
| Q82792668 | Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms |
| Q40231357 | Electron paramagnetic resonance study of iron oxalate in calcium oxalate renal stones |
| Q35661301 | Elemental Content of Calcium Oxalate Stones from a Canine Model of Urinary Stone Disease |
| Q71301308 | Elevation of the metastable limits and absence of container surface nucleation for calcium oxalate crystallization in a urothelial-lined system as compared to glass containers |
| Q33774091 | Elongation factor Tu on Escherichia coli isolated from urine of kidney stone patients promotes calcium oxalate crystal growth and aggregation |
| Q67581216 | Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria |
| Q27303089 | Endoscopic and histologic findings in a cohort of uric acid and calcium oxalate stone formers |
| Q84108637 | Engineering calcium oxalate crystal formation in Arabidopsis |
| Q73296860 | Enlargement of a lower pole calcium oxalate stone: a theoretical examination of the role of crystal nucleation, growth, and aggregation |
| Q44235178 | Enlargement of calcium oxalate stones to clinically significant size in an in-vitro stone generator |
| Q57098209 | Enthalpy of dissolution and thermal dehydration of calcium oxalate hydrates |
| Q68996976 | Enzyme release from polymorphonuclear leukocytes during interaction with calcium oxalate microcrystals |
| Q33535462 | Epidemiology of canine calcium oxalate uroliths. Identifying risk factors |
| Q38578034 | Epidemiology, Pathogenesis and diagnosis of calcium oxalate urolithiasis |
| Q30829528 | Epitaxial Relationships in Urolithiasis: The Calcium Oxalate Monohydrate—Hydroxyapatite System |
| Q46684043 | Epitaxial deposition of calcium oxalate on uric acid rich stone matrix is induced by a 29 kDa protein |
| Q42707826 | Erythrocyte oxidative stress in patients with calcium oxalate stones correlates with stone size and renal tubular damage |
| Q43055209 | Establishment of a novel colorimetric assay for high-throughput analysis of calcium oxalate crystal growth modulation |
| Q73326742 | Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule |
| Q52430282 | Estimation by infrared spectrophotometer of the calcium oxalate dihydrate to calcium oxalate monohydrate ratio. |
| Q67556908 | Estimation of the state of saturation of brushite and calcium oxalate in urine: a comparison of three methods |
| Q33858018 | Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis |
| Q70877585 | Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? |
| Q70877588 | Etiology of calcium oxalate nephrolithiasis in rats. II. The role of the papilla in stone formation |
| Q72229433 | Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats |
| Q39732749 | Etiopathogenesis, clinical manifestations, and management of canine calcium oxalate urolithiasis |
| Q71508650 | Evaluation of a routine method for determination of calcium oxalate crystal growth inhibition in diluted urine samples |
| Q71886909 | Evaluation of a simple test to estimate urine saturation with calcium oxalate in stone-forming patients |
| Q43325861 | Evaluation of factors associated with development of calcium oxalate urolithiasis in cats. |
| Q84128468 | Evaluation of methods for urine inhibitory potential for precipitation of calcium oxalate |
| Q71496203 | Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis |
| Q51562935 | Evaluation of urinary and serum metabolites in Asian small-clawed otters (Aonyx cinerea) with calcium oxalate urolithiasis. |
| Q67819023 | Evaluation of urine and serum metabolites in miniature schnauzers with calcium oxalate urolithiasis |
| Q73888400 | Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers |
| Q43257400 | Evening primrose oil supplementation increases citraturia and decreases other urinary risk factors for calcium oxalate urolithiasis |
| Q39378429 | Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers |
| Q70468629 | Evidence of a link between erythrocyte band 3 phosphorylation and anion transport in patients with 'idiopathic' calcium oxalate nephrolithiasis |
| Q28278402 | Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization |
| Q47857379 | Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals |
| Q36994464 | Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure |
| Q70087475 | Examination of the urinary potential of hyperuricosuric patients to retard calcium oxalate precipitation |
| Q78847533 | Excretion of urinary metabolites in calcium oxalate urolithiasis. Effect of tryptophan and vitamin B6 administration |
| Q64078042 | Exosomes from Human Umbilical Cord Mesenchymal Stem Cells Reduce Damage from Oxidative Stress and the Epithelial-Mesenchymal Transition in Renal Epithelial Cells Exposed to Oxalate and Calcium Oxalate Monohydrate |
| Q40941037 | Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. |
| Q35884937 | Experimental calcium oxalate nephrolithiasis in the rat. Role of the renal papilla |
| Q69618216 | Experimental calcium oxalate retinopathy compared with cystine- and tyrosine-induced retinal damage. An ophthalmoscopical, histological, and electrophysiological study |
| Q79057191 | Experimental calcium oxalate stone formation with clinical application |
| Q40710963 | Experimental determination of multiple thermodynamic and kinetic risk factors for nephrolithiasis in the urine of healthy controls and calcium oxalate stone formers: does a universal discriminator exist? |
| Q36738680 | Experimental induction of calcium oxalate nephrolithiasis in mice |
| Q77546843 | Experimental nephrolithiasis in rats: the effect of ethylene glycol and vitamin D3 on the induction of renal calcium oxalate crystals |
| Q80739991 | Experimental urolithiasis: calcium oxalate stone |
| Q36479259 | Experimentally induced calcium oxalate keratopathy in rabbits |
| Q36070242 | Exploring calcium oxalate crystallization: a constant composition approach |
| Q37531517 | Exposure of Madin-Darby canine kidney (MDCK) cells to oxalate and calcium oxalate crystals activates nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase |
| Q73888395 | Expression of heparan sulfate proteoglycan mRNA in rat kidneys during calcium oxalate nephrolithiasis |
| Q45863934 | Expression of heterologous oxalate decarboxylase in HEK293 cells confers protection against oxalate induced oxidative stress as a therapeutic approach for calcium oxalate stone disease |
| Q44108666 | Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis |
| Q31794742 | Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals |
| Q77584740 | Extensive calcium oxalate crystal deposition in papillary renal cell carcinoma: report of two cases |
| Q53280638 | Externalization of phosphatidylserine via multidrug resistance 1 (MDR1)/P-glycoprotein in oxalate-treated renal epithelial cells: implications for calcium oxalate urolithiasis. |
| Q40515061 | Extract from Herniaria hirsuta coats calcium oxalate monohydrate crystals and blocks their adhesion to renal epithelial cells |
| Q46734648 | Extraction and estimation of the quantity of calcium oxalate crystals in the foliage of conifer and hardwood trees |
| Q31039039 | FKBP-12 exhibits an inhibitory activity on calcium oxalate crystal growth in vitro |
| Q57377018 | Fabrication of calcium oxalate with novel hierarchical structures mediated by amphiphilic phosphoproteins and its adsorptive removal of Congo red from aqueous solution |
| Q41220247 | Face-selective adhesion of calcium oxalate dihydrate crystals to renal epithelial cells |
| Q37408555 | Face-specific binding of prothrombin fragment 1 and human serum albumin to inorganic and urinary calcium oxalate monohydrate crystals |
| Q42961358 | Face-specific incorporation of osteopontin into urinary and inorganic calcium oxalate monohydrate and dihydrate crystals |
| Q30819492 | Factors affecting calcium oxalate dihydrate fragmented calculi regrowth. |
| Q46283668 | Factors affecting the digestibility, absorption and retention of calcium, oxalate, ethylen-diamine-tetracetic acid (disodium salt), nitril triacetic acid, lysine and protein quality (author's transl) |
| Q46928345 | Factors determining types and morphologies of calcium oxalate crystals: molar concentrations, buffering, pH, stirring and temperature |
| Q73071501 | Factors influencing the course of calcium oxalate stone disease |
| Q67393188 | Factors which influence the size of calcium oxalat crystals during their formation from saturated solutions |
| Q35031650 | Fasting urinary calcium-to-creatinine and oxalate-to-creatinine ratios in dogs with calcium oxalate urolithiasis and breed-matched controls. |
| Q54289317 | Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice. |
| Q38937622 | Feline Calcium Oxalate Urolithiasis: Risk factors and rational treatment approaches |
| Q43237168 | Fetuin-A gene polymorphism in patients with calcium oxalate stone disease |
| Q34043307 | Fibrinogen alpha chain precursor and apolipoprotein A-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study |
| Q73062783 | Fibronectin as a potent inhibitor of calcium oxalate urolithiasis |
| Q40256695 | Fibronectin inhibits endocytosis of calcium oxalate crystals by renal tubular cells |
| Q70603553 | Fine structure of calcium oxalate monohydrate renal calculi |
| Q43638730 | Folium pyrrosiae ingestion has no effect on the thermodynamic or kinetic urinary risk factors for calcium oxalate urolithiasis in healthy subjects: a poor prognosis for alternative treatment in this type of stone former |
| Q71744266 | Follow-up of drug therapy efficacy to prevent recurrence of calcium oxalate kidney stone formation |
| Q43633614 | Formation of calcium oxalate urolithiasis in experiment and its inhibition by pyridoxine and magnesium |
| Q57359846 | Formation of ring calcium oxalate patterns induced by domains in DPPC Langmuir–Blodgett films |
| Q72161095 | Formation of spherulites of calcium phosphate and crystallization of calcium oxalate in gel in a new experimental model of urinary stone formation |
| Q57870745 | Forming Cohesive Calcium Oxalate Layers on Marble Surfaces for Stone Conservation |
| Q57028468 | Fractional pretreatment of raw and calcium oxalate-extracted agave bagasse using ionic liquid and alkaline hydrogen peroxide |
| Q37542689 | Gallotannin suppresses calcium oxalate crystal binding and oxalate-induced oxidative stress in renal epithelial cells |
| Q41536038 | Genes in idiopathic calcium oxalate stone disease |
| Q40565504 | Genetic factors in calcium oxalate stone disease. |
| Q43263507 | Genetic mutation of vitamin K-dependent gamma-glutamyl carboxylase domain in patients with calcium oxalate urolithiasis |
| Q72042269 | Genetic predisposition to formation of calcium oxalate renal calculi |
| Q47103946 | Genome-Wide Gene Expression Profiling of Randall's Plaques in Calcium Oxalate Stone Formers |
| Q38511424 | Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. |
| Q41330489 | Gestational hypercalciuria causes pathological urine calcium oxalate supersaturations |
| Q31103653 | Global analysis of differentially expressed genes during progression of calcium oxalate nephrolithiasis |
| Q39667107 | Glycoprotein calcium oxalate crystal growth inhibitor in urine |
| Q41201056 | Glycosaminoglycan content, oxalate self-exchange and protein phosphorylation in erythrocytes of patients with 'idiopathic' calcium oxalate nephrolithiasis |
| Q39286733 | Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation |
| Q73550616 | Glycosaminoglycans in crystal-surface binding substances and their role in calcium oxalate crystal growth |
| Q34641976 | Glycosaminoglycans, uric acid and calcium oxalate urolithiasis |
| Q54333681 | Glycose aminoglycane excretion and concentration in the urine of patients with frequently recurrent calcium-oxalate lithiasis prior to and following Diclofenac-Na therapy. |
| Q46911529 | Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth |
| Q70485696 | Growth and characterization of calcium oxalate dihydrate crystals (weddellite) |
| Q57376539 | Growth inhibition of calcium oxalate monohydrate crystal by linear aspartic acid enantiomers investigated by in situatomic force microscopy |
| Q68438942 | Growth inhibitor of calcium oxalate monohydrate crystal in vitamin B6-deficient rat urine and kidney |
| Q39943813 | Growth of Calcium Oxalate in Gel Systems |
| Q70878004 | Growth of calcium oxalate crystals in vitro: a simple method for measurement of the inhibitory action of human urine (author's transl) |
| Q66944737 | Growth of calcium oxalate crystals. I. A model for urinary stone growth |
| Q39937428 | Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors |
| Q43766276 | Growth retardation of calcium oxalate by sodium copper chlorophyllin |
| Q71391275 | Growth retardation of weddellite (calcium oxalate dihydrate) by sodium copper chlorophyllin |
| Q68592872 | Growth studies of calcium oxalate in the presence of various ions and compounds |
| Q35836502 | Gut-inhabiting bacterium Oxalobacter formigenes: role in calcium oxalate urolithiasis |
| Q76915612 | HISTOCHEMICAL RECOGNITION OF CALCIUM OXALATE |
| Q79224185 | Heat-shock protein 25 ameliorates calcium oxalate crystal-mediated oxidative stress in renal epithelial cells |
| Q46778942 | Heavy metal stress reduces the deposition of calcium oxalate crystals in leaves of Phaseolus vulgaris |
| Q44242262 | Heparan sulfate (HS)/heparan sulfate proteoglycan (HSPG) and bikunin are up-regulated during calcium oxalate nephrolithiasis in rat kidney. |
| Q46208267 | Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis. |
| Q72859172 | Heparin sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization |
| Q47661218 | Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy |
| Q72557242 | Herbal tea: an alternative to regular tea for those who form calcium oxalate stones |
| Q51367186 | Hereditary renal hypouricemia: a cause of calcium oxalate urolithiasis in a young female. |
| Q40344588 | Heterogeneous Nucleation of Calcium Oxalate by Seeds of Monosodium Urate |
| Q39123761 | Heterogeneous Nucleation with Urate, Calcium Phosphate and Calcium Oxalate |
| Q44917709 | Heterogeneous nucleation of calcium oxalate by the action of uric acid |
| Q41037993 | Heterogeneous nucleation of calcium oxalate crystals in mammalian urine. |
| Q41692942 | Heterozygous Cystinuria and Calcium Oxalate Urolithiasis |
| Q71800402 | Heterozygous cystinuria and calcium oxalate urolithiasis |
| Q46694235 | High Concentration of Calcium Stimulates Calcium Oxalate Crystal Attachment to Rat Tubular Epithelial NRK Cells Through Osteopontin |
| Q33245505 | High Energy Pulsed Dye Laser Lithotripsy: Management of Ureteral Calcium Oxalate Monohydrate Calculi |
| Q35737408 | High Sodium-Induced Oxidative Stress and Poor Anticrystallization Defense Aggravate Calcium Oxalate Crystal Formation in Rat Hyperoxaluric Kidneys |
| Q46597410 | High calcium concentration and calcium oxalate crystals cause significant inaccuracies in the measurement of urinary osteopontin by enzyme linked immunosorbent assay. |
| Q47702434 | High calcium enhances calcium oxalate crystal binding capacity of renal tubular cells via increased surface annexin A1 but impairs their proliferation and healing |
| Q40199481 | High molecular weight substances which inhibit calcium oxalate crystal growth. 1: Relative potencies of various kinds of urinary inhibitors which were determined new assay method (author's transl) |
| Q44495207 | High molecular weight substances which inhibit calcium oxalate crystal growth. 2: Isolation and identification of a calcium oxalate crystal growth inhibitor from rat liver (author's transl) |
| Q39872335 | High molecular weight substances which inhibit calcium oxalate crystal growth. 4: Studies on the role of urinary pepsinogen and mucopolysaccharide as inhibitors of calcium oxalate crystal growth (author's transl) |
| Q30989095 | Hippuric acid as a modifier of calcium oxalate crystallisation |
| Q37338298 | Hippuric acid as a significant regulator of supersaturation in calcium oxalate lithiasis: the physiological evidence |
| Q73577534 | Histological observations of the adhesion and endocytosis of calcium oxalate crystals in MDCK cells and in rat and human kidney |
| Q36613430 | Histopathological occurrence and characterisation of calcium oxalate: a review |
| Q71323165 | Hourly urate excretion in patients with calcium oxalate stone disease |
| Q34108287 | How the overlapping timescales for peptide binding and terrace exposure lead to non-linear step dynamics during growth of calcium oxalate monohydrate |
| Q59340737 | How to perform the dusting technique for calcium oxalate stone phantoms during Ho:YAG laser lithotripsy |
| Q47743095 | Human dental microwear caused by calcium oxalate phytoliths in prehistoric diet of the lower Pecos region, Texas |
| Q30577805 | Hydration feature of urinary compounds. Evidence for molecular abnormality in calcium oxalate urolithiasis |
| Q43877482 | Hydroxyapatite induction and secondary aggregation of calcium oxalate, two important processes in calcium stone formation |
| Q78030219 | Hypercalcemia and calcium oxalate urolithiasis in cats: a report of five cases |
| Q67539076 | Hyperoxaluria and calcium oxalate nephrolithiasis after jejunoileal bypass |
| Q67772730 | Hyperoxaluria in Patients with Recurrent Calcium Oxalate Calculi: Dietary and Other Risk Factors |
| Q44529317 | Hyperoxaluria in idiopathic calcium oxalate nephrolithiasis |
| Q43661660 | Hyperuricosuric calcium oxalate nephrolithiasis |
| Q71347120 | Hyperuricosuric calcium oxalate nephrolithiasis |
| Q44168499 | Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones |
| Q70895922 | Identification of Atypical Calcium Oxalate Crystalluria Following Ethylene Glycol Ingestion |
| Q24296244 | Identification of bikunin isolated from human urine inhibits calcium oxalate crystal growth and its localization in the kidneys |
| Q44108447 | Identification of calcium oxalate crystals using alizarin red S stain |
| Q68298261 | Identification of calcium oxalate deposits in bone by electron diffraction |
| Q33227810 | Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor |
| Q33289938 | Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones |
| Q47725972 | Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects |
| Q48025978 | Identification of structural domains in inter-alpha-trypsin involved in calcium oxalate crystallization |
| Q36302785 | Idiopathic calcium oxalate nephrolithiasis: a cellular disease |
| Q70815537 | Idiopathic calcium oxalate urinary lithiasis: usefulness of Parks' and Tiselius' indices in the evaluation of the risk of stone formation |
| Q37785069 | Idiopathic calcium oxalate urolithiasis |
| Q41133065 | Idiopathic calcium oxalate urolithiasis and endogenous oxalate production |
| Q35803054 | Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment |
| Q46774167 | Images in clinical medicine. Urinary calcium oxalate crystals in ethylene glycol intoxication |
| Q68879341 | Immunochemistry of urinary calcium oxalate crystal growth inhibitor (CGI) |
| Q67920060 | Immunofluorescent Study on the Interaction between Collagen and Calcium Oxalate Crystals in the Renal Tubules |
| Q83966439 | Immunological detection of nitrosative stress-mediated modified Tamm-Horsfall glycoprotein (THP) in calcium oxalate stone formers |
| Q57374880 | Impact of Chiral Molecules on the Formation of Biominerals: A Calcium Oxalate Monohydrate Example |
| Q68012734 | Impact of allopurinol treatment on the prevention of hyperuricosuric calcium oxalate lithiasis |
| Q40288498 | Impact of hypoxia and hypercapnia on calcium oxalate toxicity in renal epithelial and interstitial cells |
| Q72299531 | Impact of sodium-potassium citrate on the diurnal variations in urinary calcium oxalate and calcium phosphate saturation levels in normal individuals |
| Q43275773 | Impact of urine sodium on urine risk factors for calcium oxalate nephrolithiasis |
| Q80149508 | Impact of various modifiers on calcium oxalate crystallization |
| Q50558028 | Importance of Erythrocyte Band III Anion Transporter (SLC4A1) on Oxalate Clearance of Calcium Oxalate Monohydrate Stone-formering Patients vs. Normal Controls |
| Q43434033 | Improved model for inhibition of pathological mineralization based on citrate-calcium oxalate monohydrate interaction |
| Q57393789 | In Situ Analysis of Europium Calcium Oxalate Crystallization Using Luminescence Microspectroscopy |
| Q33596321 | In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque |
| Q34411835 | In vitro Evaluation of Terminalia arjuna on Calcium Phosphate and Calcium Oxalate Crystallization |
| Q36369945 | In vitro calcium oxalate crystallisation methods |
| Q72283776 | In vitro calcium oxalate lithotripsy: comparison of Dornier HM3 and Siemens Lithostar |
| Q66942480 | In vitro calculogenesis: study of process of calcium oxalate accretion in distilled water & human urine |
| Q43661986 | In vitro dissolution of calcium oxalate stones with ethylenediaminetetraacetic acid and snake venom thrombin-like enzyme |
| Q80848753 | In vitro effect of lemon and orange juices on calcium oxalate crystallization |
| Q82929256 | In vitro effect of wheat bran (Triticum aestivum) extract on calcium oxalate urolithiasis crystallization |
| Q84039496 | In vitro evaluation of calcium oxalate monohydrate crystals influenced by Costus igneus aqueous extract |
| Q39734958 | In vitro evaluation of canine and feline calcium oxalate urolith fragility via shock wave lithotripsy |
| Q71276859 | In vitro formation of "urinary stones": generation of spherulites of calcium phosphate in gel and overgrowth with calcium oxalate using a new flow model of crystallization |
| Q68260097 | In vitro precipitation of calcium oxalate in the presence of whole matrix or lipid components of the urinary stones |
| Q28710166 | In vivo Drosophilia genetic model for calcium oxalate nephrolithiasis |
| Q46108269 | In vivo synthesis of calcium oxalate whiskers on CoCrMo alloy surfaces via biomineralization. |
| Q67975261 | Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon |
| Q57393774 | Incorporation of fluorescent molecules and proteins into calcium oxalate monohydrate single crystals |
| Q51373342 | Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis. |
| Q72553488 | Increased Urinary Excretion of Renal Enzymes in Idiopathic Calcium Oxalate Nephrolithiasis |
| Q51752736 | Increased calcium bioavailability in mice fed genetically engineered plants lacking calcium oxalate. |
| Q43693581 | Increased calcium oxalate crystal nucleation and aggregation by peroxidized protein of human kidney stone matrix and renal cells |
| Q32061961 | Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. |
| Q78163858 | Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats |
| Q44362303 | Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals |
| Q70685289 | Independent assessment of the growth and aggregation of calcium oxalate crystals using the Coulter counter |
| Q69467344 | Indices of lithogenic activity in patients with primitive calcium oxalate urolithiasis |
| Q43193639 | Induction of apoptosis with cisplatin enhances calcium oxalate crystal adherence to inner medullary collecting duct cells |
| Q41120189 | Induction of crystallization of calcium oxalate dihydrate in micellar solutions of anionic surfactants |
| Q69406884 | Induction of lipid peroxidation in calcium oxalate stone formation |
| Q46520341 | Influence of PSSS additive and temperature on morphology and phase structures of calcium oxalate |
| Q44746825 | Influence of a mineral water rich in calcium, magnesium and bicarbonate on urine composition and the risk of calcium oxalate crystallization |
| Q51200754 | Influence of acidifying or alkalinizing diets on bone mineral density and urine relative supersaturation with calcium oxalate and struvite in healthy cats. |
| Q83424823 | Influence of calcium oxalate crystal accumulation on the calcium content of seeds from Medicago truncatula |
| Q34276718 | Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation |
| Q52543577 | Influence of different factors on the formation of calcium oxalate stones. I. Discriminant analytical computations of morphological parameters of the pelvic-calyceal systems of calcium oxalate stone formers and controls. |
| Q52543571 | Influence of different factors on the formation of calcium oxalate stones. II. Discriminant analytical computations of morphological parameters of pelvic-calyceal systems and clinicochemical urine parameters of controls and calcium-oxalate stone for |
| Q43980994 | Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients |
| Q46472109 | Influence of hyaluronan and CD44 expression in renal tubular epithelial cells on the adherence of calcium oxalate crystal |
| Q46816676 | Influence of hydrochlorothiazide on urinary calcium oxalate relative supersaturation in healthy young adult female domestic shorthaired cats. |
| Q79815439 | Influence of hypercalcic and/or hyperoxalic diet on calcium oxalate renal stone formation in rats |
| Q37845459 | Influence of nutrition on feline calcium oxalate urolithiasis with emphasis on endogenous oxalate synthesis |
| Q68979593 | Influence of oxalate on calcium oxalate crystals formation in urine |
| Q43772030 | Influence of oxianthraquinones on the crystallization of calcium oxalate and calcium phosphate: dissolution of calciumcontaining urinary calculi (author's transl) |
| Q60115549 | Influence of pH and Salts on the Solubility of Calcium Oxalate |
| Q46816679 | Influence of prednisolone on urinary calcium oxalate and struvite relative supersaturation in healthy young adult female domestic shorthaired cats. |
| Q80790998 | Influence of radish consumption on urinary calcium oxalate excretion |
| Q71265076 | Influence of sodium pentosan polysulphate and certain inhibitors on calcium oxalate crystal growth |
| Q71511141 | Influence of the salting-out effect on the formation of calcium oxalate crystals in human urine |
| Q46929161 | Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria |
| Q44020012 | Influence of urinary sialic acid on calcium oxalate crystal formation |
| Q40266223 | Influence of urine on “in vitro” crystallization rate of calcium oxalate: determination of inhibitory activity by A [14C]oxalate technique |
| Q57351031 | Influence ofBacillus subtilis on the growth of calcium oxalate |
| Q69388909 | Infrared spectroscopy and x-ray studies of calcium oxalate urinary calculi |
| Q35632126 | Inhalation of hydrogen gas ameliorates glyoxylate-induced calcium oxalate deposition and renal oxidative stress in mice |
| Q57374898 | Inhibition Mechanism of Calcium Oxalate Crystal Growth by Cooperation Influence of Colloidal Selenium Nanoparticles and Bovine Serum Albumin |
| Q68717332 | Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro |
| Q67962404 | Inhibition by sodium-potassium citrate (CG-120) of calcium oxalate crystal growth on to kidney stone fragments obtained from extracorporeal shock wave lithotripsy |
| Q72383563 | Inhibition of Calcium Oxalate Crystallisation by Pentosan Polysulphate in Control Subjects and Stone Formers |
| Q40124798 | Inhibition of Calcium Oxalate Dihydrate Crystallization by Chemical Modifiers: I. Pyrophosphate and Methylene Blue |
| Q36951298 | Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. |
| Q49543197 | Inhibition of autophagy-attenuated calcium oxalate crystal-induced renal tubular epithelial cell injury in vivo and in vitro |
| Q82367751 | Inhibition of calcium oxalate crystal deposition on kidneys of urolithiatic rats by Hibiscus sabdariffa L. extract |
| Q30322820 | Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. |
| Q71352896 | Inhibition of calcium oxalate crystal growth in urine during treatment with allopurinol |
| Q36778774 | Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily |
| Q41039852 | Inhibition of calcium oxalate crystallisation in vitro by an extract of Bergenia ciliata |
| Q46315604 | Inhibition of calcium oxalate crystallization by commercial human serum albumin and human urinary albumin isolated from two different race groups: evidence for possible molecular differences |
| Q67967002 | Inhibition of calcium oxalate crystallization by urinary macromolecules |
| Q50905283 | Inhibition of calcium oxalate crystallization in urine. |
| Q70163732 | Inhibition of calcium oxalate monohydrate (COM) crystal growth by pyrophosphate, citrate and rat urine |
| Q57340865 | Inhibition of calcium oxalate monohydrate by poly(acrylic acid)s with different end groups |
| Q57364044 | Inhibition of calcium oxalate monohydrate crystal growth using polyelectrolytes |
| Q46056659 | Inhibition of calcium oxalate nephrotoxicity with Cymbopogon schoenanthus (Al-Ethkher). |
| Q43548863 | Inhibition of calcium oxalate precipitation by bile salts |
| Q73106189 | Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates |
| Q71600872 | Inhibition of chondroitin sulphate and heparin on the growth and agglomeration of calcium oxalate monohydrate crystals in vitro |
| Q46252223 | Inhibition of crystallization of calcium oxalate by the extraction of Tamarix gallica L. |
| Q47881900 | Inhibition of growth and aggregation of calcium oxalate crystals in vitro--a comparison of four human proteins. |
| Q43287811 | Inhibition of the crystal growth and aggregation of calcium oxalate by elemental selenium nanoparticles |
| Q46130283 | Inhibition on calcium oxalate crystallization and repair on injured renal epithelial cells of degraded soybean polysaccharide |
| Q46020444 | Inhibitions of urinary oxidative stress and renal calcium level by an extract of Quercus salicina Blume/Quercus stenophylla Makino in a rat calcium oxalate urolithiasis model. |
| Q67367385 | Inhibitor of calcium oxalate crystallisation in urine of normals and stone formers |
| Q62067710 | Inhibitors of Oxalocalcic Lithiasis: Effects of Their Interactions on Calcium Oxalate Crystallization |
| Q67565380 | Inhibitors of calcium oxalate crystallization and urolithiasis |
| Q50966224 | Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. |
| Q70334848 | Inhibitory activity of human urine on calcium oxalate crystal growth: effects of sodium urate and uric acid |
| Q36248604 | Inhibitory effect of an aqueous extract of Radix Paeoniae Alba on calcium oxalate nephrolithiasis in a rat model |
| Q74636770 | Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers |
| Q74260467 | Inhibitory effect of calcium phosphate-associated proteins on calcium oxalate crystallization: alpha2-HS-glycoprotein, prothrombin-F1 and osteopontin |
| Q68084390 | Inhibitory effect of glutamic acid and aspartic acid on calcium oxalate crystal formation |
| Q69358222 | Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin sulphate in calcium oxalate urolithiasis |
| Q42731411 | Inhibitory effect of rutin and curcumin on experimentally-induced calcium oxalate urolithiasis in rats |
| Q78625975 | Inhibitory effect of the blood on calcium oxalate precipitation |
| Q55365269 | Inhibitory effects of taraxasterol and aqueous extract of Taraxacum officinale on calcium oxalate crystallization: in vitro study. |
| Q70291869 | Inhibitory effects of urinary calcium-binding substances on calcium oxalate crystallization |
| Q67675717 | Inhibitory effects of urinary macromolecules on the crystallization of calcium oxalate |
| Q47707855 | Inhibitory potency of crystal matrix protein on the crystallization of calcium oxalate |
| Q67544105 | Injury Model of African Green Monkey Kidney Epithelial Cell and Its Modulation on Calcium Oxalate Formation |
| Q50894668 | Insights into the pathophysiology and treatment of patients with calcium oxalate nephrolithiasis. |
| Q48119451 | Integrative Analysis of miRNA and mRNA Expression Profiles in Calcium Oxalate Nephrolithiasis Rat Model |
| Q74188787 | Inter-alpha-inhibitor in urine and calcium oxalate urinary crystals |
| Q77546804 | Inter-alpha-inhibitor: a protein family involved in the inhibition of calcium oxalate crystallization |
| Q43970901 | Interaction between nephrocalcin and calcium oxalate monohydrate: a structural study |
| Q78168395 | Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal |
| Q70126486 | Interaction energies in the coagulation of calcium oxalate monohydrate |
| Q71347041 | Interaction of hyperuricuria and hyperoxaluria on renal calcium oxalate stone formation |
| Q41246947 | Interactions between calcium oxalate monohydrate crystals and Madin-Darby canine kidney cells: endocytosis and cell proliferation |
| Q74637367 | Interactions in Calcium Oxalate Hydrate/Surfactant Systems |
| Q43906605 | Interference-free sample preparation for the determination of plasma oxalate analyzed by HPLC-ER: preliminary results from calcium oxalate stone-formers and non-stone-formers |
| Q43837251 | Interleukin-1beta gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones |
| Q42536813 | Internalization of Calcium Oxalate Calculi Developed in Narrow Cavities. |
| Q44503830 | Internalization of calcium oxalate crystals by renal tubular cells: a nephron segment-specific process? |
| Q34205447 | Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate |
| Q73131779 | Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate |
| Q83116596 | Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test |
| Q80895360 | Intracellular events in the initiation of calcium oxalate stones |
| Q46533063 | Intracrystalline proteins and calcium oxalate crystal degradation in MDCK II cells |
| Q43685597 | Intracrystalline proteins and the hidden ultrastructure of calcium oxalate urinary crystals: implications for kidney stone formation |
| Q46654056 | Intracrystalline proteins and urolithiasis: a comparison of the protein content and ultrastructure of urinary calcium oxalate monohydrate and dihydrate crystals |
| Q44509157 | Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate |
| Q46278622 | Intracrystalline urinary proteins facilitate degradation and dissolution of calcium oxalate crystals in cultured renal cells. |
| Q31789816 | Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: an in vitro study |
| Q69784672 | Investigation of GAGS on 24-hour and 2-hour urines from calcium oxalate stone formers and healthy subjects |
| Q53860099 | Investigation of the possible role of sialic acid in calcium oxalate urolithiasis. |
| Q41593945 | Investigations on formation risk of calcium oxalate stones with special regard to stress (author's transl) |
| Q67746495 | Investigations on macromolecular precipitation inhibitors of calcium oxalate |
| Q72589336 | Investigations on the retention of calcium oxalate using rat experiments |
| Q35190028 | Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells |
| Q38874052 | Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury |
| Q32014102 | Irritant contact dermatitis caused by needle-like calcium oxalate crystals, raphides, in Agave tequilana among workers in tequila distilleries and agave plantations |
| Q68057979 | Is calcium oxalate an adequate explanation for nonvisualization of breast specimen calcifications? |
| Q44840945 | Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free c |
| Q71347684 | Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? |
| Q35109409 | Is precipitation of calcium phosphate an important factor for the development of calcium oxalate stones in the urinary tract |
| Q46755411 | Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis? |
| Q35639235 | Is there a role for pentosan polysulfate in the prevention of calcium oxalate stones? |
| Q71347690 | Isoelectric focusing of Tamm-Horsfall glycoproteins: a simple tool for recognizing recurrent calcium oxalate renal stone formers |
| Q80075177 | Isolated Medicago truncatula mutants with increased calcium oxalate crystal accumulation have decreased ascorbic acid levels |
| Q67427084 | Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine |
| Q72157290 | Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin |
| Q42703454 | Isolation and prevention of calcium oxalate-induced apoptotic death and oxidative stress in MDCK cells by diosgenin |
| Q30416891 | Isolation and purification of a high molecular weight substance from human urine which inhibits calcium oxalate crystal growth |
| Q70619639 | Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization |
| Q40922613 | Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid |
| Q73194743 | Isolation of Medicago truncatula mutants defective in calcium oxalate crystal formation |
| Q44615302 | Isolation of a crystal matrix protein associated with calcium oxalate precipitation in vacuoles of specialized cells |
| Q70664591 | Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine |
| Q52647134 | Isolation of intact chloroplasts with high CO2 fixation capacity from sugarbeet leaves containing calcium oxalate. |
| Q70444436 | Isolation of strontium-90, yttrium-90, promethium-147, and cerium-144 from wet ashed urine by calcium oxalate coprecipitation and sequential solvent extraction |
| Q44760498 | Isolation of urinary heparan sulfate and chondroitin sulfate and their inhibitory activity of calcium oxalate crystal growth |
| Q80895368 | Kidney models of calcium oxalate stone formation |
| Q51534203 | Kidney stone matrix proteins ameliorate calcium oxalate monohydrate induced apoptotic injury to renal epithelial cells. |
| Q67231673 | Kinetic factors influencing the dissolution behavior of calcium oxalate renal stones: a constant composition study |
| Q46135676 | Kinetics of calcium oxalate crystal growth in the presence of osteopontin isoforms: an analysis by scanning confocal interference microcopy |
| Q52944661 | Kinetics of calcium oxalate deposition in vitro. |
| Q70328805 | Kinetics of dissolution of calcium oxalate calculi with calcium-chelating irrigating solutions |
| Q67327476 | Kinetics of early time calcium oxalate nephrolithiasis |
| Q41716286 | Kinetics of the growth of Ca oxalate crystals from supersaturated solutions |
| Q33895507 | L-Ascorbic acid and L-galactose are sources for oxalic acid and calcium oxalate in Pistia stratiotes |
| Q48968893 | L-Carnitine Protects Renal Tubular Cells Against Calcium Oxalate Monohydrate Crystals Adhesion Through Preventing Cells From Dedifferentiation |
| Q31093690 | Label-free mapping of osteopontin adsorption to calcium oxalate monohydrate crystals by tip-enhanced Raman spectroscopy |
| Q38658871 | Label-free proteomic methodology for the analysis of human kidney stone matrix composition |
| Q37567536 | Lack of evidence for the association of ornithine decarboxylase (+316 G>A), spermidine/spermine acetyl transferase (-1415 T>C) gene polymorphisms with calcium oxalate stone disease |
| Q43877480 | Lack of evidence for the association of tumor necrosis factor-alpha gene promoter polymorphism with calcium oxalate stone and bladder cancer patients |
| Q51576559 | Lack of increased urinary calcium-oxalate supersaturation in long-term kidney transplant recipients. |
| Q39643813 | Lamin A/C in renal tubular cells is important for tissue repair, cell proliferation, and calcium oxalate crystal adhesion, and is associated with potential crystal receptors |
| Q34000365 | Large-scale identification of calcium oxalate monohydrate crystal-binding proteins on apical membrane of distal renal tubular epithelial cells |
| Q46963710 | Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation |
| Q53838878 | Leter: Addendum to "appraisal of calcium oxalate solubility". |
| Q69766376 | Letter: Calcium oxalate urinary-tract stones in patient's on maintenance dialysis |
| Q73839558 | Liesegang rings in cytologic samples accompanied by calcium oxalate-like crystals. A report of three cases |
| Q70035384 | Limitations of the rat remnant kidney model of chronic renal failure: absence of calcium oxalate tissue injury |
| Q44686296 | Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones |
| Q73160610 | Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis |
| Q64979119 | LncRNA-miRNA-mRNA expression variation profile in the urine of calcium oxalate stone patients. |
| Q43809616 | Localized Deposition of Calcium Oxalate around a PulmonaryAspergillus nigerFungus Ball |
| Q37919808 | Localized peripheral calcium oxalate crystal deposition caused by Aspergillus niger infection |
| Q46405828 | Long non-coding RNA CHCHD4P4 promotes epithelial-mesenchymal transition and inhibits cell proliferation in calcium oxalate-induced kidney damage |
| Q45309618 | Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients |
| Q55322221 | Losartan Ameliorates Calcium Oxalate-Induced Elevation of Stone-Related Proteins in Renal Tubular Cells by Inhibiting NADPH Oxidase and Oxidative Stress. |
| Q64069377 | Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals |
| Q69467334 | Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers |
| Q68048938 | Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males |
| Q46361440 | Low-vitamin E diet exacerbates calcium oxalate crystal formation via enhanced oxidative stress in rat hyperoxaluric kidney |
| Q37422038 | Lowering urinary oxalate excretion to decrease calcium oxalate stone disease |
| Q37330448 | M1/M2-macrophage phenotypes regulate renal calcium oxalate crystal development |
| Q46356726 | MRP-1 and BCRP Promote the Externalization of Phosphatidylserine in Oxalate-treated Renal Epithelial Cells: Implications for Calcium Oxalate Urolithiasis |
| Q72000651 | Macromolecular inhibitors of calcium oxalate crystal growth and aggregation |
| Q69207123 | Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine |
| Q34733228 | Macropinocytosis is the major mechanism for endocytosis of calcium oxalate crystals into renal tubular cells |
| Q50776917 | Madin-Darby canine kidney cells are injured by exposure to oxalate and to calcium oxalate crystals. |
| Q71756342 | Magnesium Therapy for Recurring Calcium Oxalate Urinary Calculi |
| Q71753750 | Magnesium and calcium oxalate solubility |
| Q51649550 | Magnesium excretion and calcium oxalate urolithiasis. |
| Q57224409 | Magnesium hydrogen carbonate natural mineral water enriched with K(+)-citrate and vitamin B6 improves urinary abnormalities in patients with calcium oxalate nephrolithiasis |
| Q70544133 | Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis |
| Q44552681 | Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi |
| Q70271831 | Magnesium reduces calcium oxalate crystal formation in human whole urine |
| Q51562077 | Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. |
| Q43690272 | Malic acid supplementation increases urinary citrate excretion and urinary pH: implications for the potential treatment of calcium oxalate stone disease |
| Q34129053 | Management of calcium oxalate stones. |
| Q73223996 | Mannan-binding lectin (MBL)-associated plasma protein present in human urine inhibits calcium oxalate crystal growth |
| Q67060628 | Mass Spectrométrie Trace Element Analysis of Calcium Oxalate Uroliths |
| Q33481428 | Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix |
| Q33315124 | Mass spectroscopic characteristics of low molecular weight proteins extracted from calcium oxalate stones: preliminary study |
| Q39616211 | Massive excretion of calcium oxalate from late prepupal salivary glands of Drosophila melanogaster demonstrates active nephridial-like anion transport |
| Q39670624 | Matrix Gla protein expression in NRK-52E cells exposed to oxalate and calcium oxalate monohydrate crystals. |
| Q72820899 | Matrix modulates uptake of calcium oxalate crystals and cell growth of renal epithelial cells |
| Q74098179 | Measurement of metastability, growth and aggregation of calcium oxalate in native urine. A new approach for clinical and experimental stone research |
| Q54401994 | Measurement of the risk of calcium oxalate crystallization in urine. |
| Q44158278 | Measurements of urinary state of saturation with respect to calcium oxalate and brushite (CaHPO4.2H2O) in renal stone formers |
| Q72921528 | Mechanism of allopurinol action in calcium oxalate stone formers |
| Q37082851 | Mechanism of calcium oxalate renal stone formation and renal tubular cell injury |
| Q80855001 | Mechanism of formation of human calcium oxalate renal stones on Randall's plaque |
| Q58454452 | Mechanism of inhibition of calcium oxalate crystal growth by an osteopontin phosphopeptide |
| Q50964519 | Mechanism of prevention of calcium oxalate encrustation by methylene blue and demonstration of the concentration dependence of its action. |
| Q45922873 | Mechanism underlying the low prevalence of pediatric calcium oxalate urolithiasis. |
| Q73334834 | Mechanisms involved in calcium oxalate endocytosis by Madin-Darby canine kidney cells |
| Q31904117 | Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells |
| Q46973281 | Medicago truncatula mutants demonstrate the role of plant calcium oxalate crystals as an effective defense against chewing insects |
| Q35720635 | Medical management of calcium oxalate urolithiasis |
| Q41362025 | Medical therapy, calcium oxalate urolithiasis |
| Q70033451 | Membrane interactions with calcium oxalate crystals: variation in hemolytic potentials with crystal morphology |
| Q67268439 | Membrane-associated crystallization of calcium oxalate in vitro |
| Q73397943 | Membranes and their constituents as promoters of calcium oxalate crystal formation in human urine |
| Q56457108 | Meta-Analysis of Randomized Trials for Medical Prevention of Calcium Oxalate Nephrolithiasis |
| Q44436478 | Metabolic Risk Factors in Pediatric and Adult Calcium Oxalate Urinary Stone Formers: Is There Any Difference? |
| Q36156359 | Metabolic abnormalities and the medical management of calcium oxalate nephrolithiasis. |
| Q39633194 | Metabolic assessment of recurrent and first renal calcium oxalate stone formers |
| Q77880061 | Metabolic characteristics of the elderly with recurrent calcium oxalate stones |
| Q70979158 | Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease |
| Q43075038 | Metabolic stress response patterns in urinary compositions of idiopathic calcium oxalate stone formers, patients with chronic bowel diseases and controls |
| Q35542691 | Metabolic studies on the formation of calcium oxalate stones, with special emphasis on vitamin B6 and uric acid metabolism |
| Q40689881 | Metabolic testing of the first-time calcium oxalate stone former: Is it indicated? No |
| Q74216107 | Metabolic urinary correlates of calcium oxalate dihydrate in renal stones |
| Q37117461 | Metabolomics analysis for hydroxy-L-proline-induced calcium oxalate nephrolithiasis in rats based on ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry |
| Q46801065 | Metal-ligand-coordinated vesicles and vesicle-assisted preparation of calcium oxalate |
| Q35532266 | Methods for the study of calcium oxalate crystallisation and their application to urolithiasis research |
| Q28318824 | Methylene blue and other agents as inhibitors of calcium oxalithiasis in vivo |
| Q45009236 | Micro-CT observations of the 3D distribution of calcium oxalate crystals in cotyledons during maturation and germination in Lotus miyakojimae seeds |
| Q72161098 | Microbial degradation of dietary oxalate in the human gut and urinary oxalate concentrations in patients with calcium oxalate urolithiasis and control persons |
| Q57222745 | Microorganisms and calcium oxalate stone disease |
| Q69966489 | Microstructural matrix-crystal interactions in calcium oxalate monohydrate kidney stones |
| Q70385037 | Microstructure of decalcified human calcium oxalate urinary stones |
| Q48325869 | Microstructures of Randall's plaques and their interfaces with calcium oxalate monohydrate kidney stones reflect underlying mineral precipitation mechanisms |
| Q36185864 | Microvillar injury in renal tubular epithelial cells induced by calcium oxalate crystal and the protective role of epigallocatechin-3-gallate |
| Q58004339 | Mild Tubular Damage Induces Calcium Oxalate Crystalluria in a Model of Subtle Hyperoxaluria: Evidence that a Second Hit Is Necessary for Renal Lithogenesis |
| Q57375774 | Mimicking the Biomolecular Control of Calcium Oxalate Monohydrate Crystal Growth: Effect of Contiguous Glutamic Acids |
| Q46291574 | Mimicking the growth of a pathologic biomineral: shape development and structures of calcium oxalate dihydrate in the presence of polyacrylic acid |
| Q71346913 | Mineralogic composition of 66 mixed urinary calculi of calcium oxalate and uric acid |
| Q49790690 | Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis |
| Q44758766 | Minipump induced hyperoxaluria and crystal deposition in rats: a model for calcium oxalate urolithiasis |
| Q54309479 | Mixed tumor of parotid containing calcium oxalate crystals. |
| Q46384458 | Mixed urolith (struvite and calcium oxalate) in a ferret (Mustela putorius furo). |
| Q68694407 | Mode of activation of the metabolic burst in polymorphonuclear leukocytes by calcium oxalate crystals |
| Q45087519 | Mode of crystal growth of calcium oxalate in life cycle of willow leaf (author's transl) |
| Q79931130 | Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline |
| Q79988047 | Models for protein binding to calcium oxalate surfaces |
| Q72809392 | Modification of estimation of the urinary ion-activity products of calcium oxalate and calcium phosphate |
| Q42013472 | Modifiers of calcium oxalate crystallization found in urine. I. Studies with a continuous crystallizer using an artificial urine |
| Q70140656 | Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine |
| Q69573996 | Modifiers of calcium oxalate crystallization found in urine. III. Studies on the role of Tamm-Horsfall mucoprotein and of ionic strength |
| Q46281314 | Modulation of calcium oxalate crystallization by linear aspartic acid-rich peptides |
| Q24649072 | Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning |
| Q46107596 | Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. |
| Q43812625 | Modulation of calcium oxalate monohydrate crystallization kinetics by urine of preterm neonates |
| Q41879161 | Modulation of calcium oxalate monohydrate crystallization kinetics in vitro |
| Q46278229 | Modulation of polysaccharide extracted from Laminaria on phase compositions of urinary crystal calcium oxalate |
| Q40484855 | Modulation of proliferating renal epithelial cell affinity for calcium oxalate monohydrate crystals |
| Q80111408 | Modulatory effect of the 23-kD calcium oxalate monohydrate binding protein on calcium oxalate stone formation during oxalate stress |
| Q57374460 | Molecular Mechanism of Crystal Growth Inhibition at the Calcium Oxalate/Water Interfaces |
| Q70133657 | Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis |
| Q70643747 | Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro |
| Q73131828 | Molecular detection of heparan sulfate proteoglycan mRNA in rat kidney during calcium oxalate nephrolithiasis |
| Q36643385 | Molecular modulation of calcium oxalate crystallization |
| Q36603473 | Molecular modulation of calcium oxalate crystallization by osteopontin and citrate |
| Q44329442 | Monitoring of the treatment of calcium-oxalate stone formers with the Bonn-Risk-Index |
| Q37022631 | Monocyte Mitochondrial Function in Calcium Oxalate Stone Formers |
| Q71147385 | Monohydrate calcium oxalate crystalluria in ethylene glycol poisoning |
| Q57375329 | Morphological and Phase Changes in Calcium Oxalate Crystals Induced by Sulfated Polysaccharide Extracted from AlgaeEucheuma striatum |
| Q57478995 | Morphological and micromechanical characterization of calcium oxalate (CaOx) crystals embedded in the pecan nutshell (Carya illinoinensis) |
| Q57655134 | Morphological control of calcium oxalate particles in the presence of poly-(styrene-alt-maleic acid) |
| Q46573755 | Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney |
| Q71564573 | Morphological effects of glycosaminoglycans on calcium oxalate monohydrate crystals |
| Q36576122 | Morphology and pathogenesis of urinary calculi based on data from optic polarization studies of calcium oxalate |
| Q46979143 | Morphology of crystals in calcium oxalate monohydrate kidney stones |
| Q54977848 | Mucin 4 Gene Silencing Reduces Oxidative Stress and Calcium Oxalate Crystal Formation in Renal Tubular Epithelial Cells Through the Extracellular Signal-Regulated Kinase Signaling Pathway in Nephrolithiasis Rat Model. |
| Q57864361 | Mucosal Injury From Calcium Oxalate Crystals Resembling Anaphylaxis and Angioedema |
| Q50978165 | N-acetyl-beta-D-glucosaminidase excretion in calcium oxalate stone patients and its relation to the risk of stone formation. |
| Q41877923 | Nanouric acid or nanocalcium phosphate as central nidus to induce calcium oxalate stone formation: a high-resolution transmission electron microscopy study on urinary nanocrystallites |
| Q59094630 | Natural Calcium Oxalate with Heavy Carbon |
| Q53474547 | Natural promoters of calcium oxalate monohydrate crystallization. |
| Q70748388 | Nature and significance of calcium oxalate crystals in normal human thyroid gland. A clinicopathological and immunohistochemical study |
| Q80652120 | Nephrolithiasis and nephrocalcinosis with calcium oxalate crystals in kidneys and bones |
| Q74127841 | Nephrolithiasis and nephrocalcinosis with calcium oxalate crystals in the kidneys and other organs; report of two cases |
| Q34130638 | Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals |
| Q41613582 | New and unusual forms of calcium oxalate raphide crystals in the plant kingdom |
| Q72659273 | New aspects on the composition, structure and origin of calcium oxalate monohydrate calculi |
| Q43786444 | No association of vitamin D receptor gene BsmI polymorphisms with calcium oxalate stone formation |
| Q34744378 | No contribution of ascorbic acid to renal calcium oxalate stones |
| Q52840473 | Nomograms for the estimation of the saturation of urine with calcium oxalate, calcium phosphate, magnesium ammonium phosphate, uric acid, sodium acid urate, ammonium acid urate and cystine |
| Q51020782 | Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis. |
| Q31091306 | Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children |
| Q34466178 | Novel antilithiatic cationic proteins from human calcium oxalate renal stone matrix identified by MALDI-TOF-MS endowed with cytoprotective potential: an insight into the molecular mechanism of urolithiasis |
| Q53163542 | Novel porcine model for calcium oxalate stone formation. |
| Q74123459 | Nucleation and aggregation of calcium oxalate in whole urine; spectrophotometric sedimentation analysis: a new approach to study the aggregation of calcium oxalate dihydrate |
| Q67455130 | Nucleation and growth of brushite and calcium oxalate in urine of stone-formers |
| Q70975079 | Nucleation kinetics in the calcium oxalate-sodium urate monohydrate system |
| Q77410480 | Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation |
| Q44727601 | Nucleation of calcium oxalate crystals on an imprinted polymer surface from pure aqueous solution and urine |
| Q67605255 | Nucleation,Growth,and Aggregation of Nanocrystallites in Urine of Calcium Oxalate Stone Patients as well as Kidney Stone Formation |
| Q45172531 | Nutrient intake and urine composition in calcium oxalate stone-forming dogs: comparison with healthy dogs and impact of dietary modification. |
| Q78341177 | OPTICAL CHARACTERIZATION OF CRYSTALS IN TISSUE: CYSTINE AND CALCIUM OXALATE MONOHYDRATE |
| Q39137618 | Observations Upon Calcium Oxalate Crystallization Kinetics in Simulated Urine |
| Q28327830 | Observations on calcium oxalate stone formers |
| Q68984468 | Observations on in vitro and in vivo calcium oxalate crystalluria in primary calcium stone formers and normal subjects |
| Q46512112 | Occurrence and characterisation of calcium oxalate crystals in stems and fruits of Hylocereus costaricensis and Selenicereus megalanthus (Cactaceae: Hylocereeae). |
| Q54033073 | Occurrence of calcium oxalate in karri (Eucalyptus diversicolor F. Muell.) forest ecosystems of south western Australia. |
| Q33690594 | Occurrence, types and distribution of calcium oxalate crystals in leaves and stems of some species of poisonous plants |
| Q46658070 | Oligomeric proanthocyanidins protect against HK-2 cell injury induced by oxalate and calcium oxalate monohydrate crystals |
| Q42403637 | On Oxaluria and the Treatment of Calcium Oxalate Deposit from the Urine, with a Method for the Solution of Calcium Oxalate Calculus whilst in the Urinary Passages |
| Q59103397 | On human blood, rock art and calcium oxalate: further studies on organic carbon content and radiocarbon age of materials relating to Australian rock art |
| Q39477011 | On the Presence of Insoluble Salts of Calcium (Oxalate and Phosphate) in Renal Calculi in Large Amount in a Preponderating Number of Cases, and the Bearing of this Finding upon Calcium in Gout and Allied Conditions |
| Q47905538 | On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides |
| Q52652557 | On the origin of calcium oxalate monohydrate papillary renal stones. |
| Q41497119 | On the possible role of glycosaminoglycans as natural inhibitors of calcium oxalate stones |
| Q46291905 | Oriented growth of calcium oxalate monohydrate crystals beneath phospholipid monolayers |
| Q43064351 | Origin and types of calcium oxalate monohydrate papillary renal calculi |
| Q37781054 | Orlistat and calcium oxalate crystalluria: an association that needs consideration |
| Q33539825 | Orthosiphon grandiflorum has a protective effect in a calcium oxalate stone forming rat model |
| Q43632739 | Osteocalcin gene Hind III polymorphism is not correlated with calcium oxalate stone disease |
| Q77342542 | Osteopontin antisense oligonucleotide inhibits adhesion of calcium oxalate crystals in Madin-Darby canine kidney cell |
| Q72325021 | Osteopontin inhibits nucleation of calcium oxalate crystals |
| Q44265632 | Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules |
| Q37164533 | Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition. |
| Q44004680 | Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells |
| Q30410361 | Osteotropic cancer diagnosis by an osteocalcin inspired molecular imaging mimetic |
| Q30759942 | Over-expression of anti-CD75 reactive proteins on distal and collecting renal tubular epithelial cells in calcium-oxalate stone-forming kidneys in Egypt |
| Q35895618 | Overweight and obesity: risk factors in calcium oxalate stone disease? |
| Q45159339 | Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers |
| Q50524090 | Oxalate and calcium oxalate crystals are injurious to renal epithelial cells: results of in vivo and in vitro studies. |
| Q44354199 | Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants |
| Q35154245 | Oxalate and sucralose absorption in idiopathic calcium oxalate stone formers |
| Q67786748 | Oxalate as a promoter in calcium oxalate nephrolithiasis |
| Q35175713 | Oxalate binding proteins in calcium oxalate nephrolithiasis |
| Q112158992 | Oxalate content of green juices and strategies for reduction of soluble oxalate content |
| Q43866988 | Oxalate influx rate in red blood cells in calcium oxalate nephrolithiasis |
| Q50476426 | Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. |
| Q40757848 | Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells |
| Q57227866 | Oxalate pretreatment and use of a physical developer render the Kossa method selective and sensitive for calcium |
| Q34302488 | Oxalate reduces calcium availability in the pads of the prickly pear cactus through formation of calcium oxalate crystals |
| Q71690909 | Oxalate transport and calcium oxalate renal stone disease |
| Q35863258 | Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease? |
| Q112866706 | Oxalic acid availability in human foods |
| Q36677659 | Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. |
| Q26829226 | Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis |
| Q73827946 | Oxalosis with renal calcinosis due to calcium oxalate |
| Q72999966 | Oxalosis; possible inborn error of metabolism with nephrolithiasis and nephrocalcinosis due to calcium oxalate as the predominating features |
| Q43139185 | Oxidative renal cell injury induced by calcium oxalate crystal and renoprotection with antioxidants: a possible role of oxidative stress in nephrolithiasis |
| Q50919478 | Oxygen nano-bubble water reduces calcium oxalate deposits and tubular cell injury in ethylene glycol-treated rat kidney. |
| Q28542616 | Ozone-induced responses in Croton floribundus Spreng. (Euphorbiaceae): metabolic cross-talk between volatile organic compounds and calcium oxalate crystal formation |
| Q55279793 | Papillary and nonpapillary calcium oxalate monohydrate renal calculi: comparative study of etiologic factors. |
| Q53480859 | Parenteral ambroxol treatment causes xanthine and calcium oxalate stones in rats. |
| Q70608277 | Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis |
| Q38737367 | Pathogenesis of calcium oxalate urinary stone disease: species comparison of humans, dogs, and cats. |
| Q40645279 | Pathogenic factors in calcium oxalate stones: Epidemiological investigation |
| Q77546841 | Pathological and immunocytochemical changes in chronic calcium oxalate nephrolithiasis in the rat |
| Q39545072 | Patient and environmental factors associated with calcium oxalate urolithiasis in dogs |
| Q82143004 | Patient education: tips for preventing calcium oxalate kidney stones |
| Q34874834 | Peeping into human renal calcium oxalate stone matrix: characterization of novel proteins involved in the intricate mechanism of urolithiasis |
| Q72743490 | Pentosan Polysulfate As An Inhibitor of Calcium Oxalate Crystal Growth |
| Q35050613 | Peptides of Matrix Gla protein inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals |
| Q43170564 | Pharmacological and toxicological effects of Paronychia argentea in experimental calcium oxalate nephrolithiasis in rats |
| Q30788859 | Phase transformation of calcium oxalate dihydrate-monohydrate: effects of relative humidity and new spectroscopic data |
| Q69736655 | Phase transitions of calcium oxalate trihydrate and epitaxy in the weddellite-whewellite system |
| Q37262536 | Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis |
| Q43651200 | Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals |
| Q37345818 | Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization |
| Q28291901 | Phosphorylation of osteopontin peptides mediates adsorption to and incorporation into calcium oxalate crystals |
| Q74645814 | Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells: its role in urolithiasis |
| Q70126484 | Physical chemical studies of calcium oxalate crystallization |
| Q71074514 | Physicochemical basis for the formation of calcium oxalate renal stones. Estimation of the degree of urine saturation with the activity product ratio (CPA) (author's transl) |
| Q40886608 | Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis |
| Q46430843 | Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis |
| Q45171018 | Piridoxilate-associated calcium oxalate urinary calculi: a new metabolic drug-induced nephrolithiasis |
| Q54134700 | Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. |
| Q78016647 | Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure |
| Q50931681 | Polyanionic inhibitors of calcium oxalate crystal agglomeration in urine. |
| Q70553662 | Polyhedral microcalcifications at mammography: histologic correlation with calcium oxalate |
| Q43708460 | Polysaccharide from coccoliths (CaCO3 biomineral). Influence on crystallization of calcium oxalate monohydrate |
| Q51659884 | Possibilities of computing urine parameters as a means of classification of normals and patients suffering from calcium oxalate lithiasis. |
| Q72523678 | Possible Role of Carbohydrate-Induced Calciuria in Calcium Oxalate Kidney-Stone Formation |
| Q69425134 | Possible role of Tamm-Horsfall glycoprotein in calcium oxalate crystallisation |
| Q38637926 | Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis |
| Q28254324 | Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis |
| Q44491095 | Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall's plugs and calcium oxalate crystalluria in a computer model of renal function |
| Q56828027 | Precipitation of Amorphous Calcium Oxalate in Aqueous Solution |
| Q79723832 | Precipitation of calcium oxalate from homogeneous solution by cation release |
| Q73131793 | Precipitation of calcium oxalate monohydrate at phospholipid monolayers |
| Q74220360 | Predicting the crystallization potential of urine from cats and dogs with respect to calcium oxalate and magnesium ammonium phosphate (struvite) |
| Q38995822 | Predictive factors of extracorporeal shock wave lithotripsy success for urinary stones |
| Q64246327 | Predictors of Uric Acid Stones: Mean Stone Density, Stone Heterogeneity Index, and Variation Coefficient of Stone Density by Single-Energy Non-Contrast Computed Tomography and Urinary pH |
| Q43185994 | Preparation of calcium oxalate by vesicle modification in the catanionic surfactant system CDS/TTABr/H2O. |
| Q30853751 | Preparation of calcium oxalate-bromopyrogallol red inclusion sorbent and application to treatment of cationic dye and heavy metal wastewaters |
| Q44295326 | Presence and racemisation of amino acids in calcium oxalate patinas. A case study from the Baptistery in Parma, Italy. |
| Q54330633 | Presence of Oxalobacter formigenes in the intestinal tract is associated with the absence of calcium oxalate urolith formation in dogs. |
| Q54140233 | Presence of amino acids in calculi of calcium oxalate |
| Q68355330 | Presence of calcium oxalate crystals in the mammalian thyroid gland |
| Q67819019 | Prevalence of calcium oxalate uroliths in miniature schnauzers |
| Q71837319 | Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease |
| Q64063989 | Prevention of Calcium Nephrolithiasis: The Influence of Diuresis on Calcium Oxalate Crystallization in Urine |
| Q71246891 | Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300 |
| Q38123964 | Primary hyperoxaluria type 1 with systemic calcium oxalate deposition: case report and literature review |
| Q24337342 | Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis |
| Q78917257 | Primary hyperoxaluria. I. Clinical and pathologic findings in a patient with calcium oxalate nephrocalcinosis |
| Q45067118 | Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy |
| Q42816596 | Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin? |
| Q67968860 | Procedure for the measurement of calcium oxalate and phosphate crystals in urine |
| Q45886346 | Production of calcium oxalate crystals by the basidiomycete Moniliophthora perniciosa, the causal agent of witches' broom disease of Cacao |
| Q44112964 | Production of calcium oxalate monohydrate, dihydrate or trihydrate. A comparative study |
| Q79134659 | Production of calcium oxalate renal calculi in vitamin B6-deficient rats. Study of the influence of urine pH |
| Q67972320 | Promotive effect of urine from patients with primary hyperparathyroidism on calcium oxalate crystal aggregation in an in vitro whole urine system |
| Q71386450 | Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score |
| Q46471961 | Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial |
| Q35217548 | Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model |
| Q44489134 | Prophylaxis of calcium oxalate stones by Herniaria hirsuta on experimentally induced nephrolithiasis in rats |
| Q33464133 | Prophylaxis of experimentally induced calcium oxalate nephrolithiasis in rats by Zhulingtang, a traditional Chinese herbal formula |
| Q44590161 | Prospective Study on the Efficacy of a Selective Treatment and Risk Factors for Relapse in Recurrent Calcium Oxalate Stone Patients |
| Q38675030 | Protective Effects of Pistacia lentiscus L. fruit extract against calcium oxalate monohydrate induced proximal tubular injury |
| Q73514446 | Protective effect of triterpenes on calcium oxalate crystal-induced peroxidative changes in experimental urolithiasis |
| Q58576781 | Protective potential of Angelica sinensis polysaccharide extract against ethylene glycol-induced calcium oxalate urolithiasis |
| Q46213021 | Protective use of calcium in case of osteoporosis versus calcium oxalate stones |
| Q49719089 | Protein Network Analysis and Functional Studies of Calcium Oxalate Crystal-Induced Cytotoxicity in Renal Tubular Epithelial Cells |
| Q30322720 | Protein electrostatic surface distribution can determine whether calcium oxalate crystal growth is promoted or inhibited. |
| Q73235859 | Proteoglycan core protein in human urine and its possible role on calcium oxalate urolithiasis |
| Q46475233 | Proteolysis and partial dissolution of calcium oxalate: a comparative, morphological study of urinary crystals from black and white subjects |
| Q43043129 | Proteome changes in human monocytes upon interaction with calcium oxalate monohydrate crystals |
| Q44804092 | Proteomic analysis of a rare urinary stone composed of calcium carbonate and calcium oxalate dihydrate: a case report |
| Q42784845 | Proteomic analysis of altered proteins in distal renal tubular cells in response to calcium oxalate monohydrate crystal adhesion: Implications for kidney stone disease |
| Q39930004 | Proteomic analysis of calcium oxalate monohydrate crystal-induced cytotoxicity in distal renal tubular cells |
| Q41964895 | Pseudomorphoses in calcium oxalate urinary calculi |
| Q39717892 | Pseudomorphs of barite and biogenic ZnS after phyto-crystals of calcium oxalate (whewellite) in the peat layer of a poor fen. |
| Q80218860 | Pulmonary Aspergillus-associated calcium oxalate crystals |
| Q73426842 | Pure silicate fragment in a recurrent stone former of calcium oxalate |
| Q70729963 | Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium |
| Q71070836 | Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine |
| Q71153582 | Pyridoxine therapy in patients with renal calcium oxalate calculi |
| Q36598250 | Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine |
| Q72019476 | Quantification of Crystal Growth of Calcium Oxalate in Gel and its Modification by Urinary Constituents in a New Flow Model of Crystallization |
| Q43861715 | Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients |
| Q49577256 | Quantitative Mineralogical Composition of Calculi and Urine Abnormalities for Calcium Oxalate Stone Formers: A Single-Center Results. |
| Q54331122 | Quantitative analysis of colonization with real-time PCR to identify the role of Oxalobacter formigenes in calcium oxalate urolithiasis. |
| Q67340800 | Quantitative element investigations in urine, serum, kidney and muscle tissue of calcium oxalate stone patients |
| Q44082868 | Quiz page. Diabetic nephropathy and extensive, superimposed, intratubular, calcium oxalate crystals, due to enteric hyperoxaluria |
| Q72582572 | Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis |
| Q71779820 | Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine |
| Q62702221 | Raman spectroscopic analysis of the calcium oxalate producing extremotolerant lichen Circinaria gyrosa |
| Q46830538 | Raman spectroscopy study of calcium oxalate extracted from cacti stems |
| Q38237482 | Randall's plaque as the origin of calcium oxalate kidney stones |
| Q36449199 | Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis |
| Q46842401 | Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones |
| Q52870729 | Randomized trial of allopurinol in the prevention of calcium oxalate calculi. |
| Q44635975 | Randomized trials in the prevention of recurrent calcium oxalate stones |
| Q45116574 | Rapid Communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate |
| Q83486083 | Rare calcium oxalate monohydrate calculus attached to the wall of the renal pelvis |
| Q43225640 | Rate and frequency of recurrence of uroliths after an initial ammonium urate, calcium oxalate, or struvite urolith in cats. |
| Q72505804 | Re: Ascorbate acid overdosing: a risk factor for calcium oxalate nephrolithiasis |
| Q70683170 | Re: Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis |
| Q44398121 | Re: Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups |
| Q83674055 | Re: Ethylene glycol induces calcium oxalate crystal deposition in malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis |
| Q77162358 | Re: Metabolic urinary correlates of calcium oxalate dihydrate in renal stones |
| Q83477496 | Re: Serum testosterone may be associated with calcium oxalate urolithogenesis (from: Watson JM, Shrewsberry AB, Taghechian S, et al. J Endourol 2010;24:1183-1187) |
| Q47397607 | Re: Stewart et al.: stone size limits the use of hounsfield units for prediction of calcium oxalate stone composition (Urology 2015;85:292-295). |
| Q45275254 | Re: The role of Oxalobacter formigenes colonization in calcium oxalate stone disease |
| Q70616553 | Re: Transmembrane oxalate exchange and its relationship to idiopathic calcium oxalate nephrolithiasis |
| Q82529855 | Re: diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation |
| Q83424101 | Re: primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis |
| Q38047594 | Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations |
| Q41928309 | Reactive oxygen species may unite many mechanisms by which calcium oxalate stones form |
| Q40332945 | Reactive oxygen species mediated calcium oxalate crystal-induced expression of MCP-1 in HK-2 cells |
| Q34454068 | Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis |
| Q21146676 | Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate decarboxylase prevents renal calcium oxalate stone deposition in experimental rats |
| Q73694515 | Recurrent calcium oxalate nephrolithiasis induced by naftidrofuryl oxalate |
| Q77761482 | Recurrent calcium oxalate urolithiasis in a man with familial periodic paralysis and hypokalemia |
| Q42966925 | Red blood cell membrane fragments but not intact red blood cells promote calcium oxalate monohydrate crystal growth and aggregation |
| Q53924088 | Red blood cell transmembrane oxalate flux in calcium-oxalate nephrolithiasis. |
| Q68064752 | Reduction of urinary oxalate by combined calcium and citrate administration without increase in urinary calcium oxalate stone formers |
| Q39529402 | Reevaluation of the plant "gemstones": Calcium oxalate crystals sustain photosynthesis under drought conditions. |
| Q46466794 | Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers |
| Q38672152 | Regulation of bone mineral density in the grey squirrel, Sciurus carolinensis: Bioavailability of calcium oxalate, and implications for bark stripping |
| Q40902061 | Regulation of renal epithelial cell affinity for calcium oxalate monohydrate crystals |
| Q41555017 | Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals |
| Q36068696 | Reinjury risk of nano-calcium oxalate monohydrate and calcium oxalate dihydrate crystals on injured renal epithelial cells: aggravation of crystal adhesion and aggregation |
| Q44643903 | Relation between calcium oxalate hydrate form found in renal calculi and some urinary parameters |
| Q71403165 | Relation of phosphate to formation of calcium oxalate urinary calculi |
| Q47883230 | Relations between oxalic acid, calcium, magnesium and creatinine excretion in normal men and male patients with calcium oxalate kidney stones |
| Q74459930 | Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers |
| Q31920735 | Relaxation of micro indentations in calcium oxalate urinary stones |
| Q35757534 | Relevance of dietary protein concentration and quality as risk factors for the formation of calcium oxalate stones in cats |
| Q46127206 | Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer |
| Q54258137 | Renal Allograft With Calcium Oxalate Deposition: Association with Urinary Tract Infection and Development of Interstitial Fibrosis. |
| Q48264028 | Renal Calcium Oxalate Deposits Induce a Pro-Atherosclerotic and Pro-Osteoporotic Response in Mice |
| Q49822963 | Renal Epithelial Cell Injury Induced by Calcium Oxalate Monohydrate Depends on their Structural Features: Size, Surface, and Crystalline Structure. |
| Q61445749 | Renal and Ureteric Stone Composition: A five year retrospective study for Northern Ireland |
| Q74130622 | Renal calcium oxalate binding protein: studies on its properties |
| Q35058062 | Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney |
| Q41124598 | Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals |
| Q50532552 | Renal epithelial cell injury and its promoting role in formation of calcium oxalate monohydrate. |
| Q35608154 | Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals |
| Q57717692 | Renal excretion of calcium, oxalate and magnesium between 3 and 16 years: the value of overnight urine. The Cimitile Study |
| Q51602886 | Renal handling of calcium in hypercalciuric calcium oxalate nephrolithiasis. |
| Q37208998 | Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease |
| Q73345746 | Renal injury mediated calcium oxalate nephrolithiasis: role of lipid peroxidation |
| Q46979443 | Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients |
| Q44783596 | Renal intratubular crystallisation of calcium oxalate and naftidrofuryl oxalate |
| Q46744364 | Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones |
| Q83276736 | Renal oxidative vulnerability due to changes in mitochondrial-glutathione and energy homeostasis in a rat model of calcium oxalate urolithiasis |
| Q34622282 | Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: a case series study |
| Q71266282 | Renal papillary changes in patient with calcium oxalate lithiasis |
| Q66916670 | Renal stone formation. The inhibitory effect of urine on calcium oxalate precipitation |
| Q43237329 | Renal toxicity of ethylene glycol results from internalization of calcium oxalate crystals by proximal tubule cells |
| Q46967936 | Renal transplantation in cats with calcium oxalate urolithiasis: 19 cases (1997-2004). |
| Q52737104 | Renal tubular calcium oxalate crystal deposition. Its possible relation to methoxyflurane anesthesia |
| Q39663022 | Renal tubular cell membranes inhibit growth but promote aggregation of calcium oxalate monohydrate crystals |
| Q43240432 | Renal tubular epithelial cell injury and oxidative stress induce calcium oxalate crystal formation in mouse kidney. |
| Q35978549 | Renal tubular injury induced by ischemia promotes the formation of calcium oxalate crystals in rats with hyperoxaluria |
| Q38719523 | Response of renal tubular cells to differential types and doses of calcium oxalate crystals: Integrative proteome network analysis and functional investigations |
| Q41532576 | Response surface methodology based extraction of Tribulus terrestris leads to an upsurge of antilithiatic potential by inhibition of calcium oxalate crystallization processes |
| Q58559315 | Response to Lange re: Calcium Oxalate Urolithiasis: A Case of Missing Microbes? |
| Q72615892 | Retardation of calcium oxalate formation by polyacidic peptides |
| Q70619281 | Retardation of calcium oxalate precipitation by glutamic-oxalacetic-transaminase activity |
| Q39980004 | Retardation of dissolution and growth of calcium oxalate monohydrate |
| Q67882638 | Retention of calcium oxalate crystals in renal tubules |
| Q57098173 | Revealing the Crystal Structure of Anhydrous Calcium Oxalate, Ca[C2O4], by a Combination of Atomistic Simulation and Rietveld Refinement |
| Q43083211 | Reverse engineering the kidney: modelling calcium oxalate monohydrate crystallization in the nephron |
| Q72366651 | Reversible acute renal failure with calcium oxalate cast nephropathy--possible role of ascorbic acid |
| Q46288325 | Reversible inhibition of calcium oxalate monohydrate growth by an osteopontin phosphopeptide |
| Q44667681 | Risk factor analysis and relative supersaturation as tools for identifying calcium oxalate stone-forming dogs |
| Q63441836 | Risk factors associated with calcium oxalate urolithiasis in dogs evaluated at general care veterinary hospitals in the United States |
| Q39948676 | Risk factors for the incidence of calcium oxalate uroliths or magnesium ammonium phosphate uroliths for dogs in Ontario, Canada, from 1998 to 2006 |
| Q44683678 | Risk factors for urinary calcium oxalate crystals as revealed by their specific enzymatic assay |
| Q71716644 | Risk factors in urinary calcium oxalate stone formation and their relation to urinary calcium oxalate supersaturation |
| Q40912345 | Risk formulas in calcium oxalate urolithiasis |
| Q38955951 | Risk of Chronic Kidney Disease in Brushite Stone Formers Compared With Idiopathic Calcium Oxalate Stone Formers |
| Q57223708 | Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women |
| Q42165375 | Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen |
| Q38891343 | Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis |
| Q68206946 | Role of Agglomeration in Calcium Oxalate Monohydrate Urolith Development |
| Q44103148 | Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India |
| Q44644812 | Role of Oxalobacter formigenes in calcium oxalate stone disease: a study from North India. |
| Q44211274 | Role of Tamm-Horsfall protein and uromodulin in calcium oxalate crystallization |
| Q73593564 | Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals |
| Q77546829 | Role of calcium oxalate monohydrate crystal interactions with renal epithelial cells in the pathogenesis of nephrolithiasis: a review |
| Q46149245 | Role of cellular oxalate in oxalate clearance of patients with calcium oxalate monohydrate stone formation and normal controls |
| Q39380164 | Role of gut microbiota against calcium oxalate |
| Q40661956 | Role of heparan sulfate proteoglycan (syndecan-1) on the renal epithelial cells during calcium oxalate monohydrate crystal attachment. |
| Q46269263 | Role of inter-alpha-inhibitor and its related proteins in experimentally induced calcium oxalate urolithiasis. Localization of proteins and expression of bikunin gene in the rat kidney |
| Q37116381 | Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone |
| Q46977143 | Role of lipids in urinary stones: studies of calcium oxalate precipitation at phospholipid langmuir monolayers |
| Q69175868 | Role of magnesium in the growth of calcium oxalate monohydrate and calcium oxalate dihydrate crystals |
| Q40546454 | Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis |
| Q70758189 | Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones |
| Q46428921 | Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin |
| Q80895355 | Role of renal epithelial cells in the initiation of calcium oxalate stones |
| Q73131804 | Role of sex hormones in experimental calcium oxalate nephrolithiasis |
| Q46380977 | Role of the organic matter in calcium oxalate lithiasis |
| Q83211651 | Role of uric acid in different types of calcium oxalate renal calculi |
| Q46692972 | Role of urinary bikunin in the inhibition of calcium oxalate crystallization |
| Q44845030 | Role of urinary zinc and copper on calcium oxalate stone formation |
| Q43973657 | Role of uropontin in calcium oxalate lithogenesis |
| Q52356823 | Roles of Macrophage Exosomes in Immune Response to Calcium Oxalate Monohydrate Crystals. |
| Q53588608 | Rottlerin, a polyphenolic compound from the fruits of Mallotus phillipensis (Lam.) Müll.Arg., impedes oxalate/calcium oxalate induced pathways of oxidative stress in male wistar rats. |
| Q39211110 | Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis |
| Q46281369 | SEM, XRD and FTIR investigation on crystal growth of calcium oxalate modulated by sodium tartrate |
| Q40107050 | SaRNA-mediated activation of TRPV5 reduces renal calcium oxalate deposition in rat via decreasing urinary calcium excretion |
| Q71508869 | Sampling errors in the determination of urine calcium and oxalate: solubility of calcium oxalate in HCl-urine mixtures |
| Q67431781 | Saturation-Inhibition Index as a Measure of the Risk of Calcium Oxalate Stone Formation in the Urinary Tract |
| Q41280879 | Scanning Electron Microscopic Study of Calcium Oxalate Concretions Grown in Gel System and Calcium Oxalate Stones |
| Q72580373 | Scanning electron microscopic study of the effect of citrate and pyrophosphate on calcium oxalate crystal morphology |
| Q61773835 | Scanning electron microscopy and molecular modeling of inhibition of calcium oxalate monohydrate crystal growth by citrate and phosphocitrate |
| Q66974430 | Scanning electron microscopy of calcium oxalate crystal formation in experimental nephrolithiasis |
| Q36618675 | Scanning electron microscopy studies of the structure of calcium oxalate urinary calculi |
| Q64936939 | Search for crystals in synovial fluid |
| Q46591968 | Second prize: Comprehensive proteomic analysis of human calcium oxalate monohydrate kidney stone matrix |
| Q40674033 | Secondary cutaneous oxalosis: cutaneous deposition of calcium oxalate dihydrate after long-term hemodialysis |
| Q39148429 | Secreted products of macrophages exposed to calcium oxalate crystals induce epithelial mesenchymal transition of renal tubular cells via RhoA-dependent TGF-β1 pathway |
| Q55419541 | Selected medical aspects of the problem of calcium oxalate stones: a review. |
| Q36710345 | Sensitivity and specificity of 24-hour urine chemistry levels for detecting elevated calcium oxalate and calcium phosphate supersaturation. |
| Q72344578 | Separate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: differences between stone formers and normal control subjects |
| Q38663685 | Serum antioxidant enzyme levels are decreased in patients with urinary calcium oxalate stones |
| Q51609347 | Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. |
| Q35005689 | Serum estradiol and testosterone levels in kidney stones disease with and without calcium oxalate components in naturally postmenopausal women |
| Q42999469 | Serum testosterone may be associated with calcium oxalate urolithogenesis |
| Q79488995 | Serum, urinary and stone zinc, iron, magnesium and copper levels in idiopathic calcium oxalate stone patients |
| Q41243516 | Shape-dependent cellular toxicity on renal epithelial cells and stone risk of calcium oxalate dihydrate crystals |
| Q45962637 | Shock wave induced kidney injury promotes calcium oxalate deposition. |
| Q36909368 | Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations |
| Q41033073 | Should Recurrent Calcium Oxalate Stone formers become Vegetarians? |
| Q38236336 | Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? |
| Q43795982 | Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals |
| Q79832377 | Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation |
| Q70126493 | Significance of glycosaminoglycans for the formation of calcium oxalate stones |
| Q68463962 | Simple method for the study of heterogeneous nucleation in calcium oxalate urolithiasis |
| Q43613565 | Simple tests to determine urinary risk factors and calcium oxalate crystallization in the outpatient clinic |
| Q51463857 | Simplified estimates of ion-activity products of calcium oxalate and calcium phosphate in mouse urine. |
| Q64997794 | Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. |
| Q61816619 | Sirt3 suppresses calcium oxalate-induced renal tubular epithelial cell injury via modification of FoxO3a-mediated autophagy |
| Q37620614 | Size-dependent cellular uptake mechanism and cytotoxicity toward calcium oxalate on Vero cells |
| Q36618548 | Size-shape analysis of calcium oxalate crystals in the study of stone formation. |
| Q40344585 | Sodium Urate Accelerates Precipitation of Calcium Oxalate In Vitro |
| Q46235316 | Sodium fluoride dissolution of human calcium oxalate/phosphate stone particles |
| Q45067711 | Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo |
| Q67318989 | Solubility of Calcium Oxalate in 1-Alkanols and Ethanol-Water Mixtures |
| Q71301285 | Solubility of calcium oxalate in human urine, simulated urine, and water |
| Q70123595 | Solubility of calcium oxalate monohydrate and hydroxyapatite in EDTA solutions |
| Q72859169 | Solubility, inhibited growth and dissolution kinetics of calcium oxalate crystals in solutions, containing hippuric acid |
| Q39305972 | Solubility, structure, and morphology in the co-precipitation of cadmium and zinc with calcium-oxalate |
| Q43654448 | Some observations on the demonstration of calcium oxalate in tissue sections |
| Q43111869 | Spatial and temporal clustering of calcium oxalate and magnesium ammonium phosphate uroliths in dogs living in Ontario, Canada between 1998 and 2006. |
| Q64044875 | Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria |
| Q35940200 | Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals |
| Q73131807 | Specific modulatory effect of arachidonic acid on human red blood cell oxalate transport: clinical implications in calcium oxalate nephrolithiasis |
| Q52550613 | Specificity in calcium oxalate adherence to papillary epithelial cells in cultures. |
| Q44834447 | Specificity of growth inhibitors and their cooperative effects in calcium oxalate monohydrate crystallization |
| Q46059170 | Spontaneous urinary calcium oxalate crystallization in hypercalciuric children. |
| Q62590861 | Stabilization of Calcium Oxalate Metastable Phases by Oligo(l-glutamic acid): Effect of Peptide Chain Length |
| Q46947561 | Stabilization of calcium oxalate suspension by urinary macromolecules, probably an efficient protection from stone formation |
| Q35079441 | Stabilization of submicron calcium oxalate suspension by chondroitin sulfate C may be an efficient protection from stone formation |
| Q46284873 | Stable amorphous calcium oxalate: synthesis and potential intermediate in biomineralization |
| Q72652082 | Staining with glyoxal-bis-(2-hydroxy-anil) to identify calcium oxalate in urinary stones |
| Q69598795 | Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers |
| Q52696384 | State of translocated Ca2+ by sarcoplasmic reticulum inferred from kinetic analysis of calcium oxalate precipitation |
| Q67236100 | Stimulation of synovial fibroblasts by calcium oxalate and monosodium urate monohydrate. A mechanism of connective tissue degradation in oxalosis and gout |
| Q34369828 | Stone clearance after extracorporeal shockwave lithotripsy in patients with solitary pure calcium oxalate stones smaller than 1.0 cm in the proximal ureter, with special reference to monohydrate and dihydrate content |
| Q44508645 | Stone recurrence predictive score (SRPS) for patients with calcium oxalate stones. |
| Q38284080 | Stone size limits the use of Hounsfield units for prediction of calcium oxalate stone composition |
| Q45936096 | Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats. |
| Q24545733 | Strategies for preventing calcium oxalate stones |
| Q39505193 | Stress as a principal cause of calcium oxalate urolithiasis |
| Q59084375 | Structure of Calcium Oxalate Monohydrate |
| Q67257184 | Structure of calcium oxalate stones in thin sections |
| Q44276072 | Studies of sodium pentosan polysulphate (SPP) therapy on the urinary stone disease. Experimental studies on the calcium oxalate crystallization and the effects in healthy subjects |
| Q45938618 | Studies of urinary calcium oxalate crystallization in clinical research. |
| Q44945920 | Studies on bladder stone disease in Thailand. XV. Factors affecting the solubility of calcium oxalate |
| Q74001841 | Studies on calcium oxalate binding proteins: effect of lipid peroxidation |
| Q71643333 | Studies on calcium oxalate monohydrate crystallization: influence of inhibitors |
| Q70794088 | Studies on crystalluria in calcium oxalate stone formers |
| Q66986540 | Studies on distribution of inorganic elements in urinary stones by electron probe X-ray microanalyser. Report 1. Calcium oxalate stone and calcium oxalate and calcium phosphate stone (author's transl) |
| Q72336813 | Studies on structure of calcium oxalate monohydrate renal papillary calculi. Mechanism of formation |
| Q51655400 | Studies on the crystallization tendency of calcium oxalate in urine--a study of experimental and computer-assisted determination of the risk of urinary calculi formation |
| Q46011036 | Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation. |
| Q68479748 | Studies on tryptophan metabolism in calcium oxalate urolithiasis |
| Q43940438 | Studies on urinary calcium ion activity in urolithiasis, 2. The relationship to calcium oxalate crystal formation and the effects of magnesium and citrate |
| Q71047907 | Studies on urolithiasis: crystal aggregation in calcium oxalate stone formers (author's transl) |
| Q38788768 | Studies using a porcine model: what insights into human calcium oxalate stone formation mechanisms has this model facilitated? |
| Q46436577 | Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions |
| Q51527459 | Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects. |
| Q67671879 | Study of factors affecting calcium oxalate crystalline aggregation |
| Q53711228 | Study of inhibition mechanisms of glycosaminoglycans on calcium oxalate monohydrate crystals by atomic force microscopy. |
| Q70564174 | Study of the microstructure of renal stones: uric acid and calcium oxalate |
| Q71289267 | Study on calcium oxalate monohydrate renal uroliths. I. Qualitative properties |
| Q71289273 | Study on calcium oxalate monohydrate renal uroliths. III. Composition and density |
| Q28282783 | Study on irritation of calcium oxalate crystal in Araceae plants |
| Q42912520 | Study on nano- and microcrystallites in the urines of calcium oxalate stone formers |
| Q36575951 | Studying inhibition of calcium oxalate stone formation: an in vitro approach for screening hydrogen sulfide and its metabolites |
| Q41445271 | Submicroscopic Investigations on Calcium Oxalate Stone Genesis |
| Q74329147 | Substituting milk for apple juice does not increase kidney stone risk in most normocalciuric adults who form calcium oxalate stones |
| Q40229114 | Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. |
| Q70042080 | Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate |
| Q36480347 | Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. |
| Q33409620 | Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals |
| Q68858977 | Supersaturation levels and crystallization rates of calcium oxalate from urines of normal humans and stone formers determined by a 14C-oxalate technique |
| Q37206519 | Surface aggregation of urinary proteins and aspartic Acid-rich peptides on the faces of calcium oxalate monohydrate investigated by in situ force microscopy |
| Q41141403 | Surface exposure of phosphatidylserine increases calcium oxalate crystal attachment to IMCD cells |
| Q35999345 | Surface heat shock protein 90 serves as a potential receptor for calcium oxalate crystal on apical membrane of renal tubular epithelial cells |
| Q69590476 | Surface interaction between glycosaminoglycans and calcium oxalate |
| Q68923699 | Surface phase transition of hydrated calcium oxalate crystal in the presence of normal and stone-formers' urine |
| Q69644421 | Surface studies of calcium oxalate dihydrate single crystals during dissolution in the presence of stone-formers' urine |
| Q69410408 | Surface studies of calcium oxalate dihydrate single crystals during dissolution in the presence of urine |
| Q73424115 | Suspected calcium oxalate raphide irritation in a black rhinoceros (Diceros bicornis) due to ingestion of Xanthosoma mafaffa |
| Q30976050 | Synthesis of calcium oxalate trihydrate: New data by vibrational spectroscopy and synchrotron X-ray diffraction. |
| Q39764434 | Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy |
| Q33687636 | Systematic evaluation for effects of urine pH on calcium oxalate crystallization, crystal-cell adhesion and internalization into renal tubular cells |
| Q46744283 | TAP 2 gene Msp-I polymorphism might be associated with calcium oxalate stone disease |
| Q78235978 | THE EFFECT OF URINARY AMINO ACIDS UPON THE SOLUBILITY OF CALCIUM OXALATE |
| Q81124118 | THE RAPHIDES OF CALCIUM OXALATE |
| Q70376652 | Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro |
| Q36761702 | Tamm-Horsfall glycoprotein--inhibitor or promoter of calcium oxalate monohydrate crystallization processes? |
| Q72149591 | Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectroscopy |
| Q72712638 | Tamm-Horsfall mucoprotein reduces promotion of calcium oxalate crystal aggregation induced by urate in human urine in vitro |
| Q36644826 | Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies |
| Q28504800 | Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation |
| Q34933656 | Tea polyphenol protects against HK-2 cell injury induced by oxalate and calcium oxalate monohydrate crystals |
| Q57365218 | Templating the Nucleation of Calcium Oxalate Monohydrate via Micropatterned Self-Assembled Monolayers on Gold |
| Q47966804 | Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis |
| Q39631531 | Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals |
| Q43834893 | Testing the predictability of the relative urinary supersaturation from the Bonn-Risk-Index for calcium oxalate stone formation |
| Q36805215 | Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats |
| Q71054371 | Texture examinations on grain and thin section preparations of calcium oxalate calculi and their relations to pathogenetic parameters |
| Q57345949 | The Crystallization of Calcium Oxalate Hydrates Formed by Interaction Between Microorganisms and Minerals |
| Q27315204 | The Interaction between Enterobacteriaceae and Calcium Oxalate Deposits |
| Q64972212 | The Protective Roles of Estrogen Receptor β in Renal Calcium Oxalate Crystal Formation via Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury. |
| Q42579250 | The Relation between the Microscopic Appearance of Precipitated Calcium Oxalate and the Opacity of its Suspensions |
| Q44410372 | The Role of Osteopontin on Calcium Oxalate Crystal Formation |
| Q57351126 | The Role ofEscherichia coliform in the Biomineralization of Calcium Oxalate Crystals |
| Q67885997 | The Sarig test. A simple method to evaluate the inhibitory effect on urinary crystallization of calcium oxalate |
| Q50181814 | The Synthesized Plant Metabolite 3,4,5-Tri-O-Galloylquinic Acid Methyl Ester Inhibits Calcium Oxalate Crystal Growth in a Drosophila Model, Downregulates Renal Cell Surface Annexin A1 Expression, and Decreases Crystal Adhesion to Cells. |
| Q57167416 | The association of calcium oxalate deposition in kidney allografts with graft and patient survival |
| Q46465601 | The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions |
| Q57098186 | The basic and derivative structures of calcium oxalate monohydrate |
| Q44184044 | The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin |
| Q45114078 | The cardiac content of sarcoplasmic reticulum in the rat determined by calcium uptake rate, calcium oxalate capacity, ryanodine binding and thapsigargin titration |
| Q70980420 | The clinical significance of assessment of serum calcium oxalate saturation in the hyperoxaluria syndromes |
| Q69465610 | The composition of four-hour urine samples from patients with calcium oxalate stone disease |
| Q82142248 | The composition, optical and crystallographic properties of two calcium oxalate-chloride double salts |
| Q46822094 | The concentration of Zn, Mg and Mn in calcium oxalate monohydrate stones appears to interfere with their fragility in ESWL therapy |
| Q68233980 | The contribution of dietary purine over-consumption to hyperpuricosuria in calcium oxalate stone formers |
| Q46776473 | The correlation between tissue injury and calcium oxalate crystal production in rat's lung with experimental Aspergillus niger infection |
| Q45253461 | The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation |
| Q44533568 | The density and protein content of calcium oxalate crystals precipitated from human urine: a tool to investigate ultrastructure and the fractional volume occupied by organic matrix |
| Q73166869 | The dependence on membrane fluidity of calcium oxalate crystal attachment to IMCD membranes |
| Q44000976 | The development of continuous crystallizer and observation of formation and growth of calcium oxalate crystals |
| Q72866807 | The direct measurement of inhibitory capacity to crystal growth of calcium oxalate in undiluted urine and in other inhibitor containing solutions |
| Q70432347 | The dissolution of calcium oxalate kidney stones. A kinetic study |
| Q67746474 | The dual effect of urinary macromolecules on the crystallization of calcium oxalate endogenous in urine |
| Q69098530 | The dual role of polyelectrolytes and proteins as mineralization promoters and inhibitors of calcium oxalate monohydrate |
| Q34128357 | The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation |
| Q67327480 | The effect of allopurinol on calcium oxalate (whewellite) precipitation |
| Q54615407 | The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. |
| Q36737559 | The effect of calcium on calcium oxalate monohydrate crystal-induced renal epithelial injury |
| Q69559173 | The effect of crystalline monosodium urate on the crystallisation of calcium oxalate in whole human urine |
| Q68761521 | The effect of decreasing the concentration of urinary urate on the crystallization of calcium oxalate in undiluted human urine |
| Q69591029 | The effect of dietary refined sugars and sugar alcohols on renal calcium oxalate deposition in ethylene glycol-treated rats |
| Q44138034 | The effect of different diets on urine composition and the risk of calcium oxalate crystallisation in healthy subjects |
| Q44560849 | The effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stoneformers |
| Q69467260 | The effect of fenquizone on the urinary inhibitors of calcium oxalate urolithiasis |
| Q68039300 | The effect of glucose intake on urine saturation with calcium oxalate, calcium phosphate, uric acid and sodium urate |
| Q43646977 | The effect of glycosaminoglycans on calcium oxalate crystal formation |
| Q45185050 | The effect of glycosaminoglycans on the crystallisation of calcium oxalate |
| Q71508106 | The effect of heparan sulphate on the crystallization of calcium oxalate in undiluted, ultrafiltered human urine |
| Q48227843 | The effect of hydrodynamic and thermodynamic factors and the addition of citric acid on the precipitation of calcium oxalate dihydrate. |
| Q39480917 | The effect of intracrystalline and surface-bound osteopontin on the attachment of calcium oxalate dihydrate crystals to Madin-Darby canine kidney (MDCK) cells in ultrafiltered human urine. |
| Q40609165 | The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions |
| Q69827364 | The effect of magnesium and pyridoxine on formation of calcium oxalate sones in man |
| Q43412538 | The effect of monosodium urate on the capacity of urine, chondroitin sulphate and heparin to inhibit calcium oxalate crystal growth and aggregation |
| Q71808742 | The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells |
| Q70015393 | The effect of pH on the risk of calcium oxalate crystallization in urine |
| Q71569799 | The effect of pH on the urinary inhibition of calcium oxalate crystal growth |
| Q42146961 | The effect of preincubation of seed crystals of uric acid and monosodium urate with undiluted human urine to induce precipitation of calcium oxalate in vitro : implications for urinary stone formation |
| Q36088003 | The effect of seed crystals of hydroxyapatite and brushite on the crystallization of calcium oxalate in undiluted human urine in vitro: implications for urinary stone pathogenesis. |
| Q71301293 | The effect of seed crystals on calcium oxalate nucleation |
| Q69045059 | The effect of serum on the crystallization of calcium oxalate in whole human urine: inhibition disguised as apparent promotion |
| Q69984792 | The effect of short-term dietary changes on biochemical values in blood and urine and on some urinary risk factors for calcium oxalate stone formation in humans |
| Q71984721 | The effect of takusha and kagosou on calcium oxalate renal stones in rats |
| Q71833771 | The effect of the oxalate precursors on experimental calcium oxalate urolithogenesis in rats: acute and chronic administration |
| Q53536961 | The effect of traditional risk factors for stone disease on calcium oxalate crystal adherence in the rat bladder. |
| Q68136650 | The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration |
| Q78662936 | The effect of urea, magnesium chloride, and a low protein diet on the production of calcium oxalate vesical calculi in the rat |
| Q72894084 | The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro |
| Q69470656 | The effect of varying concentrations of calcium and magnesium upon calcium oxalate solubility |
| Q72691836 | The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin |
| Q77823096 | The effect of warfarin therapy on the charge properties of urinary prothrombin fragment 1 and crystallization of calcium oxalate in undiluted human urine |
| Q72000633 | The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers |
| Q72701036 | The effects of citrate and urine on calcium oxalate crystal aggregation |
| Q69352678 | The effects of citrate on hydroxyapatite induced calcium oxalate crystallization and on the formation of calcium phosphate crystals |
| Q68922192 | The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men |
| Q78116140 | The effects of human urine on the adhesion of calcium oxalate crystal to Madin-Darby canine kidney cells |
| Q33785784 | The effects of intracrystalline and surface-bound proteins on the attachment of calcium oxalate monohydrate crystals to renal cells in undiluted human urine |
| Q80641199 | The effects of lipopolysaccharide-induced reactive oxygen species were blunted by calcium oxalate in renal tubular epithelial cells |
| Q72360246 | The effects of magnesium and pH on experimental calcium oxalate stone disease |
| Q46430838 | The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients |
| Q67826614 | The epitaxially induced crystal growth of calcium oxalate by crystalline uric acid |
| Q67731513 | The evaluation of some biochemical parameters in pyridoxine-treated calcium oxalate renal stone formers |
| Q44209087 | The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons |
| Q34697330 | The genetic composition of Oxalobacter formigenes and its relationship to colonization and calcium oxalate stone disease |
| Q34130662 | The hole truth: intracrystalline proteins and calcium oxalate kidney stones |
| Q39667095 | The hyperuricosuric calcium oxalate stone former |
| Q51072225 | The importance of a clean face: the effect of different washing procedures on the association of Tamm-Horsfall glycoprotein and other urinary proteins with calcium oxalate crystals. |
| Q53754433 | The importance of citrates in treatment and prophylaxis of calcium oxalate urinary stones. |
| Q68733882 | The in-vivo effect of sodium-potassium citrate on the crystal growth rate of calcium oxalate and other parameters in human urine |
| Q46370232 | The influence of South African mineral water on reduction of risk of calcium oxalate kidney stone formation |
| Q43543914 | The influence of a high-oxalate/low-calcium diet on calcium oxalate renal stone risk factors in non-stone-forming black and white South African subjects |
| Q44983101 | The influence of freezer storage of urine samples on the BONN-Risk-Index for calcium oxalate crystallization |
| Q69352674 | The influence of hydroxyapatite and pyrophosphate on the formation product of calcium oxalate at different pHs |
| Q71474694 | The influence of magnesium chloride on blood and urine parameters in calcium oxalate stone patients |
| Q70291702 | The influence of polyphosphate ions on the precipitation of calcium oxalate |
| Q68965636 | The influence of serum and serum proteins on calcium oxalate crystal growth and aggregation |
| Q39266466 | The influence of uric acid on the calcium oxalate stone formation (author's transl) |
| Q68250990 | The influence of urinary macromolecules on calcium oxalate monohydrate crystal growth |
| Q39158760 | The inhibition of calcium oxalate crystal growth by multidentate organic phosphonates |
| Q74468645 | The inhibition of calcium oxalate monohydrate crystal growth by maleic acid copolymers |
| Q47203410 | The inhibitory effect of kampou extracts on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model |
| Q71504883 | The inhibitory effect of polymeric carboxylic amino-acids and urine on calcium oxalate crystallization |
| Q54080771 | The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis. |
| Q39721844 | The initial and subsequent inflammatory events during calcium oxalate lithiasis |
| Q72336822 | The interaction between nephrocalcin and Tamm-Horsfall proteins with calcium oxalate dihydrate |
| Q59034611 | The kinetics of calcium oxalate pyrolysis. Infrared emission spectrometry as a new technique for obtaining kinetic parameters |
| Q71363202 | The kinetics of crystallization of calcium oxalate trihydrate |
| Q71301329 | The kinetics of dissolution of calcium oxalate hydrates. II. The dihydrate |
| Q70492845 | The magnesium:calcium ratio in the concentrated urines of patients with calcium oxalate calculi |
| Q41562099 | The mechanism of calcium oxalate crystal-induced haemolysis of human erythrocytes |
| Q70763751 | The nucleation and growth kinetics of calcium oxalate in the presence of some synthetic urine constituents |
| Q72794008 | The nucleation and growth of calcium oxalate monohydrate on self-assembled monolayers (SAMS) |
| Q56008567 | The occurrence of calcium oxalate in the Gidgee wattle (Acacia cambagei Baker) |
| Q67372291 | The occurrence of crystalline calcium oxalate in thyroid colloid in different functional states and ages. A light and electron microscopic study (author's transl) |
| Q51273924 | The osteopontin-controlled switching of calcium oxalate monohydrate morphologies in artificial urine provides insights into the formation of papillary kidney stones. |
| Q42419247 | The paradoxical role of urinary macromolecules in the aggregation of calcium oxalate: a further plea to increase diuresis in stone metaphylaxis |
| Q46292536 | The property changes of urine crystallites of calcium oxalate stone formers before and after taking medicine |
| Q43632735 | The reappraisal of nephrocalcin--its role in the inhibition of calcium oxalate crystal growth and interaction with divalent metal ions |
| Q44949076 | The relationship of 3' vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis |
| Q71326783 | The relationship of Oxalobacter formigenes and calcium oxalate calculi |
| Q44474723 | The relative effects of supplemental dietary calcium and oxalate on urine composition and calcium oxalate relative supersaturation in healthy adult dogs |
| Q28287913 | The role of Oxalobacter formigenes colonization in calcium oxalate stone disease |
| Q37034837 | The role of Tamm-Horsfall glycoprotein and Nephrocalcin in calcium oxalate monohydrate crystallization processes |
| Q72787094 | The role of Tamm-Horsfall mucoprotein in calcium oxalate crystallization. N-acetylcysteine--a new therapy for calcium oxalate urolithiasis |
| Q48512598 | The role of calcium oxalate crystal deposition in cerebral vessels during ethylene glycol poisoning |
| Q44951605 | The role of glycoproteins in calcium oxalate crystal development. |
| Q44071125 | The role of hyperoxaluria in the formation of calcium oxalate urinary calculi, and its association with other biochemical measurements |
| Q68285142 | The role of magnesium in calcium oxalate urolithiasis |
| Q44741699 | The role of overweight and obesity in calcium oxalate stone formation |
| Q69427198 | The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment |
| Q39856293 | The role of polymer nanosurface roughness and submicron pores in improving bladder urothelial cell density and inhibiting calcium oxalate stone formation |
| Q41583020 | The role of the papilla in idiopathic calcium oxalate nephrolithiasis |
| Q43095033 | The role of vinyl sulfonic acid homopolymer in calcium oxalate crystallization |
| Q40905649 | The scientific basis of calcium oxalate urolithiasis. Predilection and precipitation, promotion and proscription |
| Q67507782 | The significance of uric acid in calcium oxalate nephrolithiasis |
| Q72241433 | The simple demonstration of calcium oxalate crystals in kidneys of victims of ethylene glycol poisoning |
| Q43550140 | The solubility of calcium oxalate in tissue culture media |
| Q50079405 | The study of the inhibitory effect of calcium oxalate monohydrate's crystallization by two medicinal and aromatic plants: Ammi visnaga and Punica granatum |
| Q70653832 | The uric acid: cystine correlation in the urine of recurrent calcium oxalate stone-formers and healthy controls |
| Q70867100 | The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro |
| Q70403894 | The urinary excretion of citric, hippuric, and lactic acid in normal adults and in patients with calcium oxalate urinary calculus disease |
| Q69470641 | The urinary excretion of trace metals in patients with calcium oxalate urinary stone |
| Q36649228 | The use of a laser microprobe to identify calcium oxalate in histological material |
| Q69447055 | Theoretical and clinical importance of the differentiation between the two types of calcium oxalate hydrate |
| Q34489971 | Therapeutic effect of Xue Niao An on glyoxylate-induced calcium oxalate crystal deposition based on urinary metabonomics approach |
| Q40173592 | Therapeutic measures in recurrent calcium oxalate nephrolithiasis |
| Q53742515 | Therapy of calcium oxalate urolithiasis in a rhesus macaque (Macaca mulatta). |
| Q57098198 | Thermal analysis of calcium oxalate samples obtained by various preparative routes |
| Q45221697 | Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats |
| Q72366616 | Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria |
| Q37786479 | Throw no stones: how to prevent calcium oxalate renal stones |
| Q46274832 | Time-dependent subcellular structure injuries induced by nano-/micron-sized calcium oxalate monohydrate and dihydrate crystals |
| Q45111527 | Tissue lipids in experimental calcium oxalate lithiasis and the effect of DL alpha-lipoic acid |
| Q38752255 | Total flavonoids of Desmodium styracifolium attenuates the formation of hydroxy-L-proline-induced calcium oxalate urolithiasis in rats |
| Q38750637 | Toward a new insight of calcium oxalate stones in Drosophila by micro-computerized tomography |
| Q61017569 | Towards uncovering evolution of lineage-specific calcium oxalate crystal patterns in Piperales |
| Q70546127 | Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. II. Effects of Fe(III), Cr(III) and Al(III) complexes on calcium oxalate crystal growth |
| Q46984935 | Transcriptional repression mediated by 45-kDa calcium oxalate monohydrate binding protein |
| Q43438637 | Transcriptional study of hyperoxaluria and calcium oxalate nephrolithiasis in male rats: Inflammatory changes are mainly associated with crystal deposition. |
| Q69944514 | Transient hyperoxaluria after ingestion of chocolate as a high risk factor for calcium oxalate calculi |
| Q68060805 | Transmembrane oxalate exchange: its relationship to idiopathic calcium oxalate nephrolithiasis |
| Q67667193 | Treatment of calcium oxalate calculi using Reducto-Special |
| Q45213449 | Trends in the frequency of calcium oxalate uroliths in the upper urinary tract of cats |
| Q70335780 | Triamterene and renal stone formation: the influence of triamterene and triamterene stones on calcium oxalate crystallization |
| Q43747677 | Trichoderma koningii as a biomineralizing fungous agent of calcium oxalate crystals in typical Argiudolls of the Los Padres Lake natural reserve (Buenos Aires, Argentina). |
| Q28143333 | Twinned Raphides of Calcium Oxalate in Grape (Vitis): Implications for Crystal Stability and Function |
| Q69054928 | Two-carbon oxalogenesis compared in recurrent calcium oxalate stone formers and normal subjects |
| Q58132276 | UPLC/MS-Based Metabolomics Investigation of the Protective Effect of Hydrogen Gas Inhalation on Mice with Calcium Oxalate-Induced Renal Injury |
| Q41694493 | Ultrastructural events in early calcium oxalate crystal formation in rats |
| Q32044006 | Ultrastructure of selected calcium oxalate-containing urinary calculi from dogs |
| Q43451758 | Unique calcium oxalate "duplex" and "concretion" idioblasts in leaves of tribe Naucleeae (Rubiaceae). |
| Q71295567 | Unusual calcium oxalate crystals in ethylene glycol poisoning |
| Q74596707 | Unusual morphology of calcium oxalate calculi in primary hyperoxaluria |
| Q35820658 | Update: Management of calcium oxalate uroliths in dogs and cats. |
| Q38572715 | Urate and calcium oxalate stones: from repute to rhetoric to reality. |
| Q70308317 | Urate does not influence the formation of calcium oxalate crystals in whole human urine at pH 5.3. |
| Q71109054 | Uric acid and calcium oxalate nephrolithiasis |
| Q34609326 | Uric acid as inducer of calcium oxalate crystal development. |
| Q71238235 | Uric acid, monosodium urate and ammonium urate urinary relative saturations in normo-uricuric calcium oxalate stone formers |
| Q77880056 | Uric acid-binding proteins in calcium oxalate stone formers and their effect on calcium oxalate crystallization |
| Q71346906 | Uric acid/calcium oxalate nephrolithiasis. Clinical and biochemical findings in 86 patients |
| Q45255603 | Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers |
| Q28322632 | Urinary Inhibitors of the Formation of Calcium Oxalate |
| Q44590163 | Urinary Oxalate Levels and the Enteric Bacterium Oxalobacter formigenes in Patients with Calcium Oxalate Urolithiasis |
| Q67445271 | Urinary Supersaturation with Calcium Oxalate Before and During Orthophosphate Therapy |
| Q70900512 | Urinary bladder calculus and tumor response following either repeated feeding of diethylene glycol or calcium oxalate stone implantation |
| Q40602905 | Urinary calcium oxalate crystal growth inhibitors |
| Q34057003 | Urinary calcium oxalate monohydrate crystals in ethylene glycol poisoning |
| Q59407308 | Urinary calcium oxalate monohydrate crystals in ethylene glycol poisoning |
| Q41036809 | Urinary calcium oxalate saturation in 'stone formers' and normal subjects: an application of the EQUIL2 program |
| Q50946559 | Urinary calcium oxalate saturation in healthy infants and children. |
| Q44469606 | Urinary calcium oxalate supersaturation beyond nephrolithiasis. Relationship with tubulointerstitial damage |
| Q67247164 | Urinary crystal surface binding substances on calcium oxalate crystals |
| Q69373218 | Urinary enzymes and calcium oxalate urolithiasis |
| Q71240523 | Urinary excretion of urate in patients with calcium oxalate stone disease |
| Q54608856 | Urinary glycosaminoglycans and glycoproteins in a calcium oxalate crystallization system. |
| Q72229426 | Urinary glycosaminoglycans are selectively included into calcium oxalate crystals precipitated from whole human urine |
| Q41535988 | Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation |
| Q44034244 | Urinary inhibitory activity of calcium oxalate monohydrate crystal growth in stone-formers & non stone-formers |
| Q72629399 | Urinary macromolecular substances as natural inhibitors of calcium oxalate crystal aggregation |
| Q72251525 | Urinary macromolecules are promoters of calcium oxalate nucleation in human urine: turbidimetric studies |
| Q33632838 | Urinary metals in a spontaneous canine model of calcium oxalate urolithiasis |
| Q45158722 | Urinary organic acids found in B6-deficient rats and calcium oxalate calculus patients |
| Q43755502 | Urinary oxalate excretion in female calcium oxalate stone formers with and without a history of recurrent urinary tract infections |
| Q54058354 | Urinary pH in calcium oxalate stone formers: does it matter? |
| Q34037361 | Urinary peptides and calcium oxalate nephrolithiasis, a combined approach: MALDI-TOF mass spectrometry and MicroBCA Protein Assay |
| Q74231150 | Urinary phytate in calcium oxalate stone formers and healthy people--dietary effects on phytate excretion |
| Q77734284 | Urinary relative supersaturations of calcium oxalate and struvite in cats are influenced by diet |
| Q68532861 | Urinary risk factors in calcium oxalate stone disease: comparison of men and women |
| Q44575090 | Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens. |
| Q73146517 | Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren |
| Q67300745 | Urinary supersaturation with respect to brushite in patients suffering calcium oxalate lithiasis |
| Q46737438 | Urinary trefoil factor 1 is a novel potent inhibitor of calcium oxalate crystal growth and aggregation |
| Q71347035 | Urinary urate and uric acid relative saturation in normouricuric calcium oxalate stone formers with normal urinary calcium oxalate saturation |
| Q28362644 | Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis |
| Q44511531 | Urine saturation with calcium oxalate in urolithiasis |
| Q41856180 | Use of a calcium tracer to detect stone increments in a rat calcium oxalate xenoplantation model |
| Q70109056 | Use of the discriminant index in dynamic treatment to reduce recurrence of calcium oxalate kidney stones |
| Q36403173 | Using MRI to detect and differentiate calcium oxalate and calcium hydroxyapatite crystals in air-bubble-free phantom |
| Q52252357 | Validation by image analysis of a turbidimetric method to study calcium oxalate crystallization. |
| Q41843928 | Variability of protein content in calcium oxalate monohydrate stones |
| Q69847904 | Variations in the activity of urinary inhibitors in calcium oxalate urolithiasis |
| Q70788685 | Variations in urine composition during the day in patients with calcium oxalate stone disease |
| Q44421001 | Vascular endothelial growth factor gene polymorphism is associated with calcium oxalate stone disease |
| Q46903507 | Vickers hardness studies of calcium oxalate monohydrate and brushite urinary stones. |
| Q64111983 | Vitamin D metabolism in dogs with and without hypercalciuric calcium oxalate urolithiasis |
| Q46552906 | Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status |
| Q35919757 | Vorinostat protects against calcium oxalate-induced kidney injury in mice |
| Q30309263 | What is the best diet to prevent recurrent calcium oxalate stones in patients with idiopathic hypercalciuria? |
| Q44471702 | Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells |
| Q42677807 | Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls? |
| Q80540234 | Wu-Ling-San formula inhibits the crystallization of calcium oxalate in vitro |
| Q37357212 | Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis - a prospective randomized controlled trial. |
| Q36732451 | Zeta potential distribution on calcium oxalate crystal and Tamm-Horsfall protein surface analyzed with Doppler electrophoretic light scattering |
| Q47338902 | Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization. |
| Q70436465 | ["Leaded" calcium oxalate calculi, or double lead colic] |
| Q46704629 | [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. |
| Q68034502 | [A comparison of methods for the determination of intrarenal calcium oxalate crystallization after glyoxalate administration in rabbits] |
| Q72651878 | [Adhesion of calcium oxalate crystal to Madin-Darby canine kidney cells: quantitative determination and effects of glycosaminoglycans (GAG) and cell injuries on adhesion] |
| Q82730638 | [Bariatric surgery, calcium oxalate urinary stones and oxalate nephropathy] |
| Q71992420 | [Biochemical effects of potassium citrate in the treatment of calcium oxalate lithiasis] |
| Q78811390 | [Biological efficiency of calcium oxalate in the young rat. Effect of vitamin D2.] |
| Q69098093 | [Calcium excretion in patients with calcium oxalate calculi in acid administration] |
| Q71135400 | [Calcium oxalate activity products and discriminant analysis of urinary parameters as basis for a calcium oxalate screening program (author's transl)] |
| Q69477351 | [Calcium oxalate calculi] |
| Q72382922 | [Calcium oxalate calculus: therapy and prevention] |
| Q72184946 | [Calcium oxalate crystals in fruiting bodies of mushroom culture] |
| Q73282528 | [Calcium oxalate in urinary sediment and calculi] |
| Q73408411 | [Calcium oxalate lithiasis. Relationship between biochemical risk factors and crystalline phase of the stone] |
| Q71305418 | [Calcium oxalate microcrystals associated with arthropathy of the knees in hemodialysis] |
| Q84079700 | [Calcium oxalate urolithiasis] |
| Q77745929 | [Calcium-dependent calcium oxalate lithiasis (type IIa). The importance of urinary citrate and the calcium/citrate ratio] |
| Q72864842 | [Case of enteric hyperoxaluria resulting in calcium oxalate calculi following ileectomy] |
| Q79354615 | [Chemical and crystallographic aspects of calcium oxalate calculosis.] |
| Q72822385 | [Clinical features of passed calcium oxalate monohydrate and dihydrate stones] |
| Q70768796 | [Comparative study of urinary calcium, oxalate and uric acid in calcium oxalate lithiasis] |
| Q69794632 | [Comparison of calcium oxalate values as indicators of risk for calcium oxalate calcinosis and the degree of urine saturation in patients with calcium urolithiasis and in healthy patients] |
| Q52387465 | [Components of Urinary Nanocrystals and Their Influence on Formation of Calcium Oxalate Stones]. |
| Q70812689 | [Computer calculations on the effect of urine components on saturation relations of calcium oxalate in the urine] |
| Q74590405 | [Crystalline calcium oxalate in human urine and its relation to oxalate stone formation; urine sifting test] |
| Q77139986 | [Crystalline precursors of calcium oxalate stones in human urine; their dependence on diet prophylaxis and therapy] |
| Q68018352 | [Crystallization of calcium oxalate in mineral waters of Cieplice health resort] |
| Q53265316 | [DIAGNOSIS OF METABOLIC DISORDERS AND METAPHYLAXIS OF RECURRENT CALCIUM OXALATE UROLITHIASIS]. |
| Q69894479 | [Determination of enzyme activities in urine of patients with calcium oxalate calculi] |
| Q76150321 | [Direct precipitation of calcium in the blood serum as calcium oxalate] |
| Q69223696 | [Distribution of calcium oxalate crystals in Angiosperms and its application in microscopic pharmacognosy] |
| Q70676430 | [Diurnal oscillations of calcium ions, total calcium and oxalates in the urine of patients with calcium oxalate urolithiasis and normal persons] |
| Q51628694 | [Diurnal variation in plasma oxalate concentration and oxalate clearance in calcium oxalate stone formers with special reference to the effect of oxalate loading] |
| Q79187427 | [Does calcium oxalate constitute a source of calcium utilizable by the rat during growth?] |
| Q50494655 | [Early diagnosis of risk for developing calcium oxalate urolithiasis]. |
| Q74315670 | [Effect of chorei-to and gorei-san on calcium oxalate crystallization in human urine] |
| Q69967134 | [Effect of etidronate disodium (EHDP) on calcium oxalate renal stones induced by synthetic 1 alpha(OH) vitamin D3 and ethylene glycol in rats] |
| Q72791332 | [Effect of proteolytic enzymes, electrolytes and other factors on the crystallization of calcium oxalate in the urine] |
| Q69263799 | [Effect of urinary material and glycosaminoglycans on calcium oxalate monohydrate crystal aggregation] |
| Q72007551 | [Effect of urine alkalization on excretion of renal citrate and degree of urine saturation with calcium oxalate in patients with calcium-oxalate urolithiasis and in healthy subjects] |
| Q70180319 | [Effects of urinary pH and acid-base balance on the formation of calcium oxalate stone] |
| Q68600620 | [Electron microscopic study of calcium oxalate microcrystals] |
| Q72542873 | [Estimation of 24-h excretion of some promotors and inhibitors of crystallization and degree of urine saturation with calcium oxalate in calcium urinary calculi] |
| Q70676634 | [Experimental and clinical studies concerning the influence of natural substances on the crystallization of calcium oxalate (author's transl)] |
| Q68711836 | [Experimental calcium oxalate nephrocalcinosis. Study of the crystal precipitations in its initial stages] |
| Q50760148 | [Expression of matrix Gla protein and bone morphogenetic protein 2 in renal papillary tissues in patients with calcium oxalate kidney stones]. |
| Q69543858 | [Facilitators of calcium oxalate renal lithiasis: heterogeneous nucleation and aggregation capacity] |
| Q72847413 | [Granulated potassium citrate in the prevention of calcium oxalate lithiasis] |
| Q67430306 | [High molecular weight substances which inhibit calcium oxalate crystal growth, 3: Studies on the characteristics of high molecular weight substances which inhibit calcium oxalate crystal growth (author's transl)] |
| Q74629387 | [Histochemical determination of calcium as calcium oxalate in ethylene glycol poisoning] |
| Q70573957 | [Hydrochlorothiazide in the metaphylaxis of recurrent calcium oxalate lithiasis] |
| Q73373028 | [Idiopathic calcium oxalate urinary lithiasis: new physiopathological approaches] |
| Q67944712 | [Incidence and characteristics of hypocitraturic calcium oxalate lithiasis] |
| Q71456325 | [Indicators of the risk of calcium oxalate urinary calculi: comparative study of the Parks' and Tiselius' indices, urinary citrate/calciuria ratio, and morning crystalluria] |
| Q73966437 | [Influence of hyaluronic acid on calcium oxalate precipitation] |
| Q78425864 | [Influence of hydrophilic colloids on oxalate precipitations and their relationship to the dispersion grade of calcium oxalate.] |
| Q79650423 | [Influence of sex on the formation of calcium oxalate deposits in the kidneys of rats poisoned by ethylene-glycol.] |
| Q71255870 | [Inhibition of calcium oxalate urolithiasis with pyridoxine and magnesium in an experiment] |
| Q77814551 | [Inhibitors in calcium oxalate crystals] |
| Q70638194 | [Inhibitory activity of urinary macromolecule upon calcium oxalate crystal aggregation using an aggregometer] |
| Q68027800 | [Inhibitory effect of CG-120 on the formation, growth and aggregation of calcium oxalate crystals in vitro] |
| Q73478621 | [Inhibitory effect of oral administration of Takusya on calcium oxalate crystallization in human whole urine] |
| Q68674615 | [Inhibitory effect of sodium copper chlorophyllin on the formation, growth and aggregation of calcium oxalate crystals in vitro] |
| Q69083916 | [Inhibitory effect of sodium pentosan polysulfate on the formation, growth and aggregation of calcium oxalate in vitro] |
| Q68922849 | [Inhibitory factors of calcium oxalate crystal growth in urinary macromolecules] |
| Q74835357 | [Isolation of prothrombin and proconvertin after absorption by calcium oxalate in alkaline pH] |
| Q70441012 | [Levels of oxalates in serum and urine in calcium oxalate urinary calculi] |
| Q71088560 | [Long-term clinical experiences with the cation exchanger UJOLYT as a metaphylactic in absorptive hypercalciuria and chronic recurring calcium oxalate lithiasis] |
| Q72557163 | [Magnesium in the prevention of calcium oxalate urinary calculi] |
| Q70608077 | [Measurements of urinary macromolecular inhibitory activity of calcium oxalate crystal aggregation] |
| Q71065773 | [Metabolic investigation of calcium oxalate urinary lithiasis. Indicators of lithogenic risk: modalities, applications and perspectives] |
| Q72334997 | [Model of calcium oxalate lithogenesis by kinetic turbidimetry] |
| Q72906342 | [Multiple calcium oxalate stone formation in a patient with glycogen storage disease type I (von Gierke's disease) and renal tubular acidosis type I: a case report] |
| Q69688581 | [Non-medicamentous prevention of calcium oxalate urinary calculi] |
| Q72120408 | [On the forms of calcium oxalate deposits in the human kidney in oxalosis] |
| Q72759013 | [Orange juice in the prevention of calcium oxalate lithiasis] |
| Q69561364 | [Oxalate loading test for outpatients with calcium oxalate stones] |
| Q71158087 | [Oxalate: its role in lithogenesis and composition of calcium oxalate lithiasis] |
| Q83224718 | [Papillary and cavitary monohydrate calcium oxalate lithiasis: comparative study of etiological factors] |
| Q68194910 | [Pathogenesis of hyperoxalurias and calcium oxalate calculi in intestinal diseases] |
| Q54766413 | [Pattern of calcium oxalate crystals in the leaves of Hydrangea genus plants (author's transl)] |
| Q51641050 | [Plasma oxalate concentration in calcium oxalate stone formers] |
| Q71139375 | [Possibilities of modelling calcium oxalate urolithiasis in an experiment] |
| Q69223723 | [Preliminary study on crystals of calcium oxalate in 57 Chinese medicines] |
| Q70979467 | [Preparation and analysis by x-ray diffraction of three crystalline forms of calcium oxalate in a mixture] |
| Q70519644 | [Pure calcium oxalate calculi] |
| Q69730665 | [Quantitative analysis of calcium oxalate stones by infrared spectroscopy] |
| Q52710688 | [Quantitative mineralogical analyzes of kidney stones and diagnosing metabolic disorders in female patients with calcium oxalate urolithiasis]. |
| Q69521120 | [Questionable significance of the chemical analysis of a single 24-hour urine sample in recurrent calcium oxalate nephrolithiasis] |
| Q67291719 | [Recurrent calcium oxalate calculi in patients treated with piridoxylate] |
| Q68061639 | [Relative risk periods for calcium oxalate stone formation: the circadian rhythm of formation in urine] |
| Q69412977 | [Resorption of oxalic acid in calcium oxalate nephrolithiasis] |
| Q70758803 | [Respective effect of calcium and oxalate on calcium oxalate crystallization in the urine] |
| Q72335006 | [Results of dietary evaluation during calcium oxalate and calcium phosphate lithiasis] |
| Q70791742 | [Rhythm of diurnal and seasonal urine excretion in calcium oxalate-urinary calculi patients and healthy humans and its effect on the incidence of calculi] |
| Q70516193 | [Role of Tamm-Horsfall mucoprotein in calcium oxalate lithogenesis] |
| Q69521095 | [Roundish crystal formations in the retina and vitreous body (calcium oxalate and scintillatio nivea)] |
| Q68690857 | [Spontaneous crystalluria in calcium oxalate stone-formers] |
| Q77814565 | [Structural characteristics of osteopontin for calcium oxalate crystal] |
| Q71242456 | [Studies of dietary influence on urinary oxalate in calcium oxalate stone formers] |
| Q54057664 | [Studies of experimental calcium oxalate stones. 1. The calcium and magnesium of renal deposition of calcium oxalate induced by ethylene glycol administration]. |
| Q70739490 | [Studies of factors related to formation of mixed uric acid and calcium oxalate stones] |
| Q70772225 | [Studies of influence of animal protein intake on the urinary risk factors of calcium oxalate stone formation] |
| Q67949200 | [Studies on calcium oxalate crystal formation in urolithiasis. Multi-regressive analysis of urinary CaOx crystalline volumes and the effects of urinary various substances on CaOx crystal formation] |
| Q69152505 | [Studies on calcium oxalate crystal formation in urolithiasis] |
| Q68689921 | [Studies on calcium oxalate crystallization propensity in human urine. 1. Basal studies for measurement using an aggregometer] |
| Q68689925 | [Studies on calcium oxalate crystallization propensity in human urine. 2. Clinical studies using an aggregometer] |
| Q68600627 | [Studies on the occurrence of texture types in calcium oxalate urinary stones] |
| Q74128817 | [Studies on the significance of protective colloids and crystalloids for the solubility of urinary calcium oxalate] |
| Q72292758 | [Studies on the solubility of calcium oxalate of plant tissues in artificial gastric juice. I.] |
| Q68077671 | [Study of calcium oxalate crystalluria by infrared analysis] |
| Q51631071 | [Study of spontaneous crystalluria in patients with calcium oxalate calculi] |
| Q69680454 | [Study of the transformation of weddellite to whewellite in calcium oxalate stones by x-ray diffraction] |
| Q33269326 | [Study on irritation of calcium oxalate crystal in raw Pinellia ternata]. |
| Q68077659 | [Study on metastable limit of calcium oxalate in whole urine using an aggregometer] |
| Q79135310 | [The destruction of the renal parenchyma by invasion by calcium oxalate crystals. 2 New cases of "renal oxalosis".] |
| Q70686011 | [The effect of different food forms on the urine composition and the risk of calcium oxalate stone formation] |
| Q50800813 | [The effect of kanpou medicine on the growth and aggregation of calcium oxalate crystals in vitro] |
| Q70170754 | [The effect of magnesium on calcium oxalate crystal shapes generated with glycosaminoglycan] |
| Q69959341 | [The effect of mineral water containing calcium on supersaturation of urine with calcium oxalate] |
| Q78172735 | [The effects of human urine on the adhesion of calcium oxalate crystal to renal tubular cells] |
| Q69451440 | [The effects of the oxalate precursors on the experimental calcium oxalate urolithiasis] |
| Q77099025 | [The formation of calcium oxalate microstones in the human urine and its response to dietetic and medicinal measures] |
| Q79358393 | [The influence of vitamin B6 on excretion of crystalline calcium oxalate in the urine of patients with oxalate calculosis] |
| Q50780700 | [The inhibitory effects of Takusha on the formation, growth and aggregation of calcium oxalate crystals in vitro] |
| Q69105000 | [The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone] |
| Q71572299 | [The role of magnesium in the origin of reno-urinary calcium oxalate lithiasis] |
| Q68594514 | [The significance of hypocitruria in calcium oxalate induced nephrolithiasis] |
| Q69463391 | [Thermal methods applied to the study of calcium oxalate lithiasis] |
| Q69968121 | [Thermogravimetric analysis of calcium oxalate urinary stones] |
| Q70452080 | [Treatment of calcium oxalate kidney stones with thiazides] |
| Q45943786 | [Update on the calcium oxalate nephrolithiasis: the problems and the direction]. |
| Q69451466 | [Urinary low molecular promoter of calcium oxalate monohydrate crystal aggregation, preliminary report] |
| Q69419082 | [Urinary material affecting calcium oxalate monohydrate stone formation] |
| Q57225198 | [Uronic-acid-rich protein: a new glycoprotein inhibiting the crystallization of calcium oxalate in vitro] |
| Q38358289 | cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals |
| Q44562606 | influence of animal feed on the development of calcium oxalate stones in the urinary tract in cats is different that expected |
| Q36518967 | p38 MAPK mediates calcium oxalate crystal-induced tight junction disruption in distal renal tubular epithelial cells |
| Q87086812 | ЭСГ/Щавелевокислая известь |
| Q21111340 | calcium oxalate binding | has part(s) | P527 |
Search more.